ADVANCES IN
Immunology T Cell Subsets: Cellular Selection, Commitment and Identity VOLUME 83
This Page Intentionally Left Blank
ADVANCES IN
Immunology T Cell Subsets: Cellular Selection, Commitment and Identity EDITED BY HARVEY CANTOR Dana-Farber Cancer Institute Department of Cancer Immunology, Boston, Massachusetts Harvard Medical School Department of Pathology, Boston, Massachusetts
LAURIE GLIMCHER Harvard School of Public Health Department of Immunology and Infectious Disease, Boston, Massachusetts Harvard Medical School Department of Pathology, Boston, Massachusetts
SERIES EDITOR FREDERICK W. ALT Howard Hughes Medical Institute Children’s Hospital, Boston, Massachusetts
VOLUME 83
Elsevier Academic Press 525 B Street, Suite 1900, San Diego, California 92101-4495, USA 84 Theobald’s Road, London WC1X 8RR, UK
This book is printed on acid-free paper. Copyright ß 2004, Elsevier Inc. All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher. The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher’s consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (www.copyright.com), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-2004 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters. 0065-2776/2004 $35.00 Permissions may be sought directly from Elsevier’s Science & Technology Right Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail:
[email protected]. You may also complete your request on-line via the Elsevier homepage (http://elsevier.com), by selecting ‘‘Customer Support’’ and then ‘‘Obtaining Permissions.’’ For all information on all Academic Press publications visit our Web site at www.books.elsevier.com ISBN: 0-12-022483-6 PRINTED IN THE UNITED STATES OF AMERICA 04 05 06 07 08 9 8 7 6 5 4 3 2
1
CONTENTS
Contributors Introduction
ix xi
Lineage Commitment and Developmental Plasticity in Early Lymphoid Progenitor Subsets David Traver and Koichi Akashi I. Introduction II. Hematopoietic Stem Cells: Clonogenic Precursors of the Hematolymphoid System III. Cell Fate Determination: How do HSCs Commit to Each of the Hematolymphoid Lineages? IV. Overview of T and B Lymphoid Differentiation V. Defining the Earliest Stage in Lymphoid Commitment: Isolation of Common Lymphoid Progenitors (CLPs) VI. Is the CLP Stage Necessary for Adult Lymphoid Differentiation? VII. Common Myeloid Progenitors as the Counterpart of CLPs VIII. Lineage Priming by Promiscuous Gene Expression in Multipotent Stem and Progenitor Cells IX. Lymphoid and Myeloid Promiscuity Demonstrated by Single-Cell Analyses X. Fate Choices Made by Combinations of Instructive Signals at Lineage Promiscuous Stages XI. Lineage Plasticity in Lymphoid Progenitors: Fate Choices are Reversible XII. Comparison of Gene Expression Profiles among Early Hematopoietic Stem and Progenitor Cells XIII. Early Lymphoid Progenitors can Differentiate into Antigen-presenting Dendritic Cells v
1 2 3 6 7 13 17 18 19 22 28 32 33
vi
CONTENTS
XIV. Fetal Hematopoietic Progenitors are Not Fully Committed to the Lymphoid and Myeloid Fates XV. Lymphoid- and Myeloid-restricted Progenitors in Human Bone Marrow XVI. Clinical Relevance XVII. Conclusion References
35 38 39 39 40
The CD4/CD8 Lineage Choice: New Insights into Epigenetic Regulation during T Cell Development Ichiro Taniuchi, Wilfried Ellmeier, and Dan R. Littman I. II. III. IV. V.
Introduction Role of Coreceptors in T Cell Development Regulation of CD4 Gene Expression Regulation of CD8 Gene Expression Conclusion References
55 56 59 77 86 86
CD4/CD8 Coreceptors in Thymocyte Development, Selection, and Lineage Commitment: Analysis of the CD4/CD8 Lineage Decision Alfred Singer and Remy Bosselut I. II. III. IV. V.
Introduction Early Thymocyte Development CD4 and CD8 Coreceptor Molecules on DP Thymocytes Selection and Commitment: Classical Models Kinetic Signaling as an Alternative to Classical Models of Lineage Commitment VI. Conclusions References
91 91 95 99 110 121 121
Development and Function of T Helper 1 Cells Anne O’Garra and Douglas Robinson I. Introduction II. Factors Inducing the Development of Th1 Cells And Their Production of IFN-g III. Role of Th1 Signaling Components in In Vivo Immune Responses
133 135 144
CONTENTS
IV. Transcriptional Regulation for Th1 Cells Producing IFN-g V. New Cytokines: What is Their Role in Th1 Cell Responses? VI. Inherited Disorders of IL-12 and IFN-g-mediated Immunity: Clinical Outcomes of Defects in Th1 Development References
vii 146 149 151 153
Th2 Cells: Orchestrating Barrier Immunity Daniel B. Stetson, David Voehringer, Jane L. Grogan, Min Xu, R. Lee Reinhardt, Stefanie Scheu, Ben L. Kelly, and Richard M. Locksley I. II. III. IV. V. VI. VII. VIII.
Introduction: History and Definitions Activation of IL-4 Expression in Naive CD4 T Cells Stabilization of IL-4 Expression in T Cells Phenotype and Genotype Analysis of Th2 Cells Mutations Impacting IL-4 Expression in T Cells Expression of IL-4 in Non-Th2 Cells Where Does Type 2 Immunity Operate? Concluding Remarks References
163 164 167 170 171 171 177 179 180
Generation, Maintenance, and Function of Memory T Cells Patrick R. Burkett, Rima Koka, Marcia Chien, David L. Boone, and Averil Ma I. II. III. IV. V.
Introduction What Is a Memory Cell? Where Do Memory CD8þ T Cells Come From? How Are Memory Cells Maintained? Conclusions References
191 192 198 212 220 221
CD8þ Effector Cells Pierre A. Henkart and Marta Catalfamo I. II. III. IV.
Effector Cells Defined Secretion as the Mechanism of Effector Function Cytotoxicity In Vivo Cytotoxicity In Vitro
233 235 236 238
viii
CONTENTS
V. VI. VII. VIII. IX.
Perforin-dependent Granule Exocytosis Pathway FasL/Fas Death Pathway Cytokine Secretory Effector Cells CD8þ T Cell Differentiation Conclusions References
238 242 243 245 249 250
An Integrated Model of Immunoregulation Mediated by Regulatory T Cell Subsets Hong Jiang and Leonard Chess I. Introduction and Objectives II. Historical Considerations: Clonal Selection Theory, Immunoregulation, and Regulatory T Cell Subsets III. The T Cell Subsets which Mediate Suppression of the Immune Response IV. An Integrated Model of Immunoregulation by NKT, CD4þCD25þ, and Qa-1 Restricted CD8þ T Cell Subsets References Index Contents of Recent Volumes
253 254 261 277 281 289 301
CONTRIBUTORS
Numbers in parenthesis indicated the pages on which the authors’ contributions begin.
Koichi Akashi (1), Dana-Farber Cancer Institute, Boston, Massachusetts 02115 David L. Boone (191), Department of Medicine and The Ben May Institute for Cancer Research, University of Chicago, Chicago, Illinois 60637 Remy Bosselut (91), Laboratory of Immune Cell Biology, National Cancer Institute, Bethesda, Maryland 20892 Patrick R. Burkett (191), Department of Medicine and The Ben May Institute for Cancer Research, University of Chicago, Chicago, Illinois 60637 Marta Catalfamo (233), National Institutes of Health, Bethesda, Maryland 20892-1360 Leonard Chess (253), Department of Medicine and Pathology, Columbia University College of Physicians and Surgeons, New York, New York 10032 Marcia Chien (191), Department of Medicine and The Ben May Institute for Cancer Research, University of Chicago, Chicago, Illinois 60637 Wilfried Ellmeier (55), University of Vienna, 1235 Vienna, Austria Jane L. Grogan (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143 Pierre A. Henkart (233), National Institutes of Health, Bethesda, Maryland 20892-1360 Hong Jiang (253), Department of Medicine and Pathology, Columbia University College of Physicians and Surgeons, New York, New York 10032 Ben L. Kelly (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143 Rima Koka (191), Department of Medicine and The Ben May Institute for Cancer Research, University of Chicago, Chicago, Illinois 60637 Dan R. Littman (55), New York University School of Medicine, New York, New York 10016 Richard M. Locksley (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143 ix
x
CONTRIBUTORS
Averil Ma (191), Department of Medicine and The Ben May Institute for Cancer Research, University of Chicago, Chicago, Illinois 60637 Anne O’Garra (133), National Institute for Medical Research, London NW7 1AA, United Kingdom R. Lee Reinhardt (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143 Douglas Robinson (133), Imperial College London, London SW7 2AZ, United Kingdom Stefanie Scheu (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143 Alfred Singer (91), Experimental Immunology Branch, National Cancer Institute, Bethesda, Maryland 20892 Daniel B. Stetson (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143 Ichiro Taniuchi (55), Kyushu University, Fukuoka 812-8582, Japan David Traver (1), Dana-Farber Cancer Institute, Boston, Massachusetts 02115 David Voehringer (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143 Min Xu (163), Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California 94143
INTRODUCTION
Until fairly recently, immunologists were most concerned with understanding genetic mechanisms that generated very large numbers of antibodies and T cell receptors from a relatively small set of genes. The discovery of recombination-based genetic mechanisms in T and B cells shifted attention to the obverse problem: how does each cell lineage and sublineage select and use a tiny fraction of the genome to establish its differentiated state? This question has resolved itself into understanding the epigenetic mechanisms that regulate lineage decisions and irreversible lineage commitment. T cell differentiation has, arguably, become the most tractable experimental system for addressing these questions in mammalian cells. The process begins with migration of precursor cells into the thymus, and ends with the formation of two major differentiated subsets. One is equipped to detect and eliminate virally infected cells; a second is programmed to interact with B cells and dendritic cells to induce antibody and/or inflammatory reactions. The surface antigens of cells at each differentiative step in this program have been extensively characterized, beginning with hematopoietic stem cells and ending with mature CD8 cells and sublineages of CD4 helper cells. Isolation and characterization of the hematopoietic stem cell (HSC) has been the foundation for analysis of the early events in thymocyte development. Traver and Akashi describe isolation of HSC from bone marrow cells according to reactivity with antibodies to sca-1, c-kit, Thy1, and CD34. To appreciate this remarkable feat, it is only necessary to imagine a baseball game, say between the Red Sox and the NY Yankees at Fenway Park. The 20,000 or so fans represent the differentiated lymphoid, myeloid and erythroid elements within the hematopoietic system. The position players on the field represent the committed progenitors for each of these lineages; the pitcher represents the hematopoietic stem cell. Genetic profiling of HSC suggests that transcriptional access can predict both their immediate and full differentiative potentials. Traver and Akashi discuss evidence of significant plasticity within HSC and progenitor xi
xii
INTRODUCTION
populations, including findings that some non-hematopoietic genes are transcriptionally accessible and/or active. Although chromatin accessibility and low level transcriptional expression do not normally lead HSC down non-hematopoietic paths, recognition that these precursor cells have alternative genetic potentials is likely to promote a search for inducing agents and receptors that might stimulate HSC to give rise to non-hematopoietic progeny. Mechanisms that underlie CD4/CD8 initial lineage choices and stabilization of these genetic decisions are the subject of reviews by Taniuchi et al. and Singer and Bosselut. Taniuchi et al. delineate the remarkably detailed and complex molecular interactions that regulate CD4 and CD8 expression at discrete stages of T cell development. Expression of the CD8 co-receptor depends mainly on interaction between silencer elements and members of the Runx transcription factor family (and other proteins) to repress CD4 gene expression at early stages of development and to facilitate epigenetic changes that stably quench CD4 gene expression in mature CD8 cells. CD8 gene expression is regulated through a quite different mechanism that depends on tandemly-arranged clusters of cis-acting enhancer elements that sequentially act on CD8 gene expression. Why does regulation of CD4 and CD8 expression depend on many layers of silencing and enhancer elements that are brought to bear at discrete stages in ontogeny? One answer comes from the need for expression of both genes followed by selection-dependent extinction of one of the pair. Additional layers of regulation might be required if additional revisions of co-receptor expression were imposed by positive selection. Singer and Bosselut suggest the possibility that DP thymocytes test TCR/coreceptor compatibility and fix mismatched cells through co-receptor revision. According to this view, TCR signaling of DP cells by MHC (class I or class II) uniformly down regulates CD8 but not CD4 expression. If unabated TCRdependent signaling in this selection intermediate validates the cell’s TCR/ CD8 pairing, the cell continues on to become a full-fledged SP CD4 cell, possibly quenching IL-7R dependent signals along the way. On the other hand, disruption of TCR signaling may direct the cell to reverse its developmental direction, through re-expression of CD8 and repression of CD4 gene expression, to yield a ‘revised’ CD8 cell. Early plasticity followed by irreversible commitment is also a major feature of Th1 and Th2 sublineage development. In the case of Th1 cells, O’Garra and Robinson discuss some of the factors that can impinge upon the STAT1-mediated signaling pathway initiated from the IFN-g receptor that induce expression of the master regulator of Th1 cells, T-bet. Like all good instructors, T-bet-dependent guidance leads to fully independent progeny
INTRODUCTION
xiii
through remodeling of target genes such as IFN-g. This is certainly not the whole story, and new cytokines that enhance the overall expression of IFN-g acting at both early and late stages of Th1 development, mainly through IFN-g, can modify this process. Stetson et al. delineate the central role of GATA-3 as the master regulator of Th2 gene transcription through integration of signals from the T cell synapse and remodeling of chromatin during Th2 development. Additional features of this differentiative path include coordinate regulation of a group of Th2 cytokine genes by inter-genic sequences, designated CNS1 and CNS2 (conserved, non-coding sequences) that facilitate locus-remodeling and epigenetic memory. Terminal cellular commitment that is independent of pioneer transcription factors also involves DNA methylation and heterochromatin patches that stably inhibit non-expressed cytokine loci. This developmental path is placed within the broader biological and clinical context of Th2 immune responses that normally discourage pathogen invasion at epithelial surfaces at the risk of allergic and hypersensitivity reactions. Henkart and Catalfamo and Burkett et al. discuss the generation of memory and cytotoxic effector cells within the CD8 lineage in the context of lineage modeling. Will a single lineage do as CD8 cells pass from effector cells to memory cells? Or do multiple lineages account for memory development, despite the fact that they add complexity to this area. We are also reminded that cytotoxic effector cells are one of the more straightforward elements of the immune response, particularly since much is know about the classic perforin dependent granule exocytosis pathway. Nonetheless, the generation and maintenance of CD8 memory cells has many fascinating biological features. The unexpected interaction in trans between IL-15 and its receptor in the support of CD8 memory, as delineated by Burkett et al., is an excellent case in point. These reviews highlight a series of remarkable new insights into the mechanisms that govern development and function of T cell lineages. As Jiang and Chess point out ‘‘in contrast, the precise biological definition of immunologic suppressive activity has largely remained an enigma’’. Current approaches to this relatively neglected problem will undoubtedly be sharpened by recent molecular insights into T cell development and potential inhibitory effects of certain cytokines. Jiang and Chess contribute a scholarly review of experimental evidence supporting the view that CD4 and CD8 development may include cells that are genetically programmed to mediate suppressive or effector activity. They cite findings that the recently-cloned transcription factor Foxp3 is expressed in a subpopulation of regulatory CD4 cells, as a step in this direction. They also summarize the increasingly impressive experimental data that defines suppressive activity mediated by a sublineage of CD8 cells that
xiv
INTRODUCTION
depend on the MHC class Ib molecule Qa-1. It is fitting that this volume end with an overview of an area of immunology that is just being revived after many years of neglect. Jiang and Chess serve to remind us that the remarkable progress that has been made in understanding epigenetic regulation of T cell development should not be viewed as the last word in this field. It may also provide a foundation for future analysis of the development of effector and regulatory sublineages of CD4 and CD8 cells. Harvey Cantor
advances in immunology, vol. 83
Lineage Commitment and Developmental Plasticity in Early Lymphoid Progenitor Subsets DAVID TRAVER AND KOICHI AKASHI Dana-Farber Cancer Institute, Boston Massachusetts 02115
I. Introduction
All blood cell types including lymphocytes are derived from HSCs that both self-renew and maintain multilineage hematopoiesis over the lifetime of the host. Differentiation is defined as the sequence of events through which immature precursors become mature, effector cells. During this stepwise commitment process, it has long been assumed that oligopotent progenitors exist that are daughters of HSCs. Whereas many findings have retrospectively suggested the existence of such cell types, prospective isolation of clonal progenitors is essential for the precise understanding of both normal and aberrant hematopoiesis. An important issue in the commitment sequence from HSCs to lymphoid cells was whether lymphocytes are directly derived from certain HSC subsets, from bipotent (T-cell/myeloid or B-cell/myeloid) progenitors, or from progenitors that exclusively give rise to all lymphoid cells, including T and B lymphocytes, and natural killer (NK) cells. Since both B and T lymphocytes display similar mechanisms for antigen receptor rearrangement and selection, it was postulated that T and B cells arise from common progenitors that have lost myeloid differentiation potential. Support for the existence of lymphoidrestricted progenitors came from studies using chromosomally marked HSCs (Abramson et al., 1977), from the results of cultured bone marrow cells transplanted into immunodeficient mice (Fulop and Phillips, 1989), and from the loss of both T and B cell subsets in patients with severe combined immunodeficiency (SCID) (Fischer, 1992; Hirschhorn, 1990). More recently, a rare population within whole mouse bone marrow was shown to generate all lymphoid subsets but that completely lacked myeloerythroid differentiation potential. These were termed common lymphoid progenitors (CLPs) (Kondo et al., 1997). Subsequently, counterpart myeloerythroid-restricted progenitors (common myeloid progenitors: CMPs) were identified (Akashi et al., 2000). Continuing studies support the concept that the lymphoid and myeloerythroid pathways diverge downstream of HSCs within the bone marrow of adult mice (Gounari et al., 2002; Igarashi et al., 2002). Using these prospectively isolated populations, lineage commitment can now be investigated directly at each of the major hematopoietic branchpoints (Fig. 1). 1 Copyright 2004, Elsevier Inc. All rights reserved. 0065-2776/04 $35.00
2
DAVID TRAVER AND KOICHI AKASHI
Fig 1 Hematopoietic commitment model based on prospective isolation of lineage-restricted progenitors. HSC, hematopoietic stem cells, CMP, common myeloid progenitors, CLP, common lymphoid progenitors; GMP, granulocyte/monocyte progenitors; MEP, megakaryocyte/erythrocyte progenitors. (See Color Insert.)
II. Hematopoietic Stem Cells: Clonogenic Precursors of the Hematolymphoid System
The search for hematopoietic stem cells began with the observation by Till and McCulloch that bone marrow transplants into lethally irradiated mice generated clonal spleen colonies, and that some of these colonies could generate multilineage hematopoiesis in serially transplanted animals (Becker, 1963; Till and McCulloch, 1961; Wu et al., 1968). Many subsequent retrospective transplantation experiments suggested that rare populations of HSCs existed within total bone marrow (Mulder and Visser, 1987; Visser et al., 1984). The modern era of HSC biology began with the first rigorous, prospective isolation of murine HSCs by cell surface phenotype (Spangrude et al., 1988; Uchida and Weissman, 1992; Uchida et al., 1994). These investigators showed that long-term, multilineage reconstitution activity was present only within a population of Lin/loThy-1.1loSca-1þ bone marrow cells. A subset of these cells displayed long-term self-renewing potential (Spangrude et al., 1991) that, at the single-cell level, could give rise to both myeloid and lymphoid outcomes (Smith et al., 1991). Subsequent studies, however, showed that the Lin/loThy-1.1loSca-1þ bone marrow fraction was heterogeneous in terms of self-renewal activity; HSCs with long-term self-renewal activity could be further subfractionated by isolating cells expressing c-Kit, a receptor for Steel
LINEAGE COMMITMENT
3
factor (Slf) (Morrison and Weissman, 1994). Another group showed that within the LinSca-1þc-Kitþ population, only CD34/lo cells are long-term HSCs, whereas the remaining CD34þ cell can display only short-term, multilineage reconstitution (Osawa et al., 1996). Both Thy-1.1loLinSca-1þc-Kitþ and CD34/loLinSca-1þc-Kitþ populations constitute 0.01% of total bone marrow cells, and we have confirmed that >60% of these populations phenotypically overlap. Multilineage, long-term reconstitution from single cells was observed in 20% and 35% of Thy-1.1loLinSca-1þc-Kitþ and CD34/loLinSca-1þc-Kitþ populations, respectively, after competitive reconstitution assays (Osawa et al., 1996; Wagers et al., 2002). Another marker for HSCs, as well as for stem cell subsets in other tissues (Goodell et al., 1997, 2001; Jackson et al., 2001; Storms et al., 2000) is the differential efflux of the intracellular dye Hoechst 33342. Hoechstlow cells, termed the side population (SP), almost exclusively contain the long-term HSC subset (Goodell et al., 1997). Purified SP cells were LinSca-1þc-Kitþ, and contained >30% of CD34/lo cells (Okuno et al., 2002). In a study in 2001, the Thy1.1loLinSca-1þc-Kitþ population was further divided by expression of the fms-like tyrosine kinase-3 (Flt-3 or Flk-2). (Adolfsson et al., 2001; Christensen and Weissman, 2001). Around 60% of Thy-1.1loLinSca-1þc-Kitþ cells express Flk-2, and long-term HSC activity was only found within Flk-2Thy-1.1 lo LinSca-1þc-Kitþ cells, enabling the further enrichment of long-term HSCs. Considering the noted inefficiency of intravenously injected cells to seed the bone marrow (Morrison et al., 1996), isolation of long-term HSCs by the above phenotypes has likely reached purity. III. Cell Fate Determination: How do HSCs Commit to Each of the Hematolymphoid Lineages?
A fundamental question is how multipotent cells select one cell fate from a choice of several. Lineage commitment and subsequent differentiation of multipotent cells likely occurs due to the selective activation and silencing of particular gene expression programs. This process likely involves the formation of transcriptional complexes at the regulatory regions of lineage-specific gene loci (Wadman et al., 1997). Changes in chromatin structure permitting or denying access to transcriptional machinery is probably critical for this process (Berger and Felsenfeld, 2001; Felsenfeld et al., 1996). The development of in vitro clonogenic assays has defined retrospective subsets of myeloerythroid progenitors that appear to have restricted differentiation capacity (Bradley and Metcalf, 1966; Pluznik and Sachs, 1965). Unfractionated bone marrow was found to contain oligopotent colony-forming units (CFU) for all myeloid lineage cells (CFU-GEMMeg or CFU-Mix) (Johnson and Metcalf, 1977; Metcalf et al., 1979), for granulocytes and
4
DAVID TRAVER AND KOICHI AKASHI
macrophages (CFU-GM), and for megakaryocytes and erythrocytes (CFUMegE). Monopotent CFU for granulocytes (CFU-G), macrophages (CFUM), erythrocytes (CFU-E), or megakaryocytes (CFU-Meg) were also found. The combinations of cell types present within these colonies supported the notion of clonal progenitor subsets with progressive loss of lineage potentials, and suggested close relationships between the GM and MegE branches of the hematopoietic tree. If multipotent HSCs indeed give rise to progenitors with progressive lineage restriction in vitro, it is logical to place these progenitors in a hierarchical order in the hematopoietic lineage map (Dexter and Testa, 1980) (Fig. 2A), and the myeloerythroid differentiation pathway might initiate from clonogenic progenitors of all mature cell types, such as CFU-GEMMeg. More precise lineal studies using in vitro blast colony formation, however, did not necessarily support this hierarchical model. Cells harvested from multipotent blast colonies (Nakahata and Ogawa, 1982) were able to efficiently form secondary colonies, and paired daughter cells derived from single blast cells frequently gave rise to different combinations of myeloid progeny when split into identical conditions (Suda et al., 1984a,b). Based on this phenomenon, ‘‘stochastic’’ commitment of HSCs to the myeloerythroid fates has been proposed (Ogawa, 1993) (Fig. 2B). This model states that the commitment decision of multipotent cells is essentially random and cell autonomous, and that differentiation is subsequently determined by the availability of survival or growth signals. Another model of hematopoietic commitment was proposed largely based on the analysis of in vitro differentiation potentials of immortalized cell lines. The ‘‘sequential determination model’’ proposed by Brown and colleagues states that there is a predetermined order of developmental choices (Brown et al., 1985, 1987) (Fig. 2C). This model proposes that HSCs undergo an intrinsic decision program to generate cells that can differentiate along one discrete pathway. While all of these commitment models accommodate intermediate progenitor cells, all have the critical caveat that retrospective in vitro lineage outcomes may not reflect the full commitment potential of each assayed cell type. First, there exists no single in vitro assay system that is permissive for each blood cell lineage. Whereas retrospective identification of a CFU-GEMM colony is often attributed to an early myeloerythroid progenitor, this colony could have equally resulted from a plated HSC that could not produce lymphocytes due to culture limitations. Second, if in vitro colony conditions are fully permissive for all myeloerythroid fates, it may be logically assumed that HSCs should always give rise to CFU-GEMMeg. It is known, however, that single Thy1.1loLinSca-1þc-Kitþ HSCs give rise to many different colony types, including burst-forming unit-erythroid (BFU-E), CFU-E, CFU-GM, CFU-Meg, and multilineage CFU-GEMMeg colonies at high frequencies (Akashi et al., 2000; Heimfeld et al., 1991; Morrison et al., 1996). It is thus still unclear
LINEAGE COMMITMENT
5
Fig 2 Historical hematopoietic commitment models. (A) The hierarchical commitment model based on cell component contained in clonogenic myeloid colonies. (B) The stochastic commitment model based on the analysis of colonies from paired daughter progenitors. (C) The sequential determination model based on the analysis of cell line phenotypes.
whether highly purified HSCs do indeed commit randomly to the various myeloerythroid fates at least in vitro, or whether these phenomena simply represent the unstable nature of in vitro assay systems. These models have been established mainly on the in vitro behavior of stem and progenitor cells to read-out myeloerythroid, but not lymphoid, differentiation. This is largely because lymphoid assay systems are inefficient compared to myeloerythroid assays, as discussed in the following section. Nonetheless, in each model, there should be a variety of lineage-restricted progenitors in early hematopoiesis that are intermediates between HSCs and mature blood cells. An important approach to understanding hematopoietic commitment was to purify lineage-restricted progenitor subsets and to test their lineal relationships.
6
DAVID TRAVER AND KOICHI AKASHI
IV. Overview of T and B Lymphoid Differentiation
Lymphoid development requires interactions between lymphoid precursor cells and stromal cells; this relationship is responsible for the expansion and selection of immature lymphocytes. The requirement of complex conditions for lymphoid development has thus hindered the precise analysis of lymphoid development and commitment processes. For T lymphocytes, the thymic stromal microenvironment is critical in the selection of developing thymocytes and in the elimination of cells expressing inappropriate T cell receptor (TCR) genes. The thymic microenvironment consists of thymic epithelial cells, macrophages, B cells, and dendritic cells. Lymphoid progenitors from the bone marrow need to seed the thymus for T cell production. It is unclear what cell population homes to thymus in normal T lymphopoiesis, which will be discussed later in this chapter. Within the thymus, the earliest thymic precursor has been identified within the fraction of CD4loCD8CD3 (triple negative; TN) cells. The earliest thymic progenitors (or proT1 cells) are CD25 þCD44þc-Kitþ, and as a population, they are capable of NK, B, and dendritic cell differentiation, but have lost most myeloid potential (Matsuzaki et al., 1993; Wu et al., 1991a,b). This supports the hypothesis that lymphoid commitment may occur in the bone marrow before cells home to the thymus. In the next proT (proT2 cells) stage, CD25þCD44þc-Kitþ proT cells begin to rearrange TCR genes. The molecules that initiate the recombination of VDJ for TCRb or of VJ for TCRg genes remain largely unclear. This rearrangement requires the two tightly regulated lymphoid-specific proteins’ recombination activation gene (RAG)-1 and RAG-2, which form a complex resulting in cleavage of DNA (McBlane et al., 1995; van Gent et al., 1996). Mice that lack RAG-1 or RAG-2 genes have a complete block of early T (and early B) cell development (Mombaerts et al., 1992; Shinkai et al., 1992). Ectopic expression of transfected RAG-1 and RAG-2 genes in nonlymphoid tissue does not result in antigen receptor rearrangement (Schatz et al., 1992), suggesting that the RAG genes do not directly instruct lymphoid commitment. Developing preT cells (CD25þCD44c-Kit) are first selected based on the appropriateness of rearranged TCRb chains coupled with the invariant preT cell receptor a chain (pTa). Cells that successfully pass through this b-selection stage are further selected by low- and high-affinity major histocompatibility (MHC) molecule interactions that positively select self-restrictive T cells and negatively select autoreactive T cells, respectively. T cell development is thus critically regulated by these two checkpoints that exist specifically in the thymus. Importantly, to estimate the T cell potential of candidate lymphoid progenitor populations, one should ensure that the assayed cell subset reaches the thymic microenvironment. For example, by intravenous transplantation, high numbers of T cell progenitors are required to obtain T cell reconstitution, whereas injection of
LINEAGE COMMITMENT
7
progenitors directly into the thymus significantly increases T cell differentiation efficiency (Kondo et al., 1997). This requirement limits the detection of T cell potential by intravenous injection alone, especially when assayed cell types possess limited expansion potential. B cell development also involves selective outgrowth of randomly generated clonal cell populations. Proper rearrangement of B cell antigen receptor (BCR) genes is required for B lymphocyte development. Despite the lack of a requirement for BCR interaction with MHC molecules, B cells need to pass through a number of developmental checkpoints; failure results in apoptotic death. Progressive commitment to the B cell lineage occurs through a phenotypically defined differentiation pathway based on the surface markers AA4.1 and CD43 (Hardy et al., 1991; Li et al., 1996). An early AA4.1þCD43þ preproB cell subset can be further subdivided into A0, A1, and A2 fractions (Allman et al., 1999) based on the additional B220 and CD4 markers. The CD4loB220 A0 fraction expresses heterogeneous levels of Sca-1, c-Kit, and Mac-1, and contains cells that can give rise to myeloid and T cell as well as B cell progeny. This population may contain Thy-1loLinSca-1þCD4lo multipotent progenitors (Morrison and Weissman, 1994). The CD4hiB220þ A1 fraction expresses low levels of Sca-1 and Mac-1, but does not express c-Kit. The A1 fraction lacks myeloid differentiation activity, and possesses minimal T cell differentiation potential as assessed by intrathymic injection. It is unknown whether the A1 fraction contains B and T biopotent precursors. The majority of CD4B220þ A2 cells are B cell-committed. Pro-B cells rearrange DH-JH genes and express B220, CD43, and HSA on their surface (Fraction B), and subsequently express 6C3/BP-1 and undergo V-DJ recombination (Fraction C). Acquisition of CD19 represents an important marker for B cell commitment and corresponds to the ability of late proB cells to proliferate in IL-7 without other stromal cell-derived factors (Hardy et al., 1991; Hayashi et al., 1990). These CD19þ precursors should be categorized in fraction B in Hardy’s classification (Tudor et al., 2000). ProB cells in fractions B and C express the surrogate light chain genes, l5 and VpreB, to form pre-BCR. Following rearrangement of the immunoglobulin light chain gene, the heavy and light chains form a complex and are expressed on the surface together with Iga and Igb to become mature B cells. V. Defining the Earliest Stage in Lymphoid Commitment: Isolation of Common Lymphoid Progenitors (CLPs)
To prospectively isolate early lymphoid-commited progenitors, one could either employ the random, biochemical approach that led to HSC isolation or a candidate approach based on lymphoid-specific cell surface markers. Both Thy-1 and Sca-1, critical markers for HSC fractionation, are also expressed
8
DAVID TRAVER AND KOICHI AKASHI
on the majority of mature T cells. Based on targeted gene disruptions, Thy-1 does not play a critical role in myeloid or lymphoid development (NostenBertrand et al., 1996), and Sca-1 functions in HSC self-renewal and granulocyte development but is not required for lymphoid development (Ito et al., 2003). As has been discussed, much is known regarding the molecular determinants of both T and B lymphocytes. Markers specific for lymphoid functions could therefore be systematically analyzed to phenotypically delineate early steps in lymphoid differentiation. The first such key molecule used to enrich for CLPs was the receptor for interleukin 7 (IL-7), an essential cytokine for both T and B cell development (Peschon et al., 1994; von Freeden-Jeffry et al., 1995) (Fig. 3). As will be discussed, mice carrying reporter genes for other functional lymphoid markers, such as the lymphoid-specific RAG-1 gene (Mombaerts et al., 1992) and the early T lymphoid preT cell receptor a chain
Fig 3 Identification of IL-7Raþ CLPs and myeloid progenitors in mouse bone marrow. (a) Cells negative for lineage (Lin) markers including B220, CD4, CD8, CD3, Gr-1, Mac-1, and TER119 were subdivided into IL-7Ra positive and negative fractions. (b) Sca-1/c-Kit profiles of LinIL-7Raþ cells. The LinIL-7RaþSca-1loc-Kitlo cells are CLPs. (c) Sca-1/c-Kit profiles of LinIL-7Ra cells. The LinIL-7RaSca-1hic-Kithi subset represents the HSC population, whereas the LinIL-7RaSca-1c-Kithi subset contains all myeloid progenitor populations. (d) The LinIL-7RaSca-1c-Kithi population is subdivided into 3 distinct myeloid progenitor subsets such as CMPs, GMPs, and MEPs, according to their FcgRII/III and CD34 profiles.
LINEAGE COMMITMENT
9
Fig 4 Phenotypic differences in primitive lymphoid progenitor subsets possessing T and B lymphoid potential. The early lymphocyte progenitor (ELP) population is defined in the bone marrow as a population that initiates RAG-1 transcription (Igarashi et al., 2002). This population corresponds to a few percent of cells within the conventional short-term HSC subset (LinSca1þc-Kitþ). Although ELPs have ‘‘lymphoid’’ RAG-1 mRNA, they still possess a weak GM potential. ELPs do not express IL-7Ra. Common lymphoid progenitors (CLPs) are cells that begin to express IL-7Ra (Kondo et al., 1997). CLPs are all transcribing the RAG-1 gene, and a small fraction of them also initiate pTa transcription, which is upregulated in thymic proT cells (Miyamoto et al., 2002). In the B lymphoid pathway in the bone marrow, PTa transcription is maintained in a minority of B220þ (c-Kit) cells, which maintain T/B bipotentiality (Gounari et al., 2002). During this sequential lymphoid development in the bone marrow, both Sca-1 and c-Kit are gradually downregulated during the transition of ELPs, CLPs, to B220þ cells. In contrast, the earliest thymic progenitors, called early T lineage progenitors (ETPs) express Sca-1 and c-Kit at a high level, and still possess weak B and GM potentials (Allman et al., 2003). It is unclear whether ETPs originate from ELPs, CLPs, or B220þpTaþ cells. Although the high expression pattern of Sca-1 and c-Kit in ELPs and ETPs may represent their direct precursor/progeny relationship, direct evidence is lacking (see text).
(pTa) (Groettrup et al., 1993), have also been used to search for the earliest lymphoid progenitors that can give rise to all lymphoid components. Lineal relationships and phenotypic overlaps among these lymphoid progenitors defined by each criterion are illustrated in Fig. 4. A. The Role of Flk-2 in Early Stem and Progenitor Cells The Flk-2/Flt-3 receptor, like c-Kit, is a cytokine tyrosine kinase receptor expressed primarily on early hematopoietic precursors (Matthews et al., 1991). Flk-2 was originally isolated based on its expression in HSCs (Mackarehtschian et al., 1995). Mice deficient in Flk-2 or Flt-3 ligand (FL) display loss of early B, NK, and dendritic cell development, and reduced numbers of T cell progenitors (Mackarehtschian et al., 1995; McKenna et al., 2000; Sitnicka et al., 2002). These phenotypes could result due to a requirement for FL signals in common precursors for each lymphoid lineage. As has been discussed, Adolfsson et al. showed that Flk-2 is not expressed in long-term reconstituting HSCs, but is upregulated in non-self-renewing cells within the LinSca-1þc-Kitþ fraction (Adolfsson et al., 2001). Importantly, these authors presented clonal data
10
DAVID TRAVER AND KOICHI AKASHI
indicating that Flk-2þSca-1þc-Kitþ cells contain cells with T, B, and myeloid (GM) potentials, supporting the existence of multipotent progenitors, although MegE potentials were not tested. Christensen et al. further subfractionated the Flk-2þSca-1þc-Kitþ population by using Thy1.1 expression (Christensen and Weissman, 2001). They showed that the Thy1.1loSca-1þc-Kitþ population can be divided into Flk-2 long-term HSC and Flk-2þ short-term HSC populations, and all Thy1.1Sca-1þc-Kitþ multipotent progenitors are Flk-2þ. In an independent study, the Thy1.1Sca-1þc-Kitþ population displayed rapid B cell reconstitution after intravenous transplantation with minimal contributions to the T and myeloid lineages (Searles et al., 2000). Compatible with these data, Flk-2 is expressed in IL-7Raþ CLPs (Kondo et al., 1997), but not in common myeloid progenitors (CMPs) (Akashi et al., 2000) (see following text). Furthermore, FL-deficient mice lack CLPs, but possess normal numbers of CMPs (Adolfsson et al., 2001). These data strongly suggest that Flt-2/FL interactions might play an important role in early lymphoid development. B. CLPs are Defined as the Most Primitive IL-7Ra-Expressing Cells A more definitive marker for lymphoid commitment might be the expression of the receptor for IL-7, an essential cytokine for both T and B cell development. The IL-7 receptor (IL-7R) is composed of the IL-7Ra chain and the common cytokine receptor g chain (g c) (Kondo et al., 1994; Noguchi et al., 1993). Mice genetically deficient for IL-7 or the IL-7 receptor (IL-7R) lack both T and B cells (Peschon et al., 1994; von Freeden-Jeffry et al., 1995), whereas mice deficient for gc lack NK cells as well as T and B lymphocytes (Cao et al., 1995; Ohbo et al., 1996). NK cell deficiency in the latter animals is due to the lack of the IL-15 receptor, which is composed of both the IL-15Ra and gc (Giri et al., 1994). The IL-7R is expressed in early pro-T and pro-B cells (Akashi et al., 1998). The critical role of IL-7 in abT cell differentiation is to maintain survival of developing T cells through the upregulation of a survivalpromoting protein, Bcl-2 (Akashi et al., 1997). Signaling through the IL-7R is necessary for the rearrangement of immunoglobulin heavy chain V segments through the activation of the pax-5 gene (Corcoran et al., 1998), and for V-J recombination of gd TCR genes through the activation of STAT5 (Maki et al., 1996). Administration of neutralizing anti-IL-7 antibodies resulted in severe inhibition of T and B lymphopoiesis, but not myelopoiesis (Bhatia et al., 1995). Taken together, these data suggested that IL-7Ra expression is one of the most reliable functional markers for lymphoid commitment. The isolation of CLPs was performed according to the following steps. First, IL-7Ra-expressing cells were devoid of myeloerythroid potential in vitro and in vivo. Second, within IL-7Raþ bone marrow cells, robust
LINEAGE COMMITMENT
11
differentiation potential to the T, B, and NK cell lineages existed within the LinSca-1loc-Kitlo population in vivo. In mice transplanted with CLPs, donorderived T and B cells began to decline after 4 to 6 weeks, indicating that this population has no significant self-renewal activity. Third, by a two-step clonogenic assay, approximately 20% of single IL-7RaþLinSca-1loc-Kitlo cells could give rise to both T and B cells. Thus, IL-7RaþLinSca-1loc-Kitlo cells contain clonogenic T and B cell progenitors and completely lack myeloerythroid differentiation potential. In a subsequent study, more than 40% of single IL-7RaþLinSca-1loc-Kitlo cells could differentiate to NK cells. The vast majority of CLPs express Flk-2 (Sitnicka et al., 2002). The clonogenic T/B bipotentiality of IL-7Ra-expressing CLPs has also been demonstrated by another group (Izon et al., 2001), using a modified fetal thymic organ culture (FTOC) system (Kawamoto et al., 1997). C. Initiation of Lymphoid Commitment May Occur Prior to the CLP Stage: Early Lymphoid Progenitors Defined by RAG-1 Transcriptional Activation The RAG genes are indispensable for the rearrangement of TCR and Ig genes, and RAG-1 or RAG-2 deficient mice display a complete loss of T and B cells (Mombaerts et al., 1992; Shinkai et al., 1992). Mice carrying GFP knocked into the RAG-1 locus were generated (Igarashi et al., 2001; Kuwata et al., 1999) and similarly assayed for early lymphoid progenitors initiating transcription of the RAG-1 gene (Igarashi et al., 2002). Over 90% of IL-7RaþLinSca-1lo c-Kitlo CLPs expressed GFP in these animals (Igarashi et al., 2002). Interestingly, RAG-1 expression was also observed in 5% of the LinSca1þc-Kitþ HSC fraction. Like CLPs (Sitnicka et al., 2002), GFPþLinSca-1þcKitþ cells also expressed Flk-2, indicating that they are not long-term HSCs (Adolfsson et al., 2001; Christensen and Weissman, 2001) but likely are committed progenitors (Igarashi et al., 2002) and included within the (Flt-2þ)Thy1.1LinSca-1þc-Kitþ population (Christensen and Weissman, 2001; Searles et al., 2000). A vast majority of LinSca-1þc-Kitþ cells and GFPþLinSca-1þcKitþ cells express CD27 (Wiesmann et al., 2000), a member of the TNF receptor family previously shown to play a role in lymphoid proliferation, differentiation, and apoptosis. RAG-1/GFPþLinSca-1þc-KitþCD27þ cells exhibited potent T, B, and NK differentiation potential after transplantation into congenic hosts. The timing of thymic T cell reconstitution of RAG-1/ GFPþLinSca-1þc-KitþCD27þ cells preceded that of CLPs by 7 days, suggesting that these cells were more immature than IL-7RaþLinSca-1locKitlo CLPs. A fraction of RAG-1/GFPþLinSca-1þc-KitþCD27þ cells, however, formed CFU-GM in vitro, indicating that this population is not entirely committed to the lymphoid fates. Furthermore, this study did not demonstrate that T and B cell progeny can originate from single
12
DAVID TRAVER AND KOICHI AKASHI
RAG-1/GFPþLinSca-1þc-KitþCD27þ cells, and therefore the homogeneity of this population is still in question. Nonetheless, these data indicate that the majority of RAG-1/GFPþLinSca-1þc-KitþCD27þ cells are committed to the lymphoid lineages, and that they likely contain cells similar to, or slightly upstream of CLPs. The authors termed this population ‘‘early lymphocyte progenitors (ELPs)’’ (Igarashi et al., 2002). D. Use of pTa Reporter Constructs to Define Early Lymphoid Progenitors The pTa protein pairs with the T cell receptor (TCR) b chain to form the pre-TCR (Groettrup et al., 1993) that plays a critical role in the efficient generation of mature T cells (Fehling et al., 1995). Since pTa is used for preTCR formation after TCRb gene rearrangement, pTa transcription should be a relatively late marker for lymphoid development as compared to RAG-1 transcription. A transgene containing a 9 kb fragment spanning all characterized pTa promoter and enhancer sequences was used to drive expression of a hCD25 minigene (Miyamoto et al., 2002; Reizis and Leder, 2001). In pTa/hCD25 transgenic mice, the expression of hCD25 was highly correlated with that of the endogenous pTa, as quantified by real-time RT-PCR analyses (Gounari et al., 2002). However, a small fraction of B220þ and CD4þ cells in the bone marrow were hCD25þ, but did not express pTa mRNA, presumably because hCD25 transcripts persist for a while after pTa downregulation. In the thymus, the expression of pTa reported by hCD25 was detected in 30% of mCD25c-KitþCD3CD4lo cells, termed the earliest thymic precursors (Wu et al., 1991b), and in the majority of mCD25þc-Kitþ proT cells, consistent with the normal expression of pTa. In the bone marrow, only 6% of Lin cells were hCD25þ, all of which displayed the IL-7RaþSca-1lo-c-Kitlo CLP phenotype, whereas only 7% of CLPs were positive for hCD25 expression (Miyamoto et al., 2002). This result indicates that CLPs are the earliest population to initiate pTa transcription, but that the majority of CLPs have not initiated pTa transcription. The transcription of pTa does not mark T cell commitment at the CLP stage, since pTa/hCD25þ CLPs differentiated into B cells at the same efficiency as pTa/hCD25þ CLPs differentiated into B cells at the same efficiency as pTa/hCD25þ CLPs. In two-step clonogenic assays similar to those used in the original CLP report (Kondo et al., 1997), single pTa/hCD25þ CLPs were demonstrated to give rise to both T and B cells (Gounari et al., 2002). This study also showed that CLP activity persists in a small cell fraction of cells phenotypically downstream from CLPs: pTa/ hCD25þCD19B220þc-Kit cells express IL-7Ra, and possess some T and B cell potential, suggesting that CLP potential is maintained in at least a fraction of B220þ cells that have downregulated c-Kit.
LINEAGE COMMITMENT
13
E. Which Markers are Most Useful to Separate the Earliest Lymphoid Progenitors? The phenotype and biological activities of each progenitor subset are summarized in Fig. 4 and Table I. From the already cited studies, it is highly likely that lymphoid commitment occurs in adult mouse bone marrow, and that CLPs are an important intermediate in steady-state hematopoiesis. Although the majority of CLP activity resides in cells within the originally described IL-7RaþLinSca-1loc-Kitlo fraction, similar activity can also be found within a population of LinSca-1þc-Kitþ HSCs (as evidenced by RAG-1/GFP mice) and within B220þCD19c-Kit cells (as evidenced by hCD25-pTa mice). The differences in the distribution of CLP activity described in these studies demonstrates the difficulty in finding markers that precisely correlate with cell functions, although IL-7Ra-expression is still the only available marker for CLPs in normal mice. In separating cells according to positive or negative marker expression, the sensitivity of each marker is critical. The threshold for positive detection will be decided by the sensitivity of the detectors and by the amount and/or longevity of antigens or reporters. For example, although IL7Raþ cells are undetectable in the LinSca-1þc-Kitþ population by FACS, IL-7Raþ cells are detectable by highly sensitive nested RT-PCR analyses. However, such low level of receptor expression may not be sufficient to transmit functional IL-7 signals. In addition, as will be discussed, the expression of lineage-related genes at low levels precedes lineage commitment in multi- or oligopotent cells. Therefore, if the marker is too sensitive, this may result in the isolation of uncommitted cells. In this context, it is likely that the CFU-GM potential detected within the RAG-1/GFPþ LinSca-1þc-Kitþ fraction is a reflection of multipotent cells with low level ‘‘priming’’ of lymphoid genes (see following text). Conversely, when a late lymphoid marker is used, such as pTa, a failure to efficiently isolate CLPs may result, since <10% of CLPs express pTa transcripts. In this context, the IL-7R is currently the most reliable and efficient marker, since sorting based on IL-7Ra expression yields lymphoid-commited cells with the complete absence of myeloerythroid potential.
VI. Is the CLP Stage Necessary for Adult Lymphoid Differentiation?
As has been discussed, the phenotypic definition of IL-7RaþLinSca-1locKitlo appears to include the majority of cells having CLP activity in mouse bone marrow. Must all lymphocytes necessarily pass through a CLP stage during their maturation? If this is not the case, then progenitors bipotent for myeloerythroid/T or myeloerythroid/B lineages might exist. Despite an intensive search, such progenitor populations have not yet been isolated.
TABLE I Characteristics of Stem and Primitive Lymphoid Progenitors
Location
Sca-1/c-Kit/Thy1
Fit-3
RAG1 activation
IL-7Ra
pTa activation
Lineage potential as a population
HSC
BM
Sca-1þc-KitþThy1lo
All lineage
ST-HSC
BM
Sca-1þc-KitþThy1
þ
All lineages
ELP CLP
BM BM
Sca-1þc-KitþThy1 Sca-1loc-KitloThy1
þþ þþ
þþ þþ
þþ
þ
T, B, NK GM* T, B, NK
PTNþB220þ
BM
Sca-1c-KitThy1
ND
ND
þþ
þþ
T, B (NK?)
ETP
Thymus
Sca-1þc-Kitþ(Thy1lo)
?
ND
/NN
ND
T, B, NK GM*, Erythroid**
Clonal T/B potential Yes (Osawa et al., 1996) Yes (Adolfsson et al., 2001) ND Yes (Kondo et al., 1997) Yes (Gounari et al., 2002) ND
HSC: hematopoietic stem cells; ST-HSC: short-term HSC; ELP: early lymphocyte progenitors (Igarashi et al., 2002); CLP: common lymphoid progenitors (Kondo et al., 1997); ETP: early T lineage progenitor (Allman et al., 2003). *: the GM potential in ELPs and ETPs was found in 3 and 1%, respectively, by methylcellulose assays. **: In a thymic population corresponding to ETPs, a few percent of cells displayed myelo-erythroid potential (Matsuzaki et al., 1993).
LINEAGE COMMITMENT
15
A population containing B/macrophage bipotent progenitors has recently been reported (Tudor et al., 2000). A B220þCD19þCD43þ(IL-7RaþSca-1) population, consisting of 0.02% of total adult bone marrow cells, contained progenitors capable of differentiation into mature B cells and macrophages. This population could not differentiate into T or NK cells by FTOC, however, nor were myeloerythroid colonies generated in the presence of a wide variety of cytokines. In liquid cultures, these cells gave rise only to macrophages. Under B cell conditions, 1% of these cells could form B cell colonies in vitro. Approximately 3% of single cell-derived colonies contained both B cells and macrophages. These data collectively indicate that a fraction of this population is bipotent for B cells and macrophages (Tudor et al., 2000). The in vivo reconstitution activity of this population was not tested, however. The frequency of combined B cell and macrophage differentiation was very low, and the expansion potential of macrophages from this population is minimal, since differentiated macrophages did not proliferate well to form colonies. The contribution of this population to macrophage development and B lymphopoiesis thus appears to be very limited. It is interesting that this population gave rise to macrophages, but not to monocytes, dendritic cells or other myeloerythroid cells. It is possible that this macrophage readout occurs only under specific in vitro conditions, representing plasticity of B cell precursors to reactivate macrophage differentiation programs, as will be discussed later in this chapter. Nonetheless, this finding suggests that an intimate developmental relationship exists between the B cell and macrophage lineages. Similar findings using prospectively isolated fetal progenitors will be discussed. Another unique population has been found within the CD3CD4loCD8 CD25CD44þ early thymic progenitor subset originally reported by Shortman et al. (Wu et al., 1991a). It has been reported that the majority of CD3CD4loCD8CD25CD44þ early thymic progenitors are c-Kitþ, and these c-Kitþ early thymic progenitors can differentiate into T, B, and NK cells (Matsuzaki et al., 1993). Minor myeloerythroid differentiation activity was also observed in this population (Matsuzaki et al., 1993). Allman et al. divided CD3CD4loCD8CD25CD44þ cells into IL-7Ra/loc-Kitþ and IL-7Raþc-Kit/lo fractions; only the former possessed T cell potential by intrathymic adoptive transfer experiments. The former should thus be identical to the c-Kitþ thymic progenitors (Matsuzaki et al., 1993). The reconstitution potential of T and B cells was compared between bone marrow CLPs and thymic IL-7Ra/loc-Kitþ cells: B cell progeny from thymic IL-7Ra/locKitþ cells was 100-fold less than that from CLPs, and the kinetics of donor B cell appearance was significantly delayed. Thymic IL-7Ra/loc-Kitþ cells, termed early T lineage progenitors (ETPs), exhibited sustained production of T cells for 4 weeks in the thymus, whereas T cell production from bone marrow CLPs began to decline 2 weeks after intrathymic transplantation, suggesting
16
DAVID TRAVER AND KOICHI AKASHI
that ETPs are more potent for T cell differentiation than CLPs. This data, however, does not fit the biological potential of CLPs in the original report (Kondo et al., 1997), in which T cell differentiation peaked at 5 weeks after intravenous transplantation of CLPs. Ig-DH-JH rearrangement was found in both CLPs and IL-7Ra/loc-Kitþ cells, whereas TCR-Db1-Jb1 rearrangement was only found from IL-7Ra/loc-Kitþ cells; importantly, B cells derived from this population also rearranged TCR-Db1-Jb1. This result suggests a common origin of T and B cell progeny from thymic IL-7Ra/loc-Kitþ cells, although clonal studies were not performed. Thymic ETPs occasionally formed GM colonies, suggesting that this population is somewhat heterogeneous. How then can IL-7Ra/loc-Kitþ ETPs be integrated into a developmental scheme including CLPs (Kondo et al., 1997) and RAG-1/GFPþSca-1þc-Kitþ ELPs (Igarashi et al., 2002)? Because the IL-7Ra/loc-Kitþ phenotype overlaps with RAG-1/GFPþSca-1þc-Kitþ ELPs that do not express IL-7Ra, and because both populations retain minimal myeloid colony-forming activity, thymic ETPs may be directly derived from RAG-1/GFPþSca-1þc-Kitþ cells and not necessarily via bone marrow CLPs (Allman et al., 2003). However, since the myeloid potential of ETPs (Allman et al., 2003) or ELPs (Igarashi et al., 2002) was observed in only a fraction of each population and was not proven to be associated with their T and B cell potential, they are still heterogeneous and could contain myeloid progenitor contaminants due to their phenotypic overlap. Allman et al. also showed that Ikaros/ mice that display a specific and early arrest in B cell development (Wang et al., 1996) possess IL-7Ra/loc-Kitþ cells but not CLPs (Allman et al., 2003). These data were interpreted to suggest that CLPs are progenitors mainly for B cells, whereas ETPs may directly originate from HSCs or multipotent progenitors, and may be responsible mainly for T cell development (Allman et al., 2003). However, it is difficult to define precursor/progeny relationships based on targeted gene disruptions, since each gene could play different roles in different lineages (Weissman, 1994). Ikaros/ mice display impaired longterm HSC activity and decreases in the number of Flt-3þSca-1þc-Kitþ progenitor cells (Nichogiannopoulou et al., 1999) that should contain RAG1/GFPþSca-1þc-Kitþ ELPs (Igarashi et al., 2002). Despite significant reductions in primitive progenitor and stem cell numbers, Ikaros/ mice possess relatively normal numbers of myeloerythroid colonies (Nichogiannopoulou et al., 1999), suggesting a compensatory mechanism in vivo. Normal numbers of thymic IL-7Ra/loc-Kitþ cells in Ikaros/ mice could thus be due to similar compensatory mechanisms in the thymus. These data, however, at least provide evidence that bone marrow CLPs and IL-7Ra/loc-Kitþ ETPs are phenotypically and functionally different. The lineal relationships between these populations remain to be determined. T cell precursors that seed the thymus from the bone marrow have been
LINEAGE COMMITMENT
17
intensively characterized (Mori et al., 2001). Two to 4 days after intravenous transplantation of whole bone marrow cells into irradiated hosts, donor-derived cells in the thymus were all CD25c-Kit cells. This surface phenotype is different from either CLPs or IL-7Ra/loc-Kitþ cells, although c-Kit expression in progenitor and stem cells could be downregulated upon rapid expansion (after 5-FU treatment, for example) (Doi et al., 1997; Randall and Weissman, 1997). The CD25c-Kit population predominantly differentiated into T and B cells by secondary intravenous transplantation into congenic hosts (Mori et al., 2001). In contrast, when whole bone marrow cells were injected directly into the thymus, bone marrow cells proliferated and displayed not only lymphoid but also myeloid differentiation in secondary hosts after intravenous transplantation, indicating that the thymic environment does not eliminate cells with myeloid progenitor potential (Mori et al., 2001). Therefore, the thymus appears to normally act as a filter, allowing lymphoid but not myeloid or multipotent progenitors to seed the thymic microenvironment. It is thus possible that the IL-7Ra/loc-Kitþ population is formed after the selective expansion of thymus-seeding bone marrow progenitors. It is critical to test directly whether intravenously injected CLPs or RAG-1/GFPþSca-1þc-Kitþ ELPs can reconstitute IL-7Ra/loc-Kitþ ETPs in the thymus, and whether IL-7Ra/loc-Kitþ ETPs can clonally differentiate into both T and B cells. VII. Common Myeloid Progenitors as the Counterpart of CLPs
As has been noted, the generation of multilineage CFU-Mix colonies led to the notion of a common myeloerythroid progenitor. Since HSCs or multipotent progenitors can also form CFU-Mix colonies, this is not direct evidence of their existence. With the discovery of CLPs, and the fact that no myeloerythroid potential existed within the IL-7Raþ bone marrow fraction, myeloid-restricted progenitors were searched for by cell surface marker within the IL-7Ra fraction of mouse bone marrow (Akashi et al., 2000). By plating various phenotypic IL-7Ra fractions into methylcellulose cultures, the vast majority of myeloid colony-forming activity was found within a IL-7RaLinSca-1cKitþ population that does not overlap with the phenotype of HSCs or CLPs. This fraction was further divided into three functionally distinct myeloid progenitor populations: FcgRII/IIIloCD34þ common myeloid progenitors (CMPs), FcgRII/IIIloCD34 megakaryocyte/erythrocyte-restricted progenitors (MEPs), and the FcgRII/IIIhiCD34þ granulocyte/monocyte-restricted progenitors (GMPs) (Fig. 3). CMPs gave rise to all myeloerythroid colony types in vitro including CFU-Mix, GMPs generated only GM-affiliated colonies (CFU-G, CFU-M, and CFU-GM), and MEPs generated only MegE-affiliated colonies (BFU-E, CFU-Meg, and CFU-MegE). Lineal studies demonstrated that CMPs differentiated into phenotypic GMPs and MEPs;
18
DAVID TRAVER AND KOICHI AKASHI
both daughter populations were replated and generated only GM- or MegErestricted progeny, respectively. The majority of single CMPs generated both GM- and MegE-related progeny in two-step culture assays (Akashi et al., 2000). Upon in vivo transfer, these populations displayed short-term production of lineages corresponding to their in vitro activities, indicating that they do not appreciably self-renew (Na Nakorn et al., 2002). These three myeloid progenitor subsets likely represent the major pathways for myeloerythoid cell differentiation since very little colony-forming activity exists outside of the IL-7RaLinSca-1c-Kitþ fraction in steady-state bone marrow. These data also indicate that the commitment of CMPs toward the megakaryocyte/erythrocyte (MegE) or the granulocyte/macrophage (GM) lineages are mutually exclusive events, since MEPs and GMPs never produced colony types outside of their noted potentials (Fig. 1). From the differentiation model illustrated in Fig. 1, it is logical to assume that GMPs and MEPs give rise to monopotent precursors. Some data suggest that this is indeed the case for at least megakaryocyte and mast cell development. Megakaryocyte-restricted progenitors (MKPs) were identified within the IL-7RaLinSca-1c-Kitþ Thy1.1 marrow fraction using an additional CD9 surface marker (Nakorn et al., 2003). MKPs were found to generate only megakaryocytes in vitro and could give rise to platelets for approximately 3 weeks when transplanted into mice. MKPs could be phenotypically isolated following culture of both CMPs and MEPs, suggesting that they are downstream of both progenitor subsets. Mast cell progenitors (MCPs) (Iwasaki and Akashi, 2001) and eosinophil progenitors (EoPs) (unpublished data) were similarly identified downstream of GMPs. One potential caveat to both studies is that, by five-color FACS, only certain combinations of surface markers can be simultaneously analyzed. It will therefore be of interest to expand these studies to nine-color FACS, for example, to simultaneously visualize MKP and MCP cell surface profiles within the context of the markers used to isolate the CMP, MEP, and GMP progenitor subsets. Similar approaches will likely yield monopotent progenitors for erythrocytes, monocytes, and granulocyte subsets. VIII. Lineage Priming by Promiscuous Gene Expression in Multipotent Stem and Progenitor Cells
The ability to prospectively isolate lineage-restricted progenitor subsets representing the major hematopoietic branchpoints enables analysis of the molecular mechanisms of lineage commitment. For genetic programs to be activated, chromatin structures that allow RNA polymerase to initiate transcription are required (Berger and Felsenfeld, 2001; Felsenfeld et al., 1996). It has been shown that the activation of chromatin remodeling can occur prior to significant expression of genes in the region of interest (Kontaraki et al.,
LINEAGE COMMITMENT
19
2000; Weintraub, 1985). These results led to the hypothesis that open chromatin structure is maintained in early hematopoietic progenitors, enabling multilineage differentiation programs to be readily accessible (Cross and Enver, 1997). This ‘‘priming’’ of genes affiliated with multiple lineages would then afford flexibility in cell fate decisions and allow multipotent precursors to rapidly respond to environmental cues. If many genes are, in fact, primed at multi- or oligopotent progenitor stages, these progenitors should then ‘‘promiscuously’’ express genes of multiple lineages at the single-cell level. This hypothesis was first tested in myeloerythroid precursors by using a multipotential myeloid cell line, FDCP-mix. In this line, activation of the b-globin locus control region, assayed by erythroid-specific DNase I hypersensitive sites, occurs prior to erythroid commitment (Jimenez et al., 1992). Furthermore, single FDCP-mix cells coexpress a variety of genes related to the GM and MegE lineages, including MPO and b-globin (Hu et al., 1997). The coexpression of MPO and b-globin was subsequently found in a fraction of human LinCD34þ cells (Hu et al., 1997) and in murine intraembryonic hematopoietic progenitors in the aorta–gonad–mesonephros region (Delassus et al., 1999). These limited data support the lineage priming model; remaining questions are whether promiscuous gene expression is found in normal stem and progenitor cells in vivo, and whether this activity is important in cell fate decisions and the progressive restriction of fate potentials along the hematopoietic hierarchy. These issues have been addressed in purified progenitor populations at both the single-cell and population levels by RT-PCR and oligonucleotide microarrays, respectively. IX. Lymphoid and Myeloid Promiscuity Demonstrated by Single-Cell Analyses
Since CMPs possess both myeloid and erythroid differentiation potentials and give rise to MEPs and GMPs with restricted, mutually exclusive potentials, highly purified single progenitors were analyzed for gene-expression profiles (Miyamoto et al., 2002). Virtually all single GMPs expressed GM-related genes such as MPO and granulocyte colony-stimulating factor receptor (G-CSFR), but did not express MegE-related genes such as b-globin or EpoR. Conversely, all single MEPs expressed b-globin and/or EpoR but not MPO or G-CSFR. In this way, the genetic ‘‘fingerprints’’ of commited GMPs and MEPs were identified. In marked contrast, 60% of single CMPs coexpressed all of these GM- and MegE-affiliated genes. Analysis of additional myeloerythroid transcription factors at the single-cell level displayed a similar pattern (Miyamoto et al., 2002): More than 50% of single CMPs expressed both PU.1, a master gene for GM and B cell development (McKercher et al., 1996; Scott et al., 1994) and NF-E2, a critical gene for erythroid/megakaryocyte differentiation and/or survival (Romeo et al., 1990; Shivdasani et al., 1995). These data
LINEAGE COMMITMENT
21
directly demonstrate that priming of many myeloerythroid genes occurs in CMPs and that quenching of gene expression inappropriate for GM and MegE-related programs occurs in downstream MEPs and GMPs, respectively (Fig. 5). Lineage promiscuity in lymphoid progenitor populations has similarly been evaluated (Miyamoto et al., 2002). In this study, expression of the T lymphoid genes, GATA-3 and CD3d, and the B lymphoid genes, l5 and Pax-5, were analyzed. GATA-3 is required for the development and/or survival of T cellcommitted precursors (Ho et al., 1991; Ting et al., 1996) and CD3d for proper functioning of the T cell receptor (van den Elsen et al., 1985). Pax-5 is a B-cellrelated transcription factor (Horcher et al., 2001; Nutt et al., 1999) and l5 (Sakaguchi and Melchers, 1986) is indispensable for preB cell receptor formation (Karasuyama et al., 1994). Virtually all single proB cells expressed l5 and Pax-5 but not GATA-3 or CD3d, whereas single proT cells expressed only GATA-3 and CD3d. In contrast, 20% of single CLPs coexpressed all of these lymphoid genes, indicating the existence of promiscuous gene expression at the CLP stage (Miyamoto et al., 2002) (Fig. 5). Cells with lineage promiscuous gene expression were then shown to be capable of differentiation into multiple lineages. Mice harboring an enhanced green fluorescent protein (EGFP) reporter knocked-in to the murine lysozyme M (LysM) locus (Faust et al., 2000) were used to obtain progenitors with active expression of LysM. In the myeloid pathway, 60% of CMPs expressed a significant level of LysM/GFP. Both LysM/GFPþ and LysM/GFP CMPs expressed erythroid b-globin demonstating coexpression of myeloerythoid genes, and displayed MegE differentiation in vitro at equal efficiencies (Miyamoto et al., 2002). In the lymphoid pathway, the effect of pTa gene expression on B cell differentiation potential was assayed using pTa/hCD25 transgenic mice (Gounari et al., 2002) (also see the previous section). Both pTa/hCD25þ and pTa/hCD25 CLPs displayed similar B cell potentials, and expression profiles of CD3d, GATA-1, Pax-5, and l5 by single cell RT-PCRs were identical (Miyamoto et al., 2002). Primed lysozyme M and pTa transcripts, therefore, do not impair cellular viability nor do they necessarily mark Fig 5 Myeloid and lymphoid promiscuity in normal hematopoietic progenitors. Single cell mutiplex-RT-PCR assays for myeloid-related (b-globin and EpoR for erythroid, G-CSFR and MPO for myelomonocytic) and for lymphoid-related genes (l5 and Pax-5 for B lymphoid, GATA-3 and CD3d for T lymphoid). The red rectangles indicate lineage promiscuous expression and white ones indicate no expression. More than 50% of single common myeloid progenitors (CMPs) coexpress both erythroid and myelomonocytic genes, and 20% of single common lymphoid progenitors (CLPs) coexpress both B and T lymphoid-related genes. These data strongly suggest that expression of lineage-related genes precedes commitment, and therefore downregulation of genes of unselected lineage might be important for bipotent progenitors to ultimately commit to certain lineages. (See Color Insert.)
22
DAVID TRAVER AND KOICHI AKASHI
commitment to myelomonocytic or T cell fates, respectively. This evidence indicates that promiscuous gene expression likely plays a key role in providing flexibility in oligopotent precursors and that priming inappropriate to particular lineages is quenched upon differentiation (Miyamoto et al., 2002). X. Fate Choices Made by Combinations of Instructive Signals at Lineage Promiscuous Stages
Single progenitor cells subjected to RT-PCR analyses revealed considerable heterogeneity of gene expression at the oligopotent CMP and CLP stages. Given the snapshotlike nature of these assays, the diversity within each fraction could represent fluctuation of expression in individual cells or distribution of stable expression patterns. Lineage promiscuity might represent a competition of lineage programs at levels below detection or at ‘‘floating’’ levels, which may be a prelude to exclusive commitment. In priming stages, multiple differentiation programs might collaborate or compete with each other until one becomes dominant. These may include crosstalk among transcription factors or transcriptional complexes. Transcription factor activity can be potentiated (Zhang et al., 1997) or suppressed (Sieweke et al., 1996; Zhang et al., 2000) by interaction with other transcription factors. Changes in levels of key transcription factors (DeKoter and Singh, 2000; Kulessa et al., 1995) could also be critical for lineage decisions. Previous work has suggested that transcription factors are critical for lineage commitment decisions. By using bi- or multipotent cell lines, it has been reported that overexpression of transcription factors, including PU.1, GATA, and C/EBP, results in the preference of one lineage fate from a choice of several (DeKoter and Singh, 2000; Kulessa et al., 1995; Nerlov and Graf, 1998; Nerlov et al., 1998; Scott et al., 1997). Some studies suggest that that the mechanism of ‘‘lineage instruction’’ by transcription factors should also include ‘‘lineage exclusion,’’ where the suppression of specific differentiation programs may be as important as ‘‘lineage specification’’ (Rothenberg and Dionne, 2002). Specific lineage exclusion by specific transcription factors may be important to ‘‘stabilize’’ fate potentials upon commitment, presumably by alteration of chromatin. Possible interactions of two competitive transcription factors at primitive progenitor stages are illustrated in Fig. 6. A. PU.1 and GATA-1 in Hematolymphoid Commitment One of the most important molecular examples of fate instruction investigated so far is the interaction between PU.1 and GATA-1. PU.1 is expressed in myeloid cells, B cells, and NK cells, but not in erythrocytes or T cells. PU.1 is expressed in HSCs at a low level, and its expression increases in CMPs and GMPs, but is absent in MEPs (Akashi et al., 2000; Miyamoto et al., 2002).
LINEAGE COMMITMENT
23
Fig 6 Schematic representation of hypothesis of lineage commitment and lineage promiscuity. In this model, commitment is operated if cells express more than threshold levels (broken line) of either of the transcription factors. Transcription factors A and B are simultaneously expressed at low levels at the bipotent stage (lineage promiscuity), and their expression levels may be fluctuated. Once commitment begins, the unused programs will be downregulated, and if either of TFs is upregulated beyond a threshold, their expression is stabilized, presumably by autoregulation. The upregulation of either of TFs might also exclude unrelated developmental programs in order to stabilize their lineage fate choice.
In the lymphoid pathway, PU.1 is expressed in CLPs and proB cells, but not in proT cells (Miyamoto et al., 2002). PU.1 binds to many myeloid gene promoters including the G-CSFR, GM-CSFR, M-CSFR CD11b, and MPO genes to regulate their expression (for review, see Tenen et al., 1997). A 1997 study reported that PU.1 also regulates expression of the IL-7R (Scott et al., 1997), which is necessary for T and B cell development (Akashi et al., 1997; Peschon et al., 1994; von Freeden-Jeffry et al., 1997). PU.1 knockout mice display variable anemia and lack all leukocytes, including monocytes, neutrophils, and B cells (Scott et al., 1994). Mice reconstituted with PU.1/ fetal liver cells exhibit a reduced number of NK cells in addition to loss of T and B cells (Colucci et al., 2001). These findings suggest that the PU.1 may play a critical role in the differentiation of HSCs into CLPs, and of CMPs into GMPs.
24
DAVID TRAVER AND KOICHI AKASHI
GATA-1 is an essential transcription factor for maturation of both megakaryocytic and erythroid precursors. GATA-1 knockout studies suggest that GATA-1 is necessary for terminal differentiation of erythrocytes and platelets (Fujiwara et al., 1996; Shivdasani et al., 1997). GATA-1 is expressed in HSCs at a low level (Akashi et al., 2000; Miyamoto et al., 2002), and its expression increases in CMPs and MEPs. GMPs or CLPs do not express GATA-1. In chickens, forced expression of GATA-1 reprograms myb-ets transformed progenitors into the erythroid, eosinophilic, and megakaryocytic pathways. During normal hematopoietic development, PU.1 expression increases as stem cells commit to the myeloid lineage, and PU.1 expression declines with erythroid differentiation as GATA-1 expression increases. It is important to understand whether the low-level expression of PU.1 and GATA-1 in HSCs represents an early stage of commitment. When GATA-1 is introduced into HSCs at a high expression level comparable to that seen within MEPs, HSCs immediately lose their self-renewal activity and commit into the MegE lineage (Iwasaki et al., 2002). It is thus highly likely that at the low expression levels normally observed in HSCs, these transcription factors do not exert lineage decisive effects. This, in turn, suggests that changes in expression levels of each transcription factor may be critical for lineage commitment. In cell line studies, PU.1 suppresses GATA-1 activity to block erythroid differentiation (Nerlov and Graf, 1998). Conversely, GATA-1 inhibits binding of PU.1 to cJun, a critical coactivator of PU.1 transactivation of myeloid promoters (Nerlov et al., 2000; Zhang et al., 1999, 2000). This mutually antagonizing effect of PU.1 and GATA-1 may play an important role in the GMP vs MEP commitment at the CMP stage. Expression levels of PU.1 and GATA-1 may be critical for cell fate decisions at hematopoietic branchpoints. For example, in a bipotent cell line, high expression levels of PU.1 instructed macrophage differentiation, whereas B cell differentiation occurred at low levels (DeKoter and Singh, 2000). In addition, once upregulated, GATA-1 and PU.1 can stabilize their own expression by positive autoregulation (Chen et al., 1995; Zhang et al., 1999). The upregulation of GATA-1 or PU.1 itself plays a critical role in exclusion of unselected lineages. A ‘‘lineage exclusive’’ effect has been clearly reported for PU.1 in T cell development (Anderson et al., 2002). In this study, fetal liver cells were retrovirally transduced with PU.1, and were cultured in fetal thymic organ culture (FTOC) systems (Anderson et al., 2002). Enforced PU.1 severely inhibited development of a/bT, g/dT, and B cells, but allowed macrophage differentiation. T cell development was blocked at the CD25þCD4CD8 stage. These immature T cell progenitors obtained in the primary FTOC could differentiate into macrophages when they were transferred into another FTOC culture system containing high oxygen levels. The reason why PU.1 inhibited B cell development may be related to the finding that high PU.1
LINEAGE COMMITMENT
25
expression directs macrophage commitment at the expense of B cells (DeKoter and Singh, 2000). This lineage exclusive effect has also been reported in the analysis of ectopic GATA-1 expression in GM and lymphoid development (Iwasaki et al., 2002). ProB cells or GM-committed cells retrovirally transduced with GATA-1 did not differentiate into lymphoid cells or GM cells, but immediately underwent apoptotic cell death in vitro (Iwasaki et al., 2002). Enforced expression of Bcl-2 in these cells did not prevent apoptosis. Enforced expression of hGM-CSFR in GATA-1þ GM-committed cells did not restore their GM differentiation (Iwasaki et al., 2002). Thus, GATA-1 appears to directly inhibit lymphoid and GM differentiation rather than inhibit ‘‘permissive’’ survival signals. Mechanisms of differentiation arrest and apoptosis induction remain to be elucidated. Similar competition of lineage programs could be involved at all of branchpoints of hematopoiesis. B. Notch1 in T Cell Commitment Notch genes encode a highly conserved family of transmembrane receptors that regulate cell fate decisions in many developmental pathways (for review, see Fleming, 1998; Robey, 1997). Notch signaling is initiated by ligand binding, including Jagged1, Jagged2, and Delta, upon which Notch is proteolytically cleaved to release its intracellular domain (NICD). NICD, the activated form of the Notch receptor, translocates into the nucleus and pairs with the murine transcription factor CSL (NICD pairs with CBF1 in humans, Su(H) in Drosophila, and Lag-1 in Caenorhabditis elegans). CSL is a DNA-binding protein that normally represses transcription by interacting with several corepressor complexes. The binding of NICD converts CSL into a transcriptional activator and induces the expression of target genes, such as the Hairy Enhancer of Split (HES) family of transcriptional repressors. The HES proteins modulate the activity of tissue-specific basic helix–loop–helix (bHLH) transcription factors, further propagating the effects of Notch signaling. Recent studies show an essential role of Notch1 signaling in the commitment of lymphoid progenitors to the T cell lineage in the thymus (for review, see Anderson et al., 2001; von Boehmer, 1999). Notch1 is not expressed in B cell progenitors such as proB and preB cells (Pui et al., 1999), whereas it is highly expressed in immature thymic T cells (Hasserjian et al., 1996; Washburn et al., 1997). Targeted conditional disruption of Notch1 (Radtke et al., 1999) or of its downstream effector Hes1 (Tomita et al., 1999) arrests T cell development at the earliest thymic stage. Interestingly, B cell development was considerably facilitated in Notch1deficient mice. In the thymus, Notch1/ cells differentiated mainly into B cells where B lymphopoiesis is normally minimal. Conversely, reconstitution of bone marrow cells retrovirally transduced with activated Notch1 showed that ectopic Notch1 causes a persistent block in early B cell differentiation and
26
DAVID TRAVER AND KOICHI AKASHI
rapid emergence of an immature bone marrow T cell population (Pui et al., 1999). In human CD34þ cord blood cells, Notch1 signaling promotes T and NK development, but inhibits B cell differentiation in vitro (Jaleco et al., 2001). Together, these data suggest that Notch1 may play a decisive role in T versus B lymphocyte commitment, although this effect has not directly been tested at the bipotent CLP stage. Additionally, within commited T cell precursors, activated Notch1 supports abT cell development at the expense of gdT cell differentiation (Washburn et al., 1997). Within abT cells, activated Notch1 skewed differentiation toward CD8þ and away from CD4þ T cells (Robey et al., 1996). Thus, Notch1 appears to play a role at multiple checkpoints in T cell development. How can Notch1 exert such decisive effects along the lymphocyte maturational pathway? One possible mechanistic interpretation is that Notch1 provides permissive signals, such as cell survival or proliferation signals (Jehn et al., 1999; von Boehmer, 1999), since enforced Notch1 signaling stimulated HSC self-renewal in vitro (Varnum-Finney et al., 2000) and blocked TCR-mediated T cell apoptosis (Jehn et al., 1999). Thus, Notch signaling in hematolymphopoiesis may be to maintain cellular viability. In this context, Notch signaling may preferentially support the survival of CD8þ abT cells (von Boehmer, 1999). However, the mechanism by which ectopic Notch1 excludes B cell development remains unknown. It is also important to analyze the interactions with molecules downstream of Notch1 that are essential for T cell development (i.e., HES-1) (Kaneta et al., 2000; Tomita et al., 1999) and B cell development (i.e., E47 (Ordentlich et al., 1998) and CSL reference). The pTa gene was identified as a transcriptional target of Notch signaling in T cells (Deftos et al., 2000). pTa encodes a transmembrane protein that pairs with the nascent TCRb chain to form the essential pre-TCR signaling complex in thymocytes (Fehling et al., 1995). pTa expression is primed in CLPs, representing ‘‘lymphoid lineage promiscuity’’; the upregulation of pTa coincides with irreversible T cell lineage commitment in both murine and human thymic precursors (Gounari et al., 2002; Miyamoto et al., 2002). pTa is required for ab but not gd T cell development (Fehling et al., 1995). This facilitation of ab lineage commitment is believed to occur by instructive signaling from the pre-TCR (Aifantis et al., 1998). The pTa enhancer can be activated by Notch signaling and contains binding sites for its nuclear effector, CSL (Reizis and Leder, 2001). Mutation of CSL-binding sites abolished enhancer induction by Notch and delayed the upregulation of pTa transgene expression during T cell lineage commitment. These results strongly suggest that Notch1 signals play a key role in T cell specification through upregulation of pTa via the CSL signaling pathway (Reizis and Leder, 2001). It is critical to analyze directly the physiological expression level and distribution of Notch1 protein in CLPs in order to test whether Notch signaling dictates the T versus B fate decision.
LINEAGE COMMITMENT
27
C. Pax-5 in B Cell Commitment Pax-5, a key molecule in B cell differentiation (Nutt et al., 1999), also plays a critical role in lymphoid commitment. In steady-state hematopoiesis, Pax-5 expression initiates at the CLP stage, is upregulated in proB cells, but is undetectable in proT or myeloid cells (Miyamoto et al., 2002). Pax-5 appears to maintain late B cell differentiation through several mechanisms including class switching of the IgH gene, regulation of immunoglobulin 30 enhancers, and transcriptional repression of J-chain genes (for review, see Busslinger et al., 2000). Upregulation of Pax-5 in proB cells is thus likely important to restrict differentiation into a B cell fate. Purified pro-B cells from Pax5-deficient (Pax5/) mice (having recombined D-VJ loci of IgH genes and expressing the l5, E2A, VpreB, Iga, and Igb genes) can differentiate into T cells, NK cells, granulocytes, macrophages, and osteoclasts, as well as B cells in vitro (Nutt et al., 1999). In this report, however, the presence of D-VJ IgH gene rearrangements in the nonlymphoid progeny of assayed pro-B cells was not tested. In contrast, in an adoptive transfer assay, injection of 0.5-1 108 Pax5/ proB cells into sublethally irradiated RAG-2-deficient mice resulted in reconstitution of T cells with D-VJ rearrangement of IgH genes, but not in reconstitution of myeloid cells (Rolink et al., 1999). The discrepancy of myeloid cell production between the in vitro and in vivo assays may be because the myeloid differentiation potential of Pax-5/ proB cells is limited and below detectable levels in vivo. Furthermore, the efficiency of T cell differentiation from Pax-5/ proB cells is quite low when compared to CLPs, since 1 103 IL-7Raþ CLPs were minimally required to fully reconstitute T cell development in sublethally irradiated Rag-2/ mice (Kondo et al., 1997). Accordingly, it is possible that only a minor fraction of Pax-5/ proB cells could commit to the T cell lineage in vivo. Nonetheless, these data indicate that, even after the onset of B lineage-associated genes transcription, differentiation programs for other lineages (at least for the T cells) remain accessible. Pax-5/ proB cells can therefore be considered to maintain CLP potential. This is compatible with recent data showing that a fraction of bone marrow B220þ cells maintain the expression of pTa and T cell potential (Gounari et al., 2002). The reduced levels of Pax5 observed in vivo in EBF/E2A double heterozygote mice suggests that these factors are upstream of Pax-5 and may regulate Pax-5 expression in B cells (O’Riordan and Grosschedl, 1999). Accordingly, EBF has been shown to bind the Pax5 promoter and induce its transcription. In mice lacking one copy of the transcription factors EBF and E2A, other genes besides Pax-5 were affected. Specifically, expression of l5, VpreB, Rag2, and mb-1 genes was substantially reduced (O’Riordan and Grosschedl, 1999). These data suggest that E2A and EBF are expressed prior to B lineage commitment and initiate transcription of many B lineage specific genes, and
28
DAVID TRAVER AND KOICHI AKASHI
that the induction of Pax5 is an important step in the pathway to B cell commitment. Does Pax-5 have an instructive effect in B cell commitment? A 2001 report formally showed that Pax-5 plays a critical role in T versus B cell development. Pax-5 was conditionally excised by CD19-cre or Mx-cre expression in mice carrying a floxed Pax-5 allele. These conditional Pax-5-deficient mice displayed preferential loss of mature B cells, inefficient lymphoblast formation and reduced serum IgG levels (Horcher et al., 2001). Furthermore, when Pax-5 was deleted from mature B cells, they rapidly lost B cell markers such as CD19, CD22, CD40, MHC class II, and IgD, but upregulated M-CSFR expression, like Pax-5/ proB cells. Rather than instructing B lymphoid commitment from CLPs, these data suggest that Pax-5 may be critical in ‘‘stabilizing’’ committed B cell precursors, in part, by suppressing myeloid gene expression. It has also been reported that retroviral transduction of Pax-5 into bone marrow progenitors profoundly inhibited myeloid colony formation, presumably by blocking signals from myelomonocytic cytokine receptors such as G-CSFR and GM-CSFR (Chiang and Monroe, 1999). However, in a later study, enforced Pax-5 expression did not suppress myeloid fates (Cotta et al., 2003). The inconsistency between these studies may be due to differences in expression levels of ectopic Pax-5. In a 2002 study, a heterozygous knock-in mouse carrying a Pax-5 gene under the control of the Ikaros locus was reported (Souabni et al., 2002). In this mouse, transgenic Pax-5 is expressed in HSCs as well as in myeloerythroid and lymphoid progenitors. Interestingly, enforced expression of Pax-5 inhibited T lymphopoiesis, whereas it augmented B lymphopoiesis as expected. Myelopoiesis was largely normal, although MegE differentiation was slightly reduced. Interestingly, enforced expression of Pax-5 in Pax-5/ proB cells suppressed Notch1 expression (Souabni et al., 2002), possibly explaining how T lymphopoiesis is inhibited. Thus, enforced Pax-5 does not possess a lineage instructive effect in uncommitted multipotent progenitors but rather functions as a master regulator of B cell development only after cells commit to the lymphoid lineages. In normal hematopoiesis, Pax-5 is expressed at a low level in CLPs together with T lymphoid genes representing their lymphoid lineage priming (Fig. 4) (Miyamoto et al., 2002). It will be interesting to test the effects of overexpression or suppression of Pax-5 and Notch1 at the CLP stage in order to understand their roles in T versus B lymphoid commitment. XI. Lineage Plasticity in Lymphoid Progenitors: Fate Choices are Reversible
The existence of promiscuous gene expression programs at the major hematopoietic branchpoints suggests that the fate potentials of each progenitor may reflect differential accessibility to specific transcriptional programs
LINEAGE COMMITMENT
29
(Akashi et al., 2003). What events are required for the transition from priming to committed stages? It is conceivable that both the upregulation of genes related to the selected lineage and the downregulation of genes irrelevant to the selected lineage are required for commitment. If the expression of critical genes is deregulated by transforming events, for example, do progenitors differentiate to lineages outside their physiological potential? Evidence suggests that this phenomenon can, in fact, occur (Graf, 2002). Lineage conversion was originally reported in murine B cell lines: PreB cell lines transformed by the Abelson virus differentiated into macrophages following treatment with a DNA demethylating agent, 5-azacytidine (Boyd and Schrader, 1982), and B cell lines immortalized with Em-myc transgenes differentiated into macrophages upon overexpression of v-raf (Klinken et al., 1988). Thus, committed B cell precursors harbor latent myelomonocytic potentials that can be activated by specific genetic alterations. Conversely, granulocytic conversion was reported in a pre-B lymphoma line (Lindeman et al., 1994). These phenomena have postulated a ‘‘close’’ relationship between the B and GM lineages, but it is unclear whether the latent GM potential in B cell lines represents residual oligopotentiality maintained from upstream progenitors or whether B and GM lineages utilize similar genetic programs. In a fraction of human acute myelogenous leukemia (AML), leukemic blasts possess lymphoid markers including monoclonal rearrangement of TCR or Ig genes (Cheng et al., 1986). Conversely, acute lymphoblastic leukemia (ALL) or even myeloma cells occasionally express myeloid markers (Akashi et al., 1991; Grogan et al., 1989). Conversions between lymphoid and myeloid leukemias have also been seen (Murphy et al., 1983; Stass et al., 1984). These ‘‘mixed’’ leukemias have been ascribed to nonphysiological differentiation induced by oncogenic events (lineage infidelity) (McCulloch, 1987; Smith et al., 1983). Recent studies demonstrate that lineage conversion can be induced in committed progenitors simply by enforcing or eliminating single differentiation-related genes such as cytokine receptors and transcription factors. A. Myelomonocytic Conversion of Lymphoid-commited Progenitors by Instructive Cytokine Signals It has been suggested that cytokine signals do not play a role in myeloid lineage determination: Mice with targeted mutations in myeloid cytokines or their receptors do not display a complete loss of specific lineages (Gillessen et al., 2001; Lieschke et al., 1994; Stanley et al., 1994; Wu et al., 1995), and myeloerythroid progenitors expressing transgenic receptors for myeloid cytokines, such as human granulocyte/macrophage colony-stimulating factor (hGM-CSF) (Nishijima et al., 1995), human granulocyte colony-stimulating factor (hG-CSF) (Yang et al., 1998, 1999), and murine interleukin-5 (IL-5)
30
DAVID TRAVER AND KOICHI AKASHI
(Takagi et al., 1995), did not affect their physiological fates. Constitutive expression of the activated form of EpoR in bone marrow cells also supports GM differentiation (Pharr et al., 1993). Mice with a targeted chimeric mutation in the G-CSF receptor (G-CSFR), where the cytoplasmic domain is replaced by the cytoplasmic portion of the EpoR, do not display any abnormality in their hematopoietic development (Semerad et al., 1999). Signals from these myeloerythroid cytokine receptors may therefore be largely redundant or may simply serve to enhance survival. Thus, the lineage-specific actions of these myeloid cytokines may rely solely upon the lineage-specific expression of their cognate receptors. At the level of CLPs, however, myelomonocytic conversion can be induced by ectopic signals from myeloid-related cytokines. GM conversion by ectopic IL-2 or retrovirally induced GM-CSF signals was also observed from proT cells with rearranged T cell receptor b genes but not in downstream preT cells or B cell progenitors (King et al., 2002; Kondo et al., 2000). In another study using hGM-CSFRa/bc double transgenic mice, >50% of hGM-CSFRþ CLPs and >20% hGM-CSFRþ proT cells gave rise to granulocytes, monocytes, and/or dendritic cells, but not MegE lineage cells in the presence of hGM-CSF (Iwasaki-Arai et al., 2003). These data collectively suggest that conversion to GM fates by ectopic GM-CSF signals can occur in CLPs and their downstream lymphoid progeny, but that this potential progressively disappears as cells become more mature. During the conversion of CLPs into the myelomonocytic lineage, a number of GM-related cytokine receptors (e.g., G-CSFR, M-CSFR) and transcription factors (e.g., C/EBPa, PU.1) were reactivated, whereas MegE-related genes such as EpoR and GATA-1 were not (Iwasaki-Arai et al., 2003). Thus, GM-CSF signals can activate GM but not MegE differentiation programs, suggesting their GM-specific ‘‘instructive’’ role in lineage commitment. Furthermore, this effect is specifically found with the GM-CSFR, since retrovirally transduced G-CSFR and M-CSFR could not induce GM conversion from CLPs. It should be interesting to test whether the transcription factors downstream of the GM-CSFR can similarly induce GM conversion from CLPs. B. Megakaryocyte/Erythrocyte Conversion from Lymphoid-commited Progenitors The loss of GM and MegE potentials in lymphoid cells might occur simultaneously as multipotent stem cells generate CLPs (Kondo et al., 1997) and common myeloid progenitors (CMPs) (Akashi et al., 2000) since each subset displayed mutually exclusive differentiation potentials. If the inducible GM potential in CLPs reflects residual multipotentiality from an upstream progenitor, it is reasonable to expect that MegE conversion could also be induced in CLPs or their lymphoid progeny.
LINEAGE COMMITMENT
31
GATA-1, a critical transcription factor for MegE development, has been reported to instruct MegE and eosinophil commitment. GATA-1 is expressed in erythroblasts, megakaryocytes, eosinophils and, mast cells. The lineage instructive effect of GATA-1 was first demonstrated in a multipotential chicken cell line transformed by the Myb-Ets-encoding E26 leukemia virus (Kulessa et al., 1995). This cell line differentiates to the GM lineages following enforced expression of PU.1 whereas enforced expression of GATA-1 caused erythroid or eosinophilic differentiation (Kulessa et al., 1995). Within the myelomonocytic lineages, overexpression of GATA transcription factors can induce MegE phenotypes (for review, see Graf, 2002). Introduction of GATA-1 into myeloid cell lines induces megakaryocyte differentiation (Visvader et al., 1992) with upregulation of MegE-affiliated genes such as the erythropoietin receptor (EpoR) and a-globin (Seshasayee et al., 1998; Yamaguchi et al., 1998). Furthermore, both GM-restricted colony-forming cells, which are selectively generated in culture, and purified GMPs can give rise to erythroblasts, megakaryocytes, and eosinophils by GATA-1 transduction (Heyworth et al., 2002; Iwasaki and Akashi, 2001). These studies suggest that GATA-1 is sufficient to reactivate the MegE and/or eosinophil differentiation programs in immature myelomonocytic cells. In a recent report, GATA-1 was retrovirally introduced into CLPs (Iwasaki et al., 2002). Strikingly, GATA-1 converted CLPs into the MegE lineages, inducing differentiation of hemoglobinized erythroblasts and mature megakaryocytes even in the absence of Tpo or Epo. Furthermore, GATA-1transduced CLPs could not differentiate into T or B cells in vivo, indicating that ectopic GATA-1 inhibited normal lymphoid differentiation from CLPs. GATA-1 altered the expression profiles of lineage-affiliated genes in CLPs into those observed in MegE-committed MEPs, inducing the upregulation of genes essential for MegE development such as FOG-1, and concomitantly downregulated genes related to the GM and lymphoid lineages including PU.1, Pax5, and IL-7Ra. The reactivation of GATA-1 appears to be sufficient for, and a minimum requirement for, MegE conversion from CLPs (Iwasaki et al., 2002). Together, these data suggest that CLPs are normally lymphoid-restricted because they have downregulated myeloerythroid genes such as GM-CSFR and GATA-1. In turn, latent GM and MegE potentials of CLPs and early T and B lymphoid precursors indicate that the GM and MegE programs are still accessible after physiological lymphoid commitment, presumably by chromatin remodeling. It is of interest to test whether CMPs, the myeloid counterpart of CLPs, possess similar ‘‘plasticity’’ for lymphoid differentiation. Observed plasticity of lineage commitment at the early stages of lymphoid development likely reflects residual multipotency from upstream priming stages. This residual multipotency appears to be latent in normal commitment progenitors, presumably by epigenetic programs that control transcriptional accessibility, as
32
DAVID TRAVER AND KOICHI AKASHI
evidenced by gene expression profiling in microarray studies (see following text). Stabilization of lineage commitment could be achieved by downregulation of master ‘‘instructive’’ genes that ectopically induce lineage conversion as well as the upregulation of gene sets to directly ‘‘exclude’’ other fate choices. XII. Comparison of Gene Expression Profiles among Early Hematopoietic Stem and Progenitor Cells
That promiscuous gene expression exists at each of the major hematopoietic branchpoints suggests that priming of multiple lineage-affiliated programs allows fate choice flexibility at each progenitor stage. The PCR studies that generated these findings used single cells and assayed only partially representative myeloid and lymphoid genes. Thus, a more global view of gene expression, including hematopoietic and nonhematopoietic genes is essential to unravel the complexity of genetic programs within early hematopoietic subsets. Oligonucleotide microarray analyses were thus performed using highly purified long-term HSCs, short-term HSCs, CMPs, and CLPs (Akashi et al., 2003). HSCs expressed a variety of myeloid (GM and MegE-affiliated) but not lymphoid genes. CMPs coexpressed many GM and MegE-affiliated genes, and CLPs coexpressed many T, B, and NK lymphoid-related genes on Affymetrix chips. Thus, genome-wide gene profiling revealed that HSCs predominantly exhibit myeloid promiscuity, and that CLPs and CMPs exclusively possess lymphoid and myeloid priming programs, respectively (Akashi et al., 2003). In short-term HSCs (or multipotential progenitors), both lymphoid and myeloid genes were primed. However, as has been mentioned, myeloid and lymphoid gene coexpression was not assayed at the single-cell level in these cell types. Therefore, these findings in ‘‘short-term HSCs’’ could be due to a combination of heterogeneous expression profiles. Nonetheless, this study strongly suggests that lineage promiscuous priming might be a common transcriptional feature in uncommitted stem and progenitor cells, and that primed genes may represent their full and immediate differentiation potentials (Miyamoto et al., 2002). This genome-wide approach discloses another important ‘‘priming’’ event at the level of HSCs. Primitive HSCs expressing CD45, a hematopoietic cellspecific marker, express approximately 70% of all nonhematopoietic genes, including genes characteristic of neuronal, endothelial, pancreatic, kidney, liver, heart, hair, epithelial, and muscle cell types (Akashi et al., 2003). These nonhematopoietic genes were detectable by nested RT-PCR in CD45þ HCS at the single- to 10-cell levels. This broad transcriptional usage, however, is lost as HSCs generate CMPs and CLPs; these cell types displayed only myeloid and lymphoid expression profiles, respectively.
LINEAGE COMMITMENT
33
These data also demonstrate that HSCs possess transcriptional accessibility for nonhematopoietic genes associated with multiple organ systems (Akashi et al., 2003). Recent reports demonstrate that murine bone marrow contains cells capable of differentiation into multiple organs, including endothelial cells, skeletal and cardiac muscle (Orlic et al., 2001), neurons and glia (Priller et al., 2001), parenchymal liver cells (Lagasse et al., 2000), and/or epithelial cells (Krause et al., 2001), as well as hematopoietic cells. While these reports suggest that the bone marrow may be special in harboring precursors of nonhematopoietic fates, the notion of HSC plasticity was challenged by a study in which mice reconstituted with single, GFPþ HSCs were extensively analyzed for GFP expression in nonhematopoietic tissues (Wagers et al., 2002). These clonal experiments demonstrated that HSCs very rarely contributed to nonhematopoietic fates, suggesting that ‘‘transdifferentiation’’ of HSCs is unlikely in this setting (Wagers et al., 2002). It was also reported that cell fusion can occur during co-culture of embryonic stem (ES) cells with HSCs or neural stem cells (NSCs). Although cell fusion was observed at an extremely rare incidence (104 to 105), ‘‘conversion’’ from NSCs (or HSCs) to other cell types could be obtained through spontaneous generation of hybrid cells rather than epigenetic reprogramming of the somatic stem cells (Terada et al., 2002; Ying et al., 2002). Thus, it is likely that ‘‘transdifferentiation’’ is a rare event under physiological conditions (Lemischka, 2002; McKay, 2002). Transdifferentiation in the settings of increased tissue renewal or tissue damage remains to be precisely addressed using prospectively isolated HSCs. Based on the findings that HSCs normally express many nonhematopoietic genes, it will be similarly interesting to search among these genes for candidate molecules that may instruct nonhematopoietic fate outcomes from bona fide HSCs. XIII. Early Lymphoid Progenitors can Differentiate into Antigen-presenting Dendritic Cells
Dendritic cells (DCs) are bone marrow-derived leukocytes that were initially defined by their high antigen presentation capacities and their ability to prime antigen responsiveness in naive T cells (Banchereau and Steinman, 1998; Hart, 1997). Since monocytes can give rise to DCs in vitro (Inaba et al., 1993), it was initially believed that DCs were of myeloid origin. It is now recognized that DCs develop from both lymphoid and myeloid precursors (Manz et al., 2001). A lymphoid origin for DCs was first reported using early thymocyte progenitors (TPs) (CD4loCD44þCD25c-Kitþ) and thymic proT cells (CD44þCD25þcKitþ). Each population is capable of generating CD8aþ DCs in vivo (Ardavin et al., 1993; Wu et al., 1996). Because the majority of thymic DCs
34
DAVID TRAVER AND KOICHI AKASHI
express CD8aþ, it was proposed that CD8a expression is a marker for DCs of lymphoid derivation, whereas conventional CD8a DCs were of ‘‘myeloid’’ origin. This model appeared to be supported by the fact that mice deficient for the myeloid transcription factors, RelB (Wu et al., 1998) or PU.1 (Guerriero et al., 2000) lack CD8a DCs, while ‘‘lymphoid’’ transcription factors, Ikaros (Wu et al., 1997), or Id2 (Hacker et al., 2003) lack only CD8aþ DC subsets. On the other hand, developmental dissociation of CD8aþ DC and T cells was reported in T cell-deficient c-Kit/ gc/ (Rodewald et al., 1999) or Notch1/ (Radtke et al., 2000) mice, suggesting that CD8a is not necessarily a marker of lymphoid derivation. Each myeloid and lymphoid progenitor subset was thus examined for DC differentiation potential. Interestingly, CMPs could generate both CD8aþ and CD8a DCs (Traver et al., 2000). Both CD8aþ and CD8a DCs were produced from CLPs and CMPs with similar efficiency on a per-cell basis (Manz et al., 2001; Wu et al., 2001). Thus, expression of CD8a is not indicative of a lymphoid origin, and the presence or absence of CD8a expression among DC subsets is likely to reflect maturation status rather than ontogeny. The precursor/progeny relationship between CD8aþ and CD8a DCs, however, is still controversial. Splenic CD8aCD11cþ DCs were reportedly able to give rise to CD8aþCD11cþ DCs (Martinez del Hoyo et al., 2002), but this finding was not supported by another report (Naik et al., 2003). It has also been suggested that the acquisition of CD8a expression is likely to initiate in splenic DC precursors that are CD11c, since CD8aþCD11c spleen cells gave rise to mature CD8aþCD11cþ DCs (Wang et al., 2002). On the other hand, both CD8aþ and CD8a DCs are reported to originate from CD11cþMHCII DC progenitors which were devoid of other myeloid or lymphoid differentiation potential (Martinez del Hoyo et al., 2002). This population was also shown to give rise to interferon (IFN)-g-producing plasmacytoid DCs (PDCs; see following text) (Martinez del Hoyo et al., 2002). These data suggest that the CD11cþMHCII DC progenitors may represent a DC stage independent of DC pathways from CLPs or CMP. It is more likely, however, that CLPs and/or CMPs generate CD11cþMHCII DC precursors that are upstream of mature CD8aþ and CD8a DCs. Interestingly, DC potential is maintained downstream of CLPs in proT cells and downstream of CMPs in GMPs, whereas DC potential is lost once B cell or megakaryocyte/erythrocyte commitment occurs (Manz et al., 2001). Although murine DCs and their precursors are usually isolated from lymphoid organs or bone marrow, human DCs are usually isolated from peripheral blood (for review, see Shortman and Liu, 2002). Human DCs can be derived from CD34þ progenitors, lymphoid restricted progenitors, and from peripheral blood monocytes, suggesting that human DCs similarly derive from both myeloid and lymphoid pathways (Caux et al., 1996; Hao et al., 2001;
LINEAGE COMMITMENT
35
Randolph et al., 1998; Romani et al., 1994; Sallusto and Lanzavecchia, 1994; Young et al., 1995). In both mice and humans, there appears to be no functional difference between lymphoid- and myeloid-derived DCs as evaluated by mixed leukocyte reactions, immunophenotyping, and cytokine production (Manz et al., 2001; Traver et al., 2000). A precursor population that immediately generates DCs capable of producing interferon a was identified in humans (Cella et al., 1999; Grouard et al., 1997; Jarrossay et al., 2001; Kadowaki et al., 2000, 2001) and subsequently in mice (Asselin-Paturel et al., 2001; Bjorck, 2001; Nakano et al., 2001). In addition to the conventional DC markers such as CD11c and MHC class II, these cells express CD45RA. This population has been termed plasmacytoid dendritic cells (PDCs) or DC2 (Liu, 2001). In humans, DCs of this phenotype were reportedly generated from at least M-CSFR-expressing myeloid progenitors (Olweus et al., 1996). On the other hand, human CD34þ cells with enforced Id2 or Id3 expression reportedly differentiated into conventional DCs, but not T, B, or PDCs (Heemskerk et al., 1997; Jaleco et al., 1999; Spits et al., 2000), suggesting that PDCs may have a lymphoid origin. Accordingly, PDCs express genes usually found in the lymphoid lineage such as preTa, 14.1, and Spi-B (Bendriss-Vermare et al., 2001; Spits et al., 2000). In our hands, murine PDC equivalents could be induced from both CLPs and CMPs (unpublished data). Thus, it is likely that PDCs as well as conventional DCs originate from both lymphoid and myeloid pathways. CLPs and proT cells, but not preT or proB cells, can differentiate into DCs (Manz et al., 2001; Traver et al., 2000; Wu et al., 1996). It is interesting to note that DC potential is contained within the same lymphoid precursor subsets that can be converted to myeloid fates by ectopic cytokine signals (Iwasaki-Arai et al., 2003) (see previous text). This correlation may suggest that ‘‘lymphoid’’ DC potential within CLPs and proT is a residual function of latent myeloid potential. It is therefore important to characterize the signals that induce DC commitment from lymphoid progenitors. XIV. Fetal Hematopoietic Progenitors are Not Fully Committed to the Lymphoid and Myeloid Fates
Although the hematopoietic hierarchy and effector cell types produced in fetal life are similar to those in adult blood development, some phenotypic and functional differences exist (Holyoake et al., 1999; Jordan et al., 1995; Morrison et al., 1995; Pawliuk et al., 1996). For example, fetal liver HSCs can generate Vg3þ and Vg4þ T cells (Ikuta et al., 1990) and B-1a lymphocytes (Hayakawa and Hardy, 2000) while adult HSCs cannot. Using surface markers similar to those used to isolate adult progenitor populations, fetal liver counterparts have been prospectively purified. These include the fetal CLPs
36
DAVID TRAVER AND KOICHI AKASHI
(LinIL-7RaþB220/loSca-1loc-Kitlo) (Mebius et al., 2001), CMPs (LinIL7RaSca-1c-KitþAA4.1FcgRII/IIIloCD34þ), GMPs (LinIL-7RaSca1c-KitþAA4.1FcgRII/IIIhiCD34þ), and MEPs (LinIL-7RaSca-1cKitþAA4.1FcgRII/IIIloCD34) (Traver et al., 2001). Each fetal population displays similar differentiation potentials, but, as will be discussed, appear to be somewhat less restricted than their adult counterparts. Clonogenic progenitors for T cells, B cells, and macrophages were demonstrated to exist within the AA4.1þFcgRII/IIIþ fraction in mouse fetal liver (Lacaud et al., 1998). Cumano et al. demonstrated clonogenic B cell and macrophage progenitors within a fetal liver AA4.1þB220Mac-1Sca-1þ fraction, although T cell differentiation potential was not tested (Cumano et al., 1992). B220þc-Kitþ fetal liver cells (also positive for the IL-7Ra chain) differentiated into T cells, B cells, and macrophages at a high frequency (Sagara et al., 1997). Interestingly, IL-7Ra expression is not a definitive marker to exclude cells with macrophage potential in fetal liver hematopoiesis. A fetal counterpart to adult CLPs, IL-7RaþB220/loSca-1loc-Kitlo cells, comprises 0.5 to 1.2% of E12.5 to E14.5 fetal liver cells. These cells are positive for AA4.1 but negative for FcgRII/III, indicating that there is no overlap with the cells reported by Lacaud et al. (1998). The populations reported by Cumano et al. (1992) and Sagara et al. (1997) should include IL-7RaþB220/loSca-1locKitlo cells. In vitro culture of fetal CLPs on S17 stromal layers showed that 5% of single cells differentiated into macrophages and B cells (Mebius et al., 2001). This population never gave rise to myeloerythroid cells other than macrophages. The burst-size of macrophage differentiation appeared minimal (Mebius et al., 2001). Accordingly, injection of fetal CLPs into the livers (Domen et al., 1998) of sublethally irradiated newborn mice showed, T, B, and NK cell-restricted differentiation without detectable macrophage progeny (Mebius et al., 2001). Taken together, these findings suggest that macrophage potential is maintained following commitment into the T/B lymphoid lineages during fetal life. In early myelopoiesis, fetal liver CMPs, which form all myeloerythroid colony types, show a relatively high propensity to differentiate into B cells (Traver et al., 2001). In limiting dilution assays, B cell frequency was 0.8% from fetal CMPs. The B cell potential in fetal CMPs has not been tested at the single-cell level and, therefore, this still could be from a minor contaminant of B cell progenitors in the phenotypic CMP fraction. T cell developmental potential, however, was completely absent as no donor-derived progeny were found following intrathymic injection of 10,000 fetal CMPs. Thus, in the model established by prospective isolation of fetal counterparts of adult progenitors, fetal CMPs and CLPs are placed downstream of HSCs as in adult hematopoiesis, allowing them to maintain a minor potential for B cell and macrophage potentials, respectively (Mebius et al., 2001; Traver et al., 2001) (Fig. 7A).
LINEAGE COMMITMENT
37
Fig 7 A developmental model in fetal liver hematopoiesis. (A) A developmental model based on purification of phenotypic counterparts of adult CMPs and CLPs in the fetal liver (FL). In this model, B cell potential in fetal CMPs and macrophage potential in fetal CLPs represent their relatively incomplete lineage restriction.
The differentiation potentials of single fetal liver LinSca-1þc-Kitþ HSCs and IL-7RaþLinSca-1þc-Kitþ lymphoid progenitors were carefully evaluated by high-oxygen FTOC in the presence of IL-3, IL-7, and SLF (Kawamoto et al., 1997, 2000). This has been termed the multilineage progenitor (MLP) assay and is powerful since it can support myelomonocytic and lymphoid fates from fetal liver progenitors. Unfortunately, this assay is not suitable to evaluate megakaryocyte/erythrocyte potential. Throughout these experiments, single progenitors giving rise only to T and B cells were never found, although T/GM, B/GM, or T/B/GM outcomes were detectable (Kawamoto et al., 1997). Myeloid progeny in this culture system mainly consisted of macrophages, with minor populations of dendritic cells and granulocytes produced. These data led to the proposal of a unique hematopoietic differentiation model that does not include the CLP stage (Katsura, 2002) (Fig. 7B). In this model, T and B lymphoid development is always associated with myelomonocytic development, and originates from the common myelolymphoid progenitor (CMMP) (Fig. 7B). How can we reconcile this model with the conventional developmental scheme based on prospective purification studies? Retrospective studies such as these base upstream developmental sequences on functional endpoints such as colony formation. The ensuing developmental models can only be justified if the assay system is fully permissive for all fate potentials of plated stem and progenitor cells. In the MLP assay system, only 5% of single fetal liver HSCs exhibited multilineage (T/B/GM) readouts. Nonetheless, the fact that T/B only differentiation was never found from single cells raises the possibility that CLPs are not a requisite step in the generation of fetal lymphocytes. As has been discussed, it is highly likely that macrophage potential is well preserved along the early lymphoid pathway in
38
DAVID TRAVER AND KOICHI AKASHI
the fetal liver (Mebius et al., 2001). This may account for the relatively high incidence of lymphoid/myeloid differentiation from fetal progenitors in the MLP assay. Interestingly, the high oxygen concentration used in the MLP assay dramatically promotes macrophage differentiation (Anderson et al., 2002). Therefore, the macrophage potentials of fetal liver cells could also be overestimated by this assay. Another group has subsequently reported that single, adult CLPs frequently gave rise to both T and B but not myeloid cells in the MLP assay (Izon et al., 2001), highlighting an apparent difference between fetal and adult CLP subsets. It will be interesting to determine the developmental boundaries at which the relatively incomplete lineage restriction observed in fetal progenitors become restricted to the lymphoid and myeloerythroid fates. XV. Lymphoid- and Myeloid-restricted Progenitors in Human Bone Marrow
In human hematopoiesis, similar progenitor populations have been isolated by cell surface phenotypes. A population having significant CLP activity has been reported to exist within the LinCD34þCD10þ subset of human bone marrow cells (Galy et al., 1995). Lymphoid potential was determined by reconstitution of human bone and thymus fragments implanted into SCID mice as well as by in vitro culture systems. LinCD34þCD10þThy-1þ multipotent HSC are CD45RA, whereas CD45RAþ LinCD34þCD10þThy-1 CLPs differentiated only into T, B, NK, and dendritic cells (Galy et al., 1995). Similar to mouse CLPs, this population expresses IL-7Ra. Many studies support the existence of human oligopotent myeloid progenitors (de Wynter et al., 2001; Fritsch et al., 1993; Huang et al., 1999; Lansdorp et al., 1990; Olweus et al., 1996, 1997; Rappold et al., 1997). Human counterparts of murine CMPs, GMPs, and MEPs were isolated from human bone marrow and cord blood cells (Manz et al., 2002). All are negative for multiple mature lineage markers, including the early lymphoid markers CD7, CD10, and IL-7Ra, and all are CD34þCD38þ. This CD34þCD38þ fraction was divided by the expression of CD45RA, an isoform of CD45 that can negatively regulate at least some classes of cytokine receptor signaling (Irie-Sasaki et al., 2001), and IL-3Ra, a receptor that, upon activation, supports proliferation and differentiation of primitive progenitors (Kimura et al., 1997). CD45RAIL3Ralo (CMPs), CD45RAþIL-3Ralo (GMPs), and CD45RAIL-3Ra (MEPs) formed distinct myeloid colony types according to their definitions at a high frequency, but possess little or no LTC-IC activity. The FcgRII/III (CD16/ CD32) that distinguishes mouse CMPs and GMPs was not detectable on human myeloid progenitor populations. CMPs give rise to MEPs and GMPs in vitro and a significant proportion of CMPs were demonstrated to possess clonal granulocyte/macrophage and megakaryocyte/erythrocyte potential
LINEAGE COMMITMENT
39
(Manz et al., 2002). Thus, the hierarchical progenitor relationships demonstrated in the mouse also exist in human hematopoiesis and can be prospectively isolated by cell surface phenotype. XVI. Clinical Relevance
Bone marrow transplantation (BMT) into myeloablated individuals often gives rise to graft versus host disease (GVHD) when using total bone marrow or mobilized peripheral blood cells. This is due to the transfer of allogeneic lymphocytes within the transplanted cells. It has been shown that transplantation of purified CD34þ HSCs alleviates the vast majority of GVHD, presumably because donor-derived lymphocytes can be educated in the host thymus to prevent alloreactivity (Link et al., 1996). Pure HSC transplants, however, are relatively slow to generate sufficient numbers of mature cell types. Using a mouse progenitor transplantation model, it has been shown that high-dose transplantation of either CMPs or MEPs was sufficient for radioprotection over a 1-month interval (Na Nakorn et al., 2002). After this time, rare surviving host HSCs recovered to produce all blood cell subsets (Na Nakorn et al., 2002). Another important complication following BMT is infection. Myeloablative irradiation and/or cytoreductive drugs cause a rapid disappearance of myelomonocytes as well as lymphocytes. This leaves a window following transplantation for opportunistic pathogens such as Aspergillus fumigatus, Pseudomonas aeruginos, and cytomegaloviruses to flourish. Using another mouse model, it was shown that transplantation of CMPs and/or GMPs in conjunction with HSC transplants could protect against otherwise lethal challenges of either pathogen due to increased numbers of myelomonocytic cells (BitMansour et al., 2002). Transplantation of CLPs in conjunction with HSCs also protected mice against murine CMV infection (Arber et al., 2003). Based on these preclinical findings, it may be of clinical interest to purify human hematopoietic progenitor subsets to augment purified HSC transplants. XVII. Conclusion
In this chapter, we have provided a current understanding of hematolymphoid development from rare HSCs that give rise to progenitor subsets that progressively lose fate potential as they differentiate down their respective lineages. The ability to prospectively isolate the major branchpoints along the hematopoietic tree allows a molecular profiling of each, both at the population and single-cell level. Transcriptional profiling at the population level has shown that the ‘‘master regulator’’ genes identified from mouse knockout studies are expressed in the progenitor subsets upstream of the noted defective lineages. Single-cell profiling has supported the hypothesis of ‘‘priming stages,’’ whereby
40
DAVID TRAVER AND KOICHI AKASHI
promiscuous, low-level expression of many genes appears to maintain flexibility in cell fate choices. Interestingly, enforced expression of single, inappropriate genes within progenitors normally exclusively commited to the lymphoid fates can reprogram myeloerythroid outcomes. This demonstrates that the nucleus maintains developmental flexibility and that the progressive loss of fate potential upon differentiation is likely controlled initially by strict regulation of growth factor receptor expression. This finding may explain the clinical observations of lineage infidelity and mixed-lineage leukemias. Future work with hematopoietic progenitor populations should allow a more precise understanding of the molecular mechanisms of lineage commitment and may help elucidate how stem cells choose between self-renewal and differentiation. References Abramson, S., Miller, R. G., and Phillips, R. A. (1977). The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J. Exp. Med. 145, 1567–1579. Adolfsson, J., Borge, O. J., Bryder, D., Theilgaard-Monch, K., Astrand-Grundstrom, I., Sitnicka, E., Sasaki, Y., and Jacobsen, S. E. (2001). Upregulation of Flt3 expression within the bone marrow Lin()Sca1(þ)c-kit(þ) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 15, 659–669. Aifantis, I., Azogui, O., Feinberg, J., Saint-Ruf, C., Buer, J., and von Boehmer, H. (1998). On the role of the pre-T cell receptor in alphabeta versus gammadelta T lineage commitment. Immunity 9, 649–655. Akashi, K., Harada, M., Shibuya, T., Fukagawa, K., Kimura, N., Sagawa, K., Yoshikai, Y., Teshima, T., Kikuchi, M., and Niho, Y. (1991). Simultaneous occurrence of myelomonocytic leukemia and multiple myeloma: Involvement of common leukemic progenitors and their developmental abnormality of ‘‘lineage infidelity.’’ J. Cell Phys. 148, 446–456. Akashi, K., He, X., Chen, J., Iwasaki, H., Niu, C., Steenhard, B., Zhang, J., Haug, J., and Li, L. (2003). Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood 101, 383–389. Akashi, K., Kondo, M., and Weissman, I. L. (1998). Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol. Rev. 165, 13–28. Akashi, K., Kondo, M., von Freeden-Jeffry, U., Murray, R., and Weissman, I. L. (1997). Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89, 1033–1041. Akashi, K., Traver, D., Miyamoto, T., and Weissman, I. L. (2000). A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197. Allman, D., Li, J., and Hardy, R. R. (1999). Commitment to the B lymphoid lineage occurs before DH–JH recombination. J. Exp. Med. 189, 735–740. Allman, D., Sambandam, A., Kim, S., Miller, J. P., Pagan, A., Well, D., Meraz, A., and Bhandoola, A. (2003). Thymopoiesis independent of common lymphoid progenitors. Nat. Immunol. 4, 168–174. Anderson, A. C., Robey, E. A., and Huang, Y. H. (2001). Notch signaling in lymphocyte development. Cur. Op. Gen. 11, 554–560. Anderson, M. K., Weiss, A. H., Hernandez-Hoyos, G., Dionne, C. J., and Rothenberg, E. V. (2002). Constitutive expression of PU.1 in fetal hematopoietic progenitors blocks T cell development at the pro-T cell stage. Immunity 16, 285–296.
LINEAGE COMMITMENT
41
Arber, C., BitMansour, A., Sparer, T. E., Higgins, J. P., Mocarski, E. S., Weissman, I. L., Shizuru, J. A., and Brown, J. M. Y. (2003). Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 2002, 2012–3834. Ardavin, C., Wu, L., Li, C.-L., and Shortman, K. (1993). Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 362, 761–763. Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O’Garra, A., Biron, C., Briere, F., and Trinchieri, G. (2001). Mouse type I IFNproducing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2, 1144–1150. Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature 392, 245–252. Becker, A., McCulloch, E., and Till, J. (1963). Cytological demonstration of the clonal nature of spleen colonies dervived from transplanted mouse marrow cells. Nature 197, 452–454. Bendriss-Vermare, N., Barthelemy, C., Durand, I., Bruand, C., Dezutter-Dambuyant, C., Moulian, N., Berrih-Aknin, S., Caux, C., Trinchieri, G., and Briere, F. (2001). Human thymus contains IFN-alpha-producing CD11c(), myeloid CD11c(þ), and mature interdigitating dendritic cells. J. Clin. Inv. 107, 835–844. Berger, S. L., and Felsenfeld, G. (2001). Chromatin goes global. Mol. Cell 8, 263–268. Bhatia, S. K., Tygrett, L. T., Grabstein, K. H., and Waldschmidt, T. J. (1995). The effect of in vivo IL-7 deprivation on T cell maturation. J. Exp. Med. 181, 1399–1409. BitMansour, A., Burns, S. M., Traver, D., Akashi, K., Contag, C. H., Weissman, I. L., and Brown, J. M. Y. (2002). Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood 100, 4660–4667. Bjorck, P. (2001). Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood 98, 3520–3526. Boyd, A. W., and Schrader, J. W. (1982). Derivation of macrophage-like lines from the pre-B lymphoma ABLS 8.1 using 5-azacytidine. Nature 297, 691–693. Bradley, T. R., and Metcalf, D. (1966). The growth of mouse bone marrow cells in vitro. Aust. J. Exp. Biol. Med. Sci. 44, 287–299. Brown, G., Bunce, C. M., and Guy, G. R. (1985). Sequential determination of lineage potentials during haemopoiesis. Br. J. Cancer 52, 681–686. Brown, G., Bunce, C. M., Howie, A. J., and Lord, J. M. (1987). Stochastic or ordered lineage commitment during hemopoiesis? Leukemia 1, 150–153. Busslinger, M., Nutt, S. L., and Rolink, A. G. (2000). Lineage commitment in lymphopoiesis. Curr. Op. Im. 12, 151–158. Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsall, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T., et al. (1995). Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2, 223–238. Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C., de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D., and Banchereau, J. (1996). CD34þ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSFþTNF alpha. J. Exp. Med. 184, 695–706. Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., and Colonna, M. (1999). Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5, 919–923. Chen, H., Ray-Gallet, D., Zhang, P., Hetherington, C. J., Gonzalez, D. A., Zhang, D. E., MoreauGachelin, F., and Tenen, D. G. (1995). PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 11, 1549–1560.
42
DAVID TRAVER AND KOICHI AKASHI
Cheng, G. Y., Minden, M. D., Toyonaga, B., Mak, T. W., and McCulloch, E. A. (1986). T cell receptor and immunoglobulin gene rearrangements in acute myeloblastic leukemia. J. Exp. Med. 163, 414–424. Chiang, M. Y., and Monroe, J. G. (1999). BSAP/Pax5A expression blocks survival and expansion of early myeloid cells implicating its involvement in maintaining commitment to the B-lymphocyte lineage. Blood 94, 3621–3632. Christensen, J. L., and Weissman, I. L. (2001). Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells. Proc. Natl. Acad. Sci. USA 98, 14541–14546. Colucci, F., Samson, S. I., DeKoter, R. P., Lantz, O., Singh, H., and Di Santo, J. P. (2001). Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 97, 2625–2632. Corcoran, A. E., Riddell, A., Krooshoop, D., and Venkitaraman, A. R. (1998). Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor. Nature 391, 904–907. Cotta, C. V., Zhang, Z., Kim, H. G., and Klug, C. A. (2003). Pax5 determines B versus T cell fate and does not block early myeloid-lineage development. Blood 101, 4342–4346. Cross, M. A., and Enver, T. (1997). The lineage commitment of haemopoietic progenitor cells. Cur. Op. Gen. 7, 609–613. Cumano, A., Paige, C. J., Iscove, N. N., and Brady, G. (1992). Bipotential precursors of B cells and macrophages in murine fetal liver. Nature 356, 612–615. de Wynter, E. A., Heyworth, C. M., Mukaida, N., Jaworska, E., Weffort-Santos, A., Matushima, K., and Testa, N. G. (2001). CCR1 chemokine receptor expression isolates erythroid from granulocyte-macrophage progenitors. J. Leukoc. Biol. 70, 455–460. Deftos, M. L., Huang, E., Ojala, E. W., Forbush, K. A., and Bevan, M. J. (2000). Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity 13, 73–84. DeKoter, R. P., and Singh, H. (2000). Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288, 1439–1441. Delassus, S., Titley, I., and Enver, T. (1999). Functional and molecular analysis of hematopoietic progenitors derived from the aorta–gonad–mesonephros region of the mouse embryo. Blood 94, 1495–1503. Dexter, T. M., and Testa, N. G. (1980). In vitro methods in haemopoiesis and lymphopoiesis. J. Immunol. M. 38, 177–190. Doi, H., Inaba, M., Yamamoto, Y., Taketani, S., Mori, S. I., Sugihara, A., Ogata, H., Toki, J., Hisha, H., Inaba, K., et al. (1997). Pluripotent hemopoietic stem cells are c-kit
LINEAGE COMMITMENT
43
Fritsch, G., Buchinger, P., Printz, D., Fink, F. M., Mann, G., Peters, C., Wagner, T., Adler, A., and Gadner, H. (1993). Rapid discrimination of early CD34þ myeloid progenitors using CD45-RA analysis. Blood 81, 2301–2309. Fujiwara, Y., Browne, C. P., Cunniff, K., Goff, S. C., and Orkin, S. H. (1996). Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc. Natl. Acad. Sci. USA 93, 12355–12358. Fulop, G. M., and Phillips, R. A. (1989). Use of scid mice to identify and quantitate lymphoidrestricted stem cells in long-term bone marrow cultures. Blood 74, 1537–1544. Galy, A., Travis, M., Cen, D., and Chen, B. (1995). Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 3, 459–473. Gillessen, S., Mach, N., Small, C., Mihm, M., and Dranoff, G. (2001). Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity. Blood 97, 922–928. Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., and Anderson, D. (1994). Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13, 2822–2830. Goodell, M. A., Jackson, K. A., Majka, S. M., Mi, T., Wang, H., Pocius, J., Hartley, C. J., Majesky, M. W., Entman, M. L., Michael, L. H., and Hirschi, K. K. (2001). Stem cell plasticity in muscle and bone marrow. Ann. NY Acad. Sci. 938, 208–218; discussion 218–220. Goodell, M. A., Rosenzweig, M., Kim, H., Marks, D. F., DeMaria, M., Paradis, G., Grupp, S. A., Sieff, C. A., Mulligan, R. C., and Johnson, R. P. (1997). Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med. 3, 1337–1345. Gounari, F., Aifantis, I., Martin, C., Fehling, H. J., Hoeflinger, S., Leder, P., von Boehmer, H., and Reizis, B. (2002). Tracing lymphopoiesis with the aid of a pTalpha-controlled reporter gene. Nat. Immunol. 3, 489–496. Graf, T. (2002). Differentiation plasticity of hematopoietic cells. Blood 99, 3089–3101. Groettrup, M., Ungewiss, K., Azogui, O., Palacios, R., Owen, M. J., Hayday, A. C., and von Boehmer, H. (1993). A novel disulfide-linked heterodimer on pre-T cells consists of the T cell receptor beta chain and a 33 kd glycoprotein. Cell 75, 283–294. Grogan, T. M., Durie, B. G., Spier, C. M., Richter, L., and Vela, E. (1989). Myelomonocytic antigen positive multiple myeloma. Blood 73, 763–769. Grouard, G., Rissoan, M. C., Filgueira, L., Durand, I., Banchereau, J., and Liu, Y. J. (1997). The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40ligand. J. Exp. Med. 185, 1101–1111. Guerriero, A., Langmuir, P. B., Spain, L. M., and Scott, E. W. (2000). PU 1 is required for myeloidderived but not lymphoid-derived dendritic cells. Blood 95, 879–885. Hacker, C., Kirsch, R. D., Ju, X. S., Hieronymus, T., Gust, T. C., Kuhl, C., Jorgas, T., Kurz, S. M., Rose-John, S., Yokota, Y., and Zenke, M. (2003). Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. 4, 380–386. Hao, Q. L., Zhu, J., Price, M. A., Payne, K. J., Barsky, L. W., and Crooks, G. M. (2001). Identification of a novel, human multilymphoid progenitor in cord blood. Blood 97, 3683–3690. Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D., and Hayakawa, K. (1991). Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173, 1213–1225. Hart, D. N. (1997). Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90, 3245–3287. Hasserjian, R. P., Aster, J. C., Davi, F., Weinberg, D. S., and Sklar, J. (1996). Modulated expression of notch1 during thymocyte development. Blood 88, 970–976.
44
DAVID TRAVER AND KOICHI AKASHI
Hayakawa, K., and Hardy, R. R. (2000). Development and function of B-1 cells. Curr. Op. Im. 12, 346–353. Hayashi, S., Kunisada, T., Ogawa, M., Sudo, T., Kodama, H., Suda, T., and Nishikawa, S. (1990). Stepwise progression of B lineage differentiation supported by interleukin 7 and other stromal cell molecules. J. Exp. Med. 171, 1683–1695. Heemskerk, M. H., Blom, B., Nolan, G., Stegmann, A. P., Bakker, A. Q., Weijer, K., Res, P. C., and Spits, H. (1997). Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 186, 1597–1602. Heimfeld, S., Hudak, S., Weissman, I., and Rennick, D. (1991). The in vitro response of phenotypically defined mouse stem cells and myeloerythroid progenitors to single or multiple growth factors. Proc. Natl. Acad. Sci. USA 88, 9902–9906. Heyworth, C., Pearson, S., May, G., and Enver, T. (2002). Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells. EMBO J. 21, 3770–3781. Hirschhorn, R. (1990). Adenosine deaminase deficiency. Immunodefic. Rev. 2, 175–198. Ho, I. C., Vorhees, P., Marin, N., Oakley, B. K., Tsai, S. F., Orkin, S. H., and Leiden, J. M. (1991). Human GATA-3: A lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. EMBO J. 10, 1187–1192. Holyoake, T. L., Nicolini, F. E., and Eaves, C. J. (1999). Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. Exp. Hematol. 27, 1418–1427. Horcher, M., Souabni, A., and Busslinger, M. (2001). Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 14, 779–790. Hu, M., Krause, D., Greaves, M., Sharkis, S., Dexter, M., Heyworth, C., and Enver, T. (1997). Multilineage gene expression precedes commitment in the hemopoietic system. Gene Dev. 11, 774–785. Huang, S., Chen, Z., Yu, J. F., Young, D., Bashey, A., Ho, A. D., and Law, P. (1999). Correlation between IL-3 receptor expression and growth potential of human CD34þ hematopoietic cells from different tissues. Stem Cells 17, 265–272. Igarashi, H., Gregory, S. C., Yokota, T., Sakaguchi, N., and Kincade, P. W. (2002). Transcription from the RAG1 locus marks the earliest lymphocyte progenitors in bone marrow. Immunity 17, 117–130. Igarashi, H., Kuwata, N., Kiyota, K., Sumita, K., Suda, T., Ono, S., Bauer, S. R., and Sakaguchi, N. (2001). Localization of recombination activating gene 1/green fluorescent protein (RAG1/GFP) expression in secondary lymphoid organs after immunization with T-dependent antigens in rag1/gfp knockin mice. Blood 97, 2680–2687. Ikuta, K., Kina, T., MacNeil, I., Uchida, N., Peault, B., Chien, Y. H., and Weissman, I. L. (1990). A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells. Cell 62, 863–874. Inaba, K., Inaba, M., Deguchi, M., Hagi, K., Yasumizu, R., Ikehara, S., Muramatsu, S., and Steinman, R. M. (1993). Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc. Natl. Acad. Sci. USA 90, 3038–3042. Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G., Griffiths, E., Krawczyk, C., Richardson, C. D., Aitken, K., et al. (2001). CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349–354. Ito, C. Y., Li, C. Y., Bernstein, A., Dick, J. E., and Stanford, W. L. (2003). Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood 101, 517–523. Iwasaki, H., and Akashi, K. (2001). Mast cells originate from granulocyte/macrophage-committed progenitors. Blood 98, 275a.
LINEAGE COMMITMENT
45
Iwasaki, H., Mizuno, S., and Akashi, K. (2002). GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythroid lineages. Blood 100, 258a. Iwasaki-Arai, J., Iwasaki, H., Miyamoto, T., Watanabe, S., and Akashi, K. (2003). Enforced GMCSF signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion. J. Exp. Med. 197, 1311–1322. Izon, D., Rudd, K., DeMuth, W., Pear, W. S., Clendenin, C., Lindsley, R. C., and Allman, D. (2001). A common pathway for dendritic cell and early B cell development. J. Immunol. 167, 1387–1392. Jackson, K. A., Majka, S. M., Wang, H., Pocius, J., Hartley, C. J., Majesky, M. W., Entman, M. L., Michael, L. H., Hirschi, K. K., and Goodell, M. A. (2001). Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J. Clin. Inv. 107, 1395–1402. Jaleco, A. C., Neves, H., Hooijberg, E., Gameiro, P., Clode, N., Haury, M., Henrique, D., and Parreira, L. (2001). Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J. Exp. Med. 194, 991–1002. Jaleco, A. C., Stegmann, A. P., Heemskerk, M. H., Couwenberg, F., Bakker, A. Q., Weijer, K., and Spits, H. (1999). Genetic modification of human B-cell development: B-cell development is inhibited by the dominant negative helix loop helix factor Id3. Blood 94, 2637–2646. Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F., and Lanzavecchia, A. (2001). Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immun. 31, 3388–3393. Jehn, B. M., Bielke, W., Pear, W. S., and Osborne, B. A. (1999). Cutting edge: Protective effects of notch-1 on TCR-induced apoptosis. J. Immunol. 162, 635–638. Jimenez, G., Griffiths, S. D., Ford, A. M., Greaves, M. F., and Enver, T. (1992). Activation of the beta-globin locus control region precedes commitment to the erythroid lineage. Proc. Natl. Acad. Sci. USA 89, 10618–10622. Johnson, G. R., and Metcalf, D. (1977). Pure and mixed erythroid colony formation in vitro stimulated by spleen-conditioned medium with no detectable erythropoietin. Proc. Natl. Acad. Sci. USA 74, 3879–3882. Jordan, C. T., Astle, C. M., Zawadzki, J., Mackarehtschian, K., Lemischka, I. R., and Harrison, D. E. (1995). Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. Exp. Hematol. 23, 1011–1015. Kadowaki, N., Antonenko, S., Lau, J. Y., and Liu, Y. J. (2000). Natural interferon alpha/betaproducing cells link innate and adaptive immunity. J. Exp. Med. 192, 219–226. Kadowaki, N., Ho, S., Antonenko, S., Malefyt, R. W., Kastelein, R. A., Bazan, F., and Liu, Y. J. (2001). Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863–869. Kaneta, M., Osawa, M., Sudo, K., Nakauchi, H., Farr, A. G., and Takahama, Y. (2000). A role for pref-1 and HES-1 in thymocyte development. J. Immunol. 164, 256–264. Karasuyama, H., Rolink, A., Shinkai, Y., Young, F., Alt, F. W., and Melchers, F. (1994). The expression of Vpre-B/lambda 5 surrogate light chain in early bone marrow precursor B cells of normal and B cell-deficient mutant mice. Cell 77, 133–143. Katsura, Y. (2002). Redefinition of lymphoid progenitors. Nat. Rev. Immunol. 2, 127–132. Kawamoto, H., Ikawa, T., Ohmura, K., Fujimoto, S., and Katsura, Y. (2000). T cell progenitors emerge earlier than B cell progenitors in the murine fetal liver. Immunity 12, 441–450. Kawamoto, H., Ohmura, K., and Katsura, Y. (1997). Direct evidence for the commitment of hematopoietic stem cells to T, B, and myeloid lineages in murine fetal liver. Int. Immunol. 9, 1011–1019. Kimura, T., Sakabe, H., Tanimukai, S., Abe, T., Urata, Y., Yasukawa, K., Okano, A., Taga, T., Sugiyama, H., Kishimoto, T., and Sonoda, Y. (1997). Simultaneous activation of signals through
46
DAVID TRAVER AND KOICHI AKASHI
gp130, c-kit, and interleukin-3 receptor promotes a trilineage blood cell production in the absence of terminally acting lineage-specific factors. Blood 90, 4767–4778. King, A. G., Kondo, M., Scherer, D. C., and Weissman, I. L. (2002). Lineage infidelity in myeloid cells with TCR gene rearrangement: A latent developmental potential of proT cells revealed by ectopic cytokine receptor signaling. Proc. Natl. Acad. Sci. USA 99, 4508–4513. Klinken, S. P., Alexander, W. S., and Adams, J. M. (1988). Hemopoietic lineage switch: V-raf oncogene converts Emu-myc transgenic B cells into macrophages. Cell 53, 857–867. Kondo, M., Scherer, D. C., Miyamoto, T., King, A. G., Akashi, K., Sugamura, K., and Weissman, I. L. (2000). Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature 407, 383–386. Kondo, M., Takeshita, T., Higuchi, M., Nakamura, M., Sudo, T., Nishikawa, S., and Sugamura, K. (1994). Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 263, 1453–1454. Kondo, M., Weissman, I. L., and Akashi, K. (1997). Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661–672. Kontaraki, J., Chen, H. H., Riggs, A., and Bonifer, C. (2000). Chromatin fine structure profiles for a developmentally regulated gene: Reorganization of the lysozyme locus before trans-activator binding and gene expression. Gene Dev. 14, 2106–2122. Krause, D. S., Theise, N. D., Collector, M. I., Henegariu, O., Hwang, S., Gardner, R., Neutzel, S., and Sharkis, S. J. (2001). Multi-organ, multi-lineage engraftment by a single bone marrowderived stem cell. Cell 105, 369–377. Kulessa, H., Frampton, J., and Graf, T. (1995). GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. Gene Dev. 9, 1250–1262. Kuwata, N., Igarashi, H., Ohmura, T., Aizawa, S., and Sakaguchi, N. (1999). Cutting edge: Absence of expression of RAG1 in peritoneal B-1 cells detected by knocking into RAG1 locus with green fluorescent protein gene. J. Immunol. 163, 6355–6359. Lacaud, G., Carlsson, L., and Keller, G. (1998). Identification of a fetal hematopoietic precursor with B cell, T cell, and macrophage potential. Immunity 9, 827–838. Lagasse, E., Connors, H., Al-Dhalimy, M., Reitsma, M., Dohse, M., Osborne, L., Wang, X., Finegold, M., Weissman, I. L., and Grompe, M. (2000). Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med. 6, 1229–1234. Lansdorp, P. M., Sutherland, H. J., and Eaves, C. J. (1990). Selective expression of CD45 isoforms on functional subpopulations of CD34þ hemopoietic cells from human bone marrow. J. Exp. Med. 172, 363–366. Lemischka, I. (2002). Rethinking somatic stem cell plasticity. Nat. Biotechnol. 20, 425. Li, Y. S., Wasserman, R., Hayakawa, K., and Hardy, R. R. (1996). Identification of the earliest B lineage stage in mouse bone marrow. Immunity 5, 527–535. Lieschke, G. J., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K. J., Basu, S., Zhan, Y. F., and Dunn, A. R. (1994). Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte, and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737–1746. Lindeman, G. J., Adams, J. M., Cory, S., and Harris, A. W. (1994). B-lymphoid to granulocytic switch during hematopoiesis in a transgenic mouse strain. Immunity 1, 517–527. Link, H., Arseniev, L., Bahre, O., Kadar, J. G., Diedrich, H., and Poliwoda, H. (1996). Transplantation of allogeneic CD34þ blood cells. Blood 87, 4903–4909. Liu, Y. J. (2001). Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106, 259–262. Mackarehtschian, K., Hardin, J. D., Moore, K. A., Boast, S., Goff, S. P., and Lemischka, I. R. (1995). Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3, 147–161.
LINEAGE COMMITMENT
47
Maki, K., Sunaga, S., and Ikuta, K. (1996). The V–J recombination of T cell receptor–gamma genes is blocked in interleukin-7 receptor-deficient mice. J. Exp. Med. 184, 2423–2427. Manz, M. G., Miyamoto, T., Akashi, K., and Weissman, I. L. (2002). Prospective isolation of human clonogenic common myeloid progenitors. Proc. Natl. Acad. Sci. USA 99, 11872–11877. Manz, M. G., Traver, D., Miyamoto, T., Weissman, I. L., and Akashi, K. (2001). Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97, 3333–3341. Martinez del Hoyo, G., Martin, P., Arias, C. F., Marin, A. R., and Ardavin, C. (2002). CD8alphaþ dendritic cells originate from the CD8alpha dendritic cell subset by a maturation process involving CD8alpha, DEC-205, and CD24 up-regulation. Blood 99, 999–1004. Matsuzaki, Y., Gyotoku, J., Ogawa, M., Nishikawa, S., Katsura, Y., Gachelin, G., and Nakauchi, H. (1993). Characterization of c-kit positive intrathymic stem cells that are restricted to lymphoid differentiation. J. Exp. Med. 178, 1283–1292. Matthews, W., Jordan, C. T., Wiegand, G. W., Pardoll, D., and Lemischka, I. R. (1991). A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65, 1143–1152. McBlane, J. F., van Gent, D. C., Ramsden, D. A., Romeo, C., Cuomo, C. A., Gellert, M., and Oettinger, M. A. (1995). Cleavage at a V(D)J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps. Cell 83, 387–395. McCulloch, E. A. (1987). Lineage infidelity or lineage promiscuity? Leukemia 1, 235. McKay, R. (2002). A more astonishing hypothesis. Nat. Biotechnol. 20, 426–427. McKenna, H. J., Stocking, K. L., Miller, R. E., Brasel, K., De Smedt, T., Maraskovsky, E., Maliszewski, C. R., Lynch, D. H., Smith, J., Pulendran, B., et al. (2000). Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95, 3489–3497. McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., and Maki, R. A. (1996). Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 15, 5647–5658. Mebius, R. E., Miyamoto, T., Christensen, J., Domen, J., Cupedo, T., Weissman, I. L., and Akashi, K. (2001). The fetal liver counterpart of adult common lymphoid progenitors gives rise to all lymphoid lineages, CD45þCD4þCD3 cells, as well as macrophages. J. Immunol. 166, 6593–6601. Metcalf, D., Johnson, G. R., and Mandel, T. E. (1979). Colony formation in agar by multipotential hemopoietic cells. J. Cell. Phys. 98, 401–420. Miyamoto, T., Iwasaki, H., Reizis, B., Ye, M., Graf, T., Weissman, I. L., and Akashi, K. (2002). Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev. Cell 3, 137–147. Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., and Papaioannou, V. E. (1992). RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877. Mori, S., Shortman, K., and Wu, L. (2001). Characterization of thymus-seeding precursor cells from mouse bone marrow. Blood 98, 696–704. Morrison, S. H., Wandycz, A. M., and Weissman, I. L. (1995). The purification and characterization of fetal liver hematopoietic cells. Proc. Natl. Acad. Sci. USA 92, 10302–10306. Morrison, S. J., Wandycz, A. M., Akashi, K., Globerson, A., and Weissman, I. L. (1996). The aging of hematopoietic stem cells. Nat. Med. 2, 1011–1016. Morrison, S. J., and Weissman, I. L. (1994). The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1, 661–673. Mulder, A. H., and Visser, J. W. M. (1987). Separation and functional analysis of bone marrow cells separated by Rhodamine-123 fluorescence. Exp. Hematol. 15, 99–104.
48
DAVID TRAVER AND KOICHI AKASHI
Murphy, S. B., Stass, S., Kalwinsky, D., and Rivera, G. (1983). Phenotypic conversion of acute leukaemia from T-lymphoblastic to myeloblastic induced by therapy with 20 -deoxycoformycin. Br. J. Haematol. 55, 285–293. Na Nakorn, T., Traver, D., Weissman, I. L., and Akashi, K. (2002). Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J. Clin. Inv. 109, 1579–1585. Naik, S., Vremec, D., Wu, L., O’Keeffe, M., and Shortman, K. (2003). CD8{alpha}þ mouse spleen dendritic cells do not originate from the CD8- dendritic cell subset. Blood 102, 601–604. Nakahata, T., and Ogawa, M. (1982). Identification in culture of a class of hemopoietic colonyforming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc. Natl. Acad. Sci. USA 79, 3843–3847. Nakano, H., Yanagita, M., and Gunn, M. D. (2001). CD11c(þ)B220(þ)Gr-1(þ) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194, 1171–1178. Nakorn, T. N., Miyamoto, T., and Weissman, I. L. (2003). Characterization of mouse clonogenic megakaryocyte progenitors. Proc. Natl. Acad. Sci. USA 100, 205–210. Nerlov, C., and Graf, T. (1998). PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Gene Dev. 12, 2403–2412. Nerlov, C., McNagny, K. M., Doderlein, G., Kowenz-Leutz, E., and Graf, T. (1998). Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Gene Dev. 12, 2413–2423. Nerlov, C., Querfurth, E., Kulessa, H., and Graf, T. (2000). GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood 95, 2543–2551. Nichogiannopoulou, A., Trevisan, M., Neben, S., Friedrich, C., and Georgopoulos, K. (1999). Defects in hemopoietic stem cell activity in Ikaros mutant mice. J. Exp. Med. 190, 1201–1214. Nishijima, I., Nakahata, T., Hirabayashi, Y., Inoue, T., Kurata, H., Miyajima, A., Hayashi, N., Iwakura, Y., Arai, K., and Yokota, T. (1995). A human GM-CSF receptor expressed in transgenic mice stimulates proliferation and differentiation of hemopoietic progenitors to all lineages in response to human GM-CSF. Mol. Biol. Ce. 6, 497–508. Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., and Leonard, W. J. (1993). Interleukin-2 receptor gamma chain: A functional component of the interleukin-7 receptor. Science 262, 1877–1880. Nosten-Bertrand, M., Errington, M. L., Murphy, K. P., Tokugawa, Y., Barboni, E., Kozlova, E., Michalovich, D., Morris, R. G., Silver, J., Stewart, C. L., et al. (1996). Normal spatial learning despite regional inhibition of LTP in mice lacking Thy-1. Nature 379, 826–829. Nutt, S. L., Heavey, B., Rolink, A. G., and Busslinger, M. (1999). Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556–562. O’Riordan, M., and Grosschedl, R. (1999). Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity 11, 21–31. Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844–2853. Ohbo, K., Suda, T., Hashiyama, M., Mantani, A., Ikebe, M., Miyakawa, K., Moriyama, M., Nakamura, M., Katsuki, M., Takahashi, K., et al. (1996). Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 87, 956–967. Okuno, Y., Iwasaki, H., Huettner, C. S., Radomska, H. S., Gonzalez, D. A., Tenen, D. G., and Akashi, K. (2002). Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 99, 6246–6251. Olweus, J., BitMansour, A., Warnke, R., Thompson, P. A., Carballido, J., Picker, L. J., and Lund-Johansen, F. (1997). Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. Proc. Natl. Acad. Sci. USA 94, 12551–12556.
LINEAGE COMMITMENT
49
Olweus, J., Thompson, P. A., and Lund-Johansen, F. (1996). Granulocytic and monocytic differentiation of CD34hi cells is associated with distinct changes in the expression of the PU.1-regulated molecules, CD64, and macrophage colony-stimulating factor receptor. Blood 88, 3741–3754. Ordentlich, P., Lin, A., Shen, C. P., Blaumueller, C., Matsuno, K., Artavanis-Tsakonas, S., and Kadesch, T. (1998). Notch inhibition of E47 supports the existence of a novel signaling pathway. Mol. Cell B. 18, 2230–2239. Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., Pickel, J., McKay, R., Nadal-Ginard, B., Bodine, D. M., et al. (2001). Bone marrow cells regenerate infarcted myocardium. Nature 410, 701–705. Osawa, M., Hanada, K., Hamada, H., and Nakauchi, H. (1996). Long-term lymphohematopoietic reconstitution by a single CD34- low/negative hematopoietic stem cell. Science 273, 242–245. Pawliuk, R., Eaves, C., and Humphries, R. K. (1996). Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo. Blood 88, 2852–2858. Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994). Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180, 1955–1960. Pharr, P. N., Hankins, D., Hofbauer, A., Lodish, H. F., and Longmore, G. D. (1993). Expression of a constitutively active erythropoietin receptor in primary hematopoietic progenitors abrogates erythropoietin dependence and enhances erythroid colony-forming unit, erythroid burstforming unit, and granulocyte/macrophage progenitor growth. Proc. Natl. Acad. Sci. USA 90, 938–942. Pluznik, D. H., and Sachs, L. (1965). The cloning of normal ‘‘mast’’ cells in tissue culture J. Cell Phys. 66, 319–324. Priller, J., Flugel, A., Wehner, T., Boentert, M., Haas, C. A., Prinz, M., Fernandez-Klett, F., Prass, K., Bechmann, I., de Boer, B. A., et al. (2001). Targeting gene-modified hematopoietic cells to the central nervous system: Use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7, 1356–1361. Pui, J. C., Allman, D., Xu, L., DeRocco, S., Karnell, F. G., Bakkour, S., Lee, J. Y., Kadesch, T., Hardy, R. R., Aster, J. C., and Pear, W. S. (1999). Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11, 299–308. Radtke, F., Ferrero, I., Wilson, A., Lees, R., Aguet, M., and MacDonald, H. R. (2000). Notch1 deficiency dissociates the intrathymic development of dendritic cells and T cells. J. Exp. Med. 191, 1085–1094. Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H. R., and Aguet, M. (1999). Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 10, 547–558. Randall, T. D., and Weissman, I. L. (1997). Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood 89, 3596–3606. Randolph, G. J., Beaulieu, S., Lebecque, S., Steinman, R. M., and Muller, W. A. (1998). Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282, 480–483. Rappold, I., Ziegler, B. L., Kohler, I., Marchetto, S., Rosnet, O., Birnbaum, D., Simmons, P. J., Zannettino, A. C., Hill, B., Neu, S., et al. (1997). Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 90, 111–125. Reizis, B., and Leder, P. (2001). The upstream enhancer is necessary and sufficient for the expression of the pre-T cell receptor alpha gene in immature T lymphocytes. J. Exp. Med. 194, 979–990. Robey, E. (1997). Notch in vertebrates. Cur. Op. Gen. 7, 551–557.
50
DAVID TRAVER AND KOICHI AKASHI
Robey, E., Chang, D., Itano, A., Cado, D., Alexander, H., Lans, D., Weinmaster, G., and Salmon, P. (1996). An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87, 483–492. Rodewald, H. R., Brocker, T., and Haller, C. (1999). Developmental dissociation of thymic dendritic cell and thymocyte lineages revealed in growth factor receptor mutant mice. Proc. Natl. Acad. Sci. USA 96, 15068–15073. Rolink, A. G., Nutt, S. L., Melchers, F., and Busslinger, M. (1999). Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors. Nature 401, 603–606. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. (1994). Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83–93. Romeo, P. H., Prandini, M. H., Joulin, V., Mignotte, V., Prenant, M., Vainchenker, W., Marguerie, G., and Uzan, G. (1990). Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature 344, 447–449. Rothenberg, E. V., and Dionne, C. J. (2002). Lineage plasticity and commitment in T-cell development. Immunol. Rev. 187, 96–115. Sagara, S., Sugaya, K., Tokoro, Y., Tanaka, S., Takano, H., Kodama, H., Nakauchi, H., and Takahama, Y. (1997). B220 expression by T lymphoid progenitor cells in mouse fetal liver. J. Immunol. 158, 666–676. Sakaguchi, N., and Melchers, F. (1986). Lambda 5, a new light-chain-related locus selectively expressed in pre-B lymphocytes. Nature 324, 579–582. Sallusto, F., and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109–1118. Schatz, D. G., Oettinger, M. A., and Schlissel, M. S. (1992). V(D)J recombination: Molecular biology and regulation. Ann. R. Immun. 10, 359–383. Scott, E. W., Fisher, R. C., Olson, M. C., Kehrli, E. W., Simon, M. C., and Singh, H. (1997). PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 6, 437–447. Scott, E. W., Simon, M. C., Anastasi, J., and Singh, H. (1994). Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265, 1573–1577. Searles, A. E., Pohlmann, S. J., Pierce, L. J., Perry, S. S., Slayton, W. B., Mojica, M. P., and Spangrude, G. J. (2000). Rapid, B lymphoid-restricted engraftment mediated by a primitive bone marrow subpopulation. J. Immunol. 165, 67–74. Semerad, C. L., Poursine-Laurent, J., Liu, F., and Link, D. C. (1999). A role for G-CSF receptor signaling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. Immunity 11, 153–161. Seshasayee, D., Gaines, P., and Wojchowski, D. M. (1998). GATA-1 dominantly activates a program of erythroid gene expression in factor-dependent myeloid FDCW2 cells. Mol. Cell B. 18, 3278– 3288. Shinkai, Y., Rathbun, G., Lam, K. P., Oltz, E. M., Stewart, V., Mendelsohn, M., Charron, J., Datta, M., Young, F., Stall, A. M., et al. (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855–867. Shivdasani, R. A., Fujiwara, Y., McDevitt, M. A., and Orkin, S. H. (1997). A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 16, 3965–3973. Shivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J., and Orkin, S. H. (1995). Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81, 695–704.
LINEAGE COMMITMENT
51
Shortman, K., and Liu, Y. J. (2002). Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2, 151–161. Sieweke, M. H., Tekotte, H., Frampton, J., and Graf, T. (1996). MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell 85, 49–60. Sitnicka, E., Bryder, D., Theilgaard-Monch, K., Buza-Vidas, N., Adolfsson, J., and Jacobsen, S. E. (2002). Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. Immunity 17, 463–472. Smith, L. G., Weissman, I. L., and Heimfeld, S. (1991). Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc. Natl. Acad. Sci. USA 88, 2788–2792. Smith, L. J., Curtis, J. E., Messner, H. A., Senn, J. S., Furthmayr, H., and McCulloch, E. A. (1983). Lineage infidelity in acute leukemia. Blood 61, 1138–1145. Souabni, A., Cobaleda, C., Schebesta, M., and Busslinger, M. (2002). Pax5 promotes B lymphopoiesis and blocks T cell development by repressing notch1. Immunity 17, 781–793. Spangrude, G. J., Aihara, Y., Weissman, I. L., and Klein, J. (1988). The stem cell antigens Sca-1 and Sca-2 subdivide thymic and peripheral T lymphocytes into unique subsets. J. Immunol. 141, 3697–3707. Spangrude, G. J., Smith, L., Uchida, N., Ikuta, K., Heimfeld, S., Friedman, J., and Weissman, I. L. (1991). Mouse hematopoietic stem cells. Blood 78, 1395–1402. Spits, H., Couwenberg, F., Bakker, A. Q., Weijer, K., and Uittenbogaart, C. H. (2000). Id2 and Id3 inhibit development of CD34(þ) stem cells into predendritic cell (pre-DC)2 but not into preDC1. Evidence for a lymphoid origin of pre-DC2. J. Exp. Med. 192, 1775–1784. Stanley, E., Lieschke, G. J., Grail, D., Metcalf, D., Hodgson, G., Gall, J. A., Maher, D. W., Cebon, J., Sinickas, V., and Dunn, A. R. (1994). Granulocyte/macrophage colony-stimulating factordeficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. USA 91, 5592–5596. Stass, S., Mirro, J., Melvin, S., Pui, C. H., Murphy, S. B., and Williams, D. (1984). Lineage switch in acute leukemia. Blood 64, 701–706. Storms, R. W., Goodell, M. A., Fisher, A., Mulligan, R. C., and Smith, C. (2000). Hoechst dye efflux reveals a novel CD7(þ)CD34() lymphoid progenitor in human umbilical cord blood. Blood 96, 2125–2133. Suda, J., Suda, T., and Ogawa, M. (1984a). Analysis of differentiation of mouse hemopoietic stem cells in culture by sequential replating of paired progenitors. Blood 64, 393–399. Suda, T., Suda, J., and Ogawa, M. (1984b). Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors. Proc. Natl. Acad. Sci. USA 81, 2520–2524. Takagi, M., Hara, T., Ichihara, M., Takatsu, K., and Miyajima, A. (1995). Multi-colony stimulating activity of interleukin 5 (IL-5) on hematopoietic progenitors from transgenic mice that express IL-5 receptor alpha subunit constitutively. J. Exp. Med. 181, 889–899. Tenen, D. G., Hromas, R., Licht, J. D., and Zhang, D. E. (1997). Transcription factors, normal myeloid development, and leukemia. Blood 90, 489–519. Terada, N., Hamazaki, T., Oka, M., Hoki, M., Mastalerz, D. M., Nakano, Y., Meyer, E. M., Morel, L., Petersen, B. E., and Scott, E. W. (2002). Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416, 542–545. Till, J. E., and McCulloch, E. A. (1961). A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14, 1419–1430. Ting, C. N., Olson, M. C., Barton, K. P., and Leiden, J. M. (1996). Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 384, 474–478. Tomita, K., Hattori, M., Nakamura, E., Nakanishi, S., Minato, N., and Kageyama, R. (1999). The bHLH gene Hes1 is essential for expansion of early T cell precursors. Gene Dev. 13, 1203–1210.
52
DAVID TRAVER AND KOICHI AKASHI
Traver, D., Akashi, K., Manz, M., Merad, M., Miyamoto, T., Engleman, E. G., and Weissman, I. L. (2000). Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. Science 290, 2152–2154. Traver, D., Miyamoto, T., Christensen, J., Iwasaki-Arai, J., Akashi, K., and Weissman, I. L. (2001). Fetal liver myelopoiesis occurs through distinct, prospectively isolatable progenitor subsets. Blood 98, 627–635. Tudor, K. S., Payne, K. J., Yamashita, Y., and Kincade, P. W. (2000). Functional assessment of precursors from murine bone marrow suggests a sequence of early B lineage differentiation events. Immunity 12, 335–345. Uchida, N., Aguila, H. L., Fleming, W. H., Jerabek, L., and Weissman, I. L. (1994). Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1. 1lo Lin-Sca-1þ hematopoietic stem cells. Blood 83, 3758–3779. Uchida, N., and Weissman, I. (1992). Searching for hematopoietic stem cells: Evidence that Thy-1. 1lo Lin-Sca-1þ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J. Exp. Med. 175, 175–184. van den Elsen, P., Bruns, G., Gerhard, D. S., Pravtcheva, D., Jones, C., Housman, D., Ruddle, F. A., Orkin, S., and Terhorst, C. (1985). Assignment of the gene coding for the T3-delta subunit of the T3-T-cell receptor complex to the long arm of human chromosome 11 and to mouse chromosome 9. Proc. Natl. Acad. Sci. USA 82, 2920–2924. van Gent, D. C., Ramsden, D. A., and Gellert, M. (1996). The RAG1 and RAG2 proteins establish the 12/23 rule in V(D)J recombination. Cell 85, 107–113. Varnum-Finney, B., Xu, L., Brashem-Stein, C., Nourigat, C., Flowers, D., Bakkour, S., Pear, W. S., and Bernstein, I. D. (2000). Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat. Med. 6, 1278–1281. Visser, J. W. M., Gauman, J. G. J., Mulder, A. H., Eliason, J. F., and de Leeuw, A. W. (1984). Isolation of murine pluripotent hemopoietic stem cells. J. Exp. Med. 59, 1576–1590. Visvader, J. E., Elefanty, A. G., Strasser, A., and Adams, J. M. (1992). GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. EMBO J. 11, 4557–4564. von Boehmer, H. (1999). T-cell development: What does Notch do for T cells? Curr. Biol. 9, R186– 188. von Freeden-Jeffry, U., Solvason, N., Howard, M., and Murray, R. (1997). The earliest T lineagecommitted cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity 7, 147–154. von Freeden-Jeffry, U., Vieira, P., Lucian, L. A., McNeil, T., Burdach, S. E., and Murray, R. (1995). Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181, 1519–1526. Wadman, I. A., Osada, H., Grutz, G. G., Agulnick, A. D., Westphal, H., Forster, A., and Rabbitts, T. H. (1997). The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1, and Ldb1/NLI proteins. EMBO J. 16, 3145–3157. Wagers, A. J., Sherwood, R. I., Christensen, J. L., and Weissman, I. L. (2002). Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297, 2256–2259. Wang, J. H., Nichogiannopoulou, A., Wu, L., Sun, L., Sharpe, A. H., Bigby, M., and Georgopoulos, K. (1996). Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537–549. Wang, Y., Zhang, Y., Yoneyama, H., Onai, N., Sato, T., and Matsushima, K. (2002). Identification of CD8alphaþCD11c- lineage phenotype-negative cells in the spleen as committed precursor of CD8alphaþ dendritic cells. Blood 100, 569–577.
LINEAGE COMMITMENT
53
Washburn, T., Schweighoffer, E., Gridley, T., Chang, D., Fowlkes, B. J., Cado, D., and Robey, E. (1997). Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell 88, 833–843. Weintraub, H. (1985). Assembly and propagation of repressed and depressed chromosomal states. Cell 42, 705–711. Weissman, I. L. (1994). Stem cells, clonal progenitors, and commitment to the three lymphocyte lineages: T, B, and NK cells. Immunity 1, 529–531. Wiesmann, A., Phillips, R. L., Mojica, M., Pierce, L. J., Searles, A. E., Spangrude, G. J., and Lemischka, I. (2000). Expression of CD27 on murine hematopoietic stem and progenitor cells. Immunity 12, 193–199. Wu, A., Till, J., Siminovitch, L., and McCulloch, E. (1968). Cytological evidence for a relationship between normal hematopoietic colony-forming cells and cells of the lymphoid system. J. Exp. Med. 127, 455–467. Wu, H., Liu, X., Jaenisch, R., and Lodish, H. F. (1995). Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83, 59–67. Wu, L., Antica, M., Johnson, G. R., Scollay, R., and Shortman, K. (1991a). Developmental potential of the earliest precursor cells from the adult mouse thymus. J. Exp. Med. 174, 1617–1627. Wu, L., Scollay, R., Egerton, M., Pearse, M., Spangrude, G. J., and Shortman, K. (1991b). CD4 expressed on earliest T-lineage precursor cells in the adult murine thymus. Nature 349, 71–74. Wu, L., D’Amico, A., Hochrein, H., O’Keeffe, M., Shortman, K., and Lucas, K. (2001). Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 98, 3376–3382. Wu, L., D’Amico, A., Winkel, K. D., Suter, M., Lo, D., and Shortman, K. (1998). RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alphaþ dendritic cells. Immunity 9, 839–847. Wu, L., Li, C. L., and Shortman, K. (1996). Thymic dendritic cell precursors: Relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J. Exp. Med. 184, 903–911. Wu, L., Nichogiannopoulou, A., Shortman, K., and Georgopoulos, K. (1997). Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. Immunity 7, 483–492. Yamaguchi, Y., Zon, L. I., Ackerman, S. J., Yamamoto, M., and Suda, T. (1998). Forced GATA-1 expression in the murine myeloid cell line M1: Induction of c-Mp1 expression and megakaryocytic/erythroid differentiation. Blood 91, 450–457. Yang, F. C., Tsuji, K., Oda, A., Ebihara, Y., Xu, M. J., Kaneko, A., Hanada, S., Mitsui, T., Kikuchi, A., Manabe, A., et al. (1999). Differential effects of human granulocyte colony-stimulating factor (hG- CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG- CSF receptor-transgenic mice. Blood 94, 950–958. Yang, F. C., Watanabe, S., Tsuji, K., Xu, M. J., Kaneko, A., Ebihara, Y., and Nakahata, T. (1998). Human granulocyte colony-stimulating factor (G-CSF) stimulates the in vitro and in vivo development but not commitment of primitive multipotential progenitors from transgenic mice expressing the human G- CSF receptor. Blood 92, 4632–4640. Ying, Q. L., Nichols, J., Evans, E. P., and Smith, A. G. (2002). Changing potency by spontaneous fusion. Nature 416, 545–548. Young, J. W., Szabolcs, P., and Moore, M. A. (1995). Identification of dendritic cell colony-forming units among normal human CD34þ bone marrow progenitors that are expanded by c-kitligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colonystimulating factor and tumor necrosis factor alpha. J. Exp. Med. 182, 1111–1119.
54
DAVID TRAVER AND KOICHI AKASHI
Zhang, D. E., Zhang, P., Wang, N. D., Hetherington, C. J., Darlington, G. J., and Tenen, D. G. (1997). Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. USA 94, 569–574. Zhang,P.,Behre,G.,Pan,J.,Iwama,A.,Wara-Aswapati,N.,Radomska,H.S.,Auron,P.E.,Tenen,D.G., and Sun, Z. (1999). Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc. Natl. Acad. Sci. USA 96, 8705–8710. Zhang, P., Zhang, X., Iwama, A., Yu, C., Smith, K. A., Mueller, B. U., Narravula, S., Torbett, B. E., Orkin, S. H., and Tenen, D. G. (2000). PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 96, 2641–2648.
advances in immunology, vol. 83
The CD4/CD8 Lineage Choice: New Insights into Epigenetic Regulation during T Cell Development ICHIRO TANIUCHI,* WILFRIED ELLMEIER,y AND DAN R. LITTMANz *RIKEN Research Center, Yokohama 230-0045, Japan y University of Vienna,1235 Vienna, Austria z New York University School of Medicine New York, NY 10016
I. Introduction
Differentiation of progenitor cells into various progeny with distinct functional properties is achieved by the regulated activation and silencing of batteries of genes. The final differentiated state is thus defined by the expression pattern of these genes, which is heritably maintained as cells undergo subsequent cell divisions. Hematopoiesis offers an ideal developmental system to study how progenitors differentiate into cells of distinct lineage and function and how differentiated states are then stably maintained. A series of transcription factors required for differentiation of erythroid, myeloid, and lymphocyte lineages have been described (Cantor and Orkin, 2001; Singh et al., 1999). Within the lymphoid lineages, activation of the Notch signaling pathway in the thymus favors T cell development, at the expense of B lymphocytes (Izon et al., 2002). This is followed by a series of developmental choices as thymocytes differentiate into T cells with distinct antigen recognition properties and effector functions. Differentiation of thymocytes and their subsequent selection results in export to peripheral secondary lymphoid organs of a large variety of cells: CD4þ T helper cells (Th), CD8þ cytotoxic cells (CTL or Tc), CD4þ regulatory or suppressor cells (Treg), CD8þ intestinal intraepithelial lymphocytes (IEL), NKT cells with restricted T cell antigen receptor (TCR) repertoires, and other T cells with restricted TCRs that localize to various peripheral organs and mucosal regions. The molecular events leading to the differentiation of each of these lineages remain largely unexplored. Expression of the CD4 and CD8 glycoproteins defines the major lineages of T lymphocyes, and is coupled to the transcriptional programs that characterize the helper and cytotoxic lineages, respectively (Killeen and Littman, 1996). Regulation of expression of the genes encoding these coreceptor molecules has been studied in some detail, with the expectation that such studies could elucidate the mechanisms involved in lineage commitment and establishment of differentiated states. These studies have revealed a complex network of positive regulatory elements in both genes, as well as an extensively characterized negative regulatory region within 55 Copyright 2004, Elsevier Inc. All rights reserved. 0065-2776/04 $35.00
56
ICHIRO TANIUCHI ET AL.
the CD4 gene. In addition, the silencer in the CD4 gene has been shown to be involved in epigenetic regulation, and there are hints that the enhancers in the CD8 gene may also function through epigenetic mechanisms that result in heritable ‘‘on’’ states of expression. The recent findings on CD4 and CD8 regulation and the general tractability of the T cell system render these genes highly attractive for studies of the general phenomenon of epigenetic regulation during development (Jaenisch and Bird, 2003; Li, 2002). This chapter discusses the role of the CD4 and CD8 co-receptors in T cell development and signal transduction, the regulation of expression of the genes that encode these proteins, and the outstanding questions that need to be addressed. We also emphasize how our understanding of the CD4 silencer can inform future studies on epigenetic regulation during mammalian development. II. Role of Coreceptors in T Cell Development
The thymus is the site where lymphoid progenitors differentiate into T cells bearing a variety of specificities and functions (von Boehmer et al., 1989). Most cells differentiate along a lineage that gives rise to cytotoxic and helper T cells with TCRab receptors specific for MHC class I and class II molecules, respectively. Cells of this lineage can be readily classified according to their expression of the coreceptor molecules, CD4 and CD8. These cell surface glycoproteins bind to membrane-proximal domains of MHC class II and class I molecules, respectively, and their cytoplasmic domains recruit the Src family protein tyrosine kinase p56lck (Lck) (Weiss and Littman, 1994). The most immature cells express neither coreceptor and are classified as double negative (DN) cells. These cells can be subdivided into four stages, based on surface expression of CD25 and CD44. At the DN3 stage (CD25þCD44lo), there is initiation of VDJ rearrangement at the TCRb locus, and cells that undergo inframe rearrangement and hence express a pre-TCR are selected for further maturation, marked by several rounds of cell division before CD25 is shut off (DN4 stage: CD25CD44lo). Cells that have completed b-selection then turn on expression of both CD4 and CD8ab heterodimers, marking the double positive (DP) stage of differentiation (von Boehmer and Fehling, 1997). These cells, which are the most abundant in the thymus, then undergo VJ rearrangement of the TCRa genes, and cells with productive rearrangements initiate expression of TCRab heterodimers. The DP thymocytes are then subjected to selection based on their aptitude to interact with MHC molecules (Goldrath and Bevan, 1999; Sebzda et al., 1999). Most cells undergo ‘‘death by neglect’’ because they fail to bind with sufficient avidity to self MHC–peptide complexes. The few cells with TCRs that bind with high affinity to MHC–peptide complexes are deleted, through an apoptotic program known as negative selection. Only the rare DP thymocytes with TCRs of intermediate affinity
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
57
for MHC transduce signals that ensure their survival and further differentiation, which is known as ‘‘positive selection.’’ Those cells selected by interacting with MHC class I proceed to become CD4CD8þ T cells (CD8 single positive or SP cells, bearing CD8ab heterodimers) with cytotoxic function, whereas those selected on MHC class II become CD4þCD8 cells (CD4 SP) with helper functions. Other lineages branch off at different stages from this major pathway of differentiation. Cells that express TCRgd differentiate from the DN precursors and migrate to various specialized mucosal regions (Hayday et al., 2001). Many of these give rise to IEL that express CD8aa homodimers (Guy-Grand et al., 2001; Lefrancois and Olson, 1994). A subset of cells with canonical TCRab rearrangements are selected at the DP stage by interacting with the class Ib molecule CD1d, and give rise to NKT cells that migrate to many tissues and make up a large proportion of T cells in the liver (Kronenberg and Gapin, 2002). In 2003, a subset of CD4 SP thymocytes was found to differentiate into regulatory T cells that keep autoreactive cells in check (Hori et al., 2003). The process by which DP thymocytes give rise to CD4 or CD8 SP cells is still poorly understood, but it is known to involve multiple steps. First, the cells undergo positive selection independently of commitment to one of the two lineages. This is known from the phenotype of mutant hd/hd (helper-deficient) mice, which lack CD4 SP cells and mature T helper cells (Keefe et al., 1999). MHC class II-restricted thymocytes undergo positive selection in these mice, but they all differentiate into CD8þ CTL. These animals thus have no defect in positive selection, but they have defective lineage commitment that results in lineage reversal of class II-restricted T cells. How cells commit to the helper versus the cytotoxic lineage remains a matter of some controversy. Early studies suggested that DP thymocytes stochastically shut off either CD4 or CD8, and undergo further selection only if they retain expression of the coreceptor appropriate for the class of MHC recognized by the TCR. Thus, cells specific for class I would undergo apoptosis if they shut off CD8, which interacts with class I, but would be further selected if they retain expression of CD8 and shut off CD4, which interacts with class II (Davis and Littman, 1994). Later studies have provided strong evidence that the strength of the TCR-initiated signal governs the fate of DP thymocytes. Enhanced activation of the protein tyrosine kinase p56lck, which interacts with both CD4 and CD8 cytoplasmic domains, resulted in biased commitment to the CD4 lineage, such that even class I-restricted thymocytes became CD4 SP cells (Hernandez-Hoyos et al., 2000). Conversely, inhibition of Lck activity resulted in deviation towards the CD8 lineage. Because the proportion of CD4 molecules with Lck bound to them is higher than that of CD8, it has been proposed that the number of Lck molecules
58
ICHIRO TANIUCHI ET AL.
recruited to the TCR complex is the factor that determines the strength of the TCR-initiated signal and, hence, instructs the lineage choice. Most recently, Singer and colleagues have proposed a modified version of the strength-of-signal instructional model, which they have termed the ‘‘coreceptor reversal’’ or ‘‘kinetic signaling’’ model (Brugnera et al., 2000; Singer, 2002). This model is based on the finding that, following positive selection signals initiated by TCR interaction with either class I or class II molecules, thymocytes down-regulate expression of CD8, resulting in CD4þCD8lo cells that are precursors of both the CD4 and CD8 SP lineages. These precursor cells have been posited to give rise to cells of either the CD4 or CD8 lineage on the basis of the strength of the TCR/coreceptor signal relative to the strength during earlier selection at the DP stage. Thus, cells selected by interaction with class II would retain a strong signal at the CD4þCD8lo stage, since the CD4 coreceptor continues to be expressed. This would direct the cells towards the CD4 SP lineage. However, if cells were selected by interaction with class I, there would be a reduced signal upon transition to the CD4þCD8lo stage, and this would result in subsequent differentiation to the CD8 SP cytotoxic T cell lineage. The reduced or interrupted signal would therefore initiate the extinction of CD4 expression and the reactivation of CD8 expression. The novelty of this model lies in the proposition that abrogation of a signal dictates a switch in developmental fate. Based on in vitro thymocyte culture experiments, Singer and colleagues have suggested that IL-7R signaling is then required in cells destined for the CD8 SP lineage. This hypothesis is supported by the finding that conditional inactivation in thymocytes of the SOCS-1 gene, a negative regulator of gc (and hence IL-7R) signaling, results in a considerable increase in CD8 SP cells (Chong et al., 2003). Although the coreceptor reversal model has yet to be experimentally confirmed, its predictions fit well with our current understanding of CD4 and CD8 gene regulation. For example, there is evidence that there are multiple stage-specific enhancers that regulate CD8 expression, with some active at the DP stage and others at various stages of CD8 SP differentiation. A better understanding of how the coreceptor genes are regulated is, hence, likely not only to contribute to the elucidation of how lineage choice occurs in DP thymocytes, but also may reveal how complex programs of differentiation, to the helper and cytotoxic lineages, are regulated. In addition, other studies have revealed an unexpected novel function of a CD8 gene enhancer that selectively regulates expression of CD8a (Madakamutil et al., 2004). This enhancer has been shown to have a key role in the generation of memory CTL, and its further characterization may provide important insight into the genetic program that governs how a small subset of effector cells is set aside to differentiate into memory cells.
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
59
III. Regulation of CD4 Gene Expression
A. Positive Regulatory Elements The CD4 locus is located in syntenic regions of murine chromosome 6 and human chromosome 12. It spans 80 kb, and its exon/intron structure is conserved in mouse and human. The lag-3 gene, which encodes a CD4-related molecule that also binds to MHC class II, is located approximately 20 kb upstream of cd4 in the mouse genome (Baixeras et al., 1992; Triebel et al., 1990). LAG-3 is expressed on all newly activated CD4þ and CD8þ T cells and on some cycling memory cells and, hence, differs significantly in its regulation from the closely linked cd4 gene. LAG-3 appears to contribute to the expansion of activated T cells by regulating their survival (Workman and Vignali, 2003). LAG-3 is also expressed on natural killer cells and contributes to the ability of these cells to kill certain target cells (Miyazaki et al., 1996). 1. The CD4 Promoter Candidate cis-regulatory elements were initially idenfied using DNase hypersensitivity (HS) analyses of the mouse cd4 locus (Gorman et al., 1987; Sands and Nikolic-Zugic, 1992; Sawada and Littman, 1991; Siu et al., 1994). One of the HS sites is immediately upstream of the transcription initiation site, and a 101-bp fragment containing this sequence had promoter activity in transient transfection assays in T cell lines. Two Myb-binding motifs were required for full promoter activity (Nakayama et al., 1993; Siu et al., 1992). Another mutatagenesis study suggested the involvement of Ets-binding sites for CD4 promoter (P4) activity (Salmon et al., 1993). All studies to date on P4 have been confined to transient expression analyses in vitro, and the promoter has not been analyzed in mice by transgenesis or targeted mutagenesis. This is particularly relevant because, for the activation of reporter genes in vivo, P4 is not sufficient and requires the help of enhancers. It will be important to determine, using chromatin immunoprecipitation (ChIP), whether Myb, Ets, and other transcription factors are associated with P4 in various subsets of thymocytes and in mature CD4 and CD8 lineage cells. Comparison of CD4 and CD8 lineage T cells may also provide valuable information as to whether the promoter is occupied by transcription factors even when the gene is silenced (in CD8þ T cells). It should be noted that lineage specificity is unlikely to be conferred by P4, since it functions in transgenic mice in conjunction with enhancers from either the cd4 or cd8 genes (Ellmeier et al., 1997). 2. CD4 Enhancer Elements Analysis of gene expression in T cell lines transfected with a reporter gene under the regulation of the CD4 promoter and various sequences corresponding to DNase hypersensitivity (HS) sites resulted in the identification of an
60
ICHIRO TANIUCHI ET AL.
enhancer located approximately 13 kb upstream of the transcriptional start site. A 339 bp fragment from this region directed expression of the reporter in an orientation- and position-independent manner, and functioned only in T cells (Sawada and Littman, 1991). The same element and its human homologue, combined with the CD4 promoter and various lengths of the mouse or human CD4 gene, directed expression of CD4 or reporter genes in thymocytes and T cells, but not in other cell lineages (Gillespie et al., 1993; Hanna et al., 1994; Killeen et al., 1993; Sawada et al., 1994; Siu et al., 1994). This T cell-specific enhancer has been referred to as the CD4 proximal enhancer (E4p). E4p contains three nuclear protein-binding sites that were identified by DNaseI footprinting with nuclear extracts from Tcell lines (Sawada and Littman, 1991). One of these is a binding motif for the HMG box family proteins, TCF1/LEF1, and the other two contain E-box motifs that bind basic helix–loop–helix proteins. Mutation of tandem E-box motifs (CD4-3) at the 30 end of the enhancer abrogated enhancer activity in transiently transfected T cell lines, whereas mutation of the TCF1/ LEF1 binding motif (CD4-2) and the 50 E-box (CD4-1) had only minor effects (Sawada and Littman, 1991). A heterodimer consisting of E2A and HEB, both basic HLH proteins, was found to bind to one of the E-boxes in CD4–3 and to be required for CD4 enhancer activity in the in vitro assays (Sawada and Littman, 1993). This is discussed in greater detail in a later section. Another HS site, mapped approximately 24 kb upstream of the transcriptional start site in murine cd4, was first characterized as a CD4 distal enhancer (E4d) (Wurster et al., 1994). However, combined with the CD4 promoter, E4d does not appear to have enhancer activity in vivo. In addition, transgenes containing both E4d and E4p were expressed not only in T cells, but also in B cells and macrophages (Siu et al., 1994). The location of E4d is adjacent to the 30 end of the neighboring lag-3, which is expressed in activated T cells and in NK cells. It is possible that E4d is involved in regulation of lag-3 expression rather than cd4 expression. The role of E4p in directing expression in all thymocytes and T lymphocytes has been challenged by two reports, which together indicate that positive regulation of CD4 expression at different stages of development is more complex than initially thought. First, von Andrian and colleagues showed that activation of mature T cells by antigen results in down-regulation of expression of a transgenic GFP reporter regulated by E4p and the CD4 promoter (Manjunath et al., 1999). Because endogenous CD4 expression is not affected by activation, this result suggests that regulatory elements other than E4p contribute to the expression of CD4 in antigen-stimulated cells. It is possible that a second enhancer, either a novel or a known one such as E4d, functions alone or in cooperation with E4p to maintain expression of CD4 in effector and memory T cells. Mutation of these enhancers within the endogenous cd4 locus will be required to reveal their physiological functions.
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
61
A second report has presented compelling evidence that the proximal CD4 enhancer may not be sufficient to direct expression of transgenic reporter genes in immature DP thymocytes (Adlam and Siu, 2003). These studies employed the 339 bp E4p and approximately 1 kb of promoter sequence 50 to the transcriptional start site. In multiple transgenic mice, this combination of regulatory sequences resulted in expression only in SP thymocytes and mature T cells, but not in DP thymocytes. However, inclusion of a sequence corresponding to a distal DNase HS site, DH17, located approximately 40 kb 30 to the cd4 locus in the first intron of the isot gene, restored expression in DP thymocytes (Fig. 1). This sequence was shown to have enhancer activity in transient transfections of a DP thymoma, but it did not function in vivo in the absence of the proximal enhancer. DH17 was shown to contain both an enhancer, in a 1.0 kb fragment that was termed TE (thymocyte enhancer), and an adjacent 0.9 kb locus control region (LCR) that confers copy numberdependent and position-independent expression of transgenes (Adlam and Siu, 2003).
Fig 1 Enhancer and promoter elements in the cd4 locus that contribute to reporter transgene expression in double positive thymocytes versus mature single positive T cells. Constructs that utilize the human CD2 transgene (hCD2) are from Sawada et al., 1994, and unpublished studies of Zou and Littman. Constructs that utilize HLA-B7 are from Adlam and Siu, 2003. E4d, distal enhancer; E4p, proximal CD4 enhancer; P4, CD4 promoter; LCR/TE, locus control region and thymic enhancer located in first intron of isot gene. DH denotes DNase hypersensitive sites in the cd4 locus. Sites within the cd4 coding region have been omitted. We propose that DH5 may encode a negative DP thymocyte regulatory element that requires TE or another unidentified enhancer for expression in immature thymocytes. (See Color Insert.)
62
ICHIRO TANIUCHI ET AL.
The conclusion that the LCR/TE is essential, along with E4p, for expression of CD4 in DP thymocytes is based on results with an impressively large number of transgenic mice. Similarly, many transgenic mice prepared with combinations of E4p, the CD4 promoter (P4), and various parts of the first cd4 intron have clearly demonstrated expression in DP thymocytes as well as in more mature T cells. For example, the human CD2 reporter was expressed in DP (and some DN) thymocytes in multiple transgenic lines prepared with E4p and P4 without inclusion of the LCR/TE from DH17 (Sawada et al., 1994). Similarly, CD4-cre mice that have been widely employed to delete genes at the DP stage were prepared with the same combination of regulatory elements (Wolfer et al., 2001). Use of E4p/P4 also directed expression of GFP and of the chemokine receptors CXCR4 and CCR5 in DP thymocytes as well as in mature T cells in both mouse and rat (Ellmeier, Deng, and Littman, unpublished; Keppler et al., 2002; Weninger and von Andrian, unpublished). The consistency observed within each of the studies that examined expression of the transgenes suggests that the discrepancy in results must be due to a subtle, but important, difference in the constructs used by the different groups (see Fig. 1). The discrepancy was discussed in an earlier review, in which it was suggested that the difference may lie in the length of the promoters used by the two laboratories (Ellmeier et al., 1999). Siu and colleagues have used a promoter sequence that includes about 1 kb 50 of the transcriptional start site, while our group has used only 0.5 kb (Adlam and Siu, 2003; Sawada et al., 1994). We propose that a sequence immediately upstream of the CD4 promoter has negative regulatory activity in DP thymocytes and, hence, requires a specific enhancer activity at this stage of development. This enhancer activity most likely involves E4p functioning in conjunction with another element, possibly the LCR/TE within the isot intron (Fig. 1). Because the region containing ISOT is not required for expression of human CD4 transgenes in DP thymocytes, it is possible that other elements, adjacent to the CD4 coding region, provide this enhancer function in both the mouse and human genes. Alternatively, the mouse and human genes may differ in their requirement for enhancers directing expression in DP thymocytes. The presence of yet another enhancer has been suggested by analysis of mice with targeted deletions of the silencer and adjacent sequences in intron I of cd4. In two separate studies aimed at analyzing silencer function (described in the following text), 6.5 kb or 1.6 kb intron sequences were deleted by homologous recombination in ES cells. In mutant mice generated from these cells, the level of cell surface CD4 expression was reduced in DP thymocytes and peripheral CD4þ T cells (Leung et al., 2001; Zou et al., 2001). Therefore, a putative positive regulatory element may have been deleted along with the CD4 silencer. The low CD4 expression was not due to residual silencer activity, since the level on CD4þ T cells from another mutant strain, in
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
63
which only 429 bp of the CD4 silencer was deleted, was similar to that from wild-type mice (Taniuchi et al., 2002b). Taken together, these results are compatible with the existence of a positive regulatory element, a CD4 intronic enhancer (E4i), adjacent to the CD4 silencer. This enhancer is not necessary for directing expression of reporter transgenes in DP thymocytes, since the combination of E4p and P4 was functional in these cells even in the absence of intron I (Ellmeier et al., 1999; Zou and Littman, unpublished). The functions of the various enhancers previously described (E4p, E4d, LCR/TE, and E4i) have only been inferred from examination of expression patterns in transgenic mice. Because of the complexity of the positive regulation of CD4, an understanding of the roles of the individual elements awaits an analysis following their systematic deletion in the murine germ line. B. Negative Regulatory Elements Involved in CD4 Silencing Early attempts to generate mice in which expression of human CD4 transgenes would faithfully reproduce the pattern of endogenous mouse CD4 expression provided the first clue that the gene is negatively regulated in CD8 lineage cells. Human CD4 transgenes that contained E4p were expressed appropriately in DP thymocytes and T helper cells (Donda et al., 1996; Gillespie et al., 1993; Hanna et al., 1994; Killeen et al., 1993; Sawada et al., 1994; Siu et al., 1994). In contrast, when the murine E4p element was combined with the human promoter fused to a cDNA/genomic minigene in which exons 1–6 were derived from the cDNA, expression of CD4 was observed in all thymocytes and in both CD4þ and CD8þ T cells of transgenic mice (Crooks and Littman, unpublished). This suggested that a negative regulatory element, located within the first 5 introns of the human CD4 gene, had been omitted in the transgene. Subsequent studies showed that lineage-specific expression of transgenes requires sequences corresponding to a DNase HS site located 1.6 kb downstream from the first exon, within the first intron of the murine cd4 locus (Sawada et al., 1994; Siu et al., 1994). A similar negative regulatory sequence in the first intron of human CD4 was subsequently described (Donda et al., 1996). Inclusion in transgenic constructs of the murine CD4 silencer (S4), which was narrowed down to a 434 bp fragment from intron 1, resulted in repression of reporter gene expression in DN and CD8 SP thymocytes and in mature CD8 lineage T cells (Sawada et al., 1994; Siu et al., 1994). The activity of the silencer was independent of its orientation or location within the transgene, and it functioned with heterologous enhancers and promoters (Sawada et al., 1994). Importantly, expression of reporter transgenes in which the 434 bp CD4 silencer was combined with E4p and the 0.5 kb murine promoter recapitulated the normal developmental pattern of CD4 expression. Repression was observed not only in CD8 SP thymocytes, but also in a subset of immature CD4CD8DN thymocytes
64
ICHIRO TANIUCHI ET AL.
(Sawada et al., 1994). Based on these observations, a two-stage model was proposed for the temporal activation of the silencer during thymocyte differentiation (Sawada et al., 1994; Siu et al., 1994). In this model, the CD4 silencer is first turned on in immature DN thymocytes followed by inactivation at subsequent stages in which both CD4 and CD8 are expressed, then turned on again specifically in those thymocytes that become cytotoxic-lineage cells. The CD4 silencer was thus proposed to be the key cis-regulatory element regulating lineage specificity of CD4 expression. Gene-targeting studies in mice have confirmed that the CD4 silencer is essential for shutting off CD4 at both the DN and CD8 SP stages of thymocyte development. Following deletion of intronic segments that included the entire silencer, CD4 was de-repressed in a subset of thymocytes corresponding to immature CD4CD8 DN thymocytes in wild-type mice, in mature (HSAlow) CD8 SP thymocytes, and in peripheral CD8þ Tcells (Leung et al., 2001; Zou et al., 2001). Because the level of CD4 expression in the silencer-deleted mice was lower in immature CD4CD8DN thymocytes than in mature cytotoxic-lineage T cells (Leung et al., 2001; Zou et al., 2001), we cannot rule out the existence of another negative regulatory element operating specifically in immature DN thymocytes. However, as the 434 bp CD4 silencer is sufficient to completely repress transgene expression in DN thymocytes, it is likely that enhancer activity in these cells is somehow lower than that in the later developmental stages. These results therefore indicate that the CD4 silencer is essential and, most likely, sufficient for full repression of CD4 expression in both DN thymocytes and mature cytotoxic-lineage T cells, and demonstrate it to be the key cis-regulatory element that regulates lineage-specific activation of the CD4 locus. The search for functional sites within the CD4 silencer, which could potentially explain its selective activity in cytotoxic lineage T cells, has relied on a combination of transfection studies and analysis of transgenic mice, as well as on DNase footprinting analysis with nuclear extracts from T cells. A murine CD4CD8þ thymoma, 1200M, was found to be ideally suited for functional studies of the 434 bp CD4 silencer in transient transfection assays. When the silencer sequence was present in triplicate, reporter gene expression was effectively repressed. This permitted further whittling of the silencer to a 101 bp core fragment (165–265) that retained full activity (Taniuchi et al., 2002b). However, the minimal sequences required for silencer activity differed between transfection assays and transgenic reporter gene assays in mouse. A 147 bp fragment containing the core CD4 silencer was inactive in transgenic mice in the absence of sequences from either the 50 or 30 flanking regions (Sawada and Littman, unpublished). This suggested that the transient repression observed in the T cell line is fundamentally different from the repression or silencing observed in vivo, possibly because changes in chromatin organization depend on specific sequences in these flanks (see following text).
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
65
DNase I footprinting assays were employed by several groups to identify functionally relevant regions within the murine and human CD4 silencer. Using nuclear extracts from mouse T cell lines, Siu and colleagues identified three regions (site I, site II, and site III) within the 434 bp murine CD4 silencer (Duncan et al., 1996) (Fig. 2). Analysis of a 50 190 bp human CD4 silencer revealed two sites (site Ih and site IIh), one of which (Ih) partially overlapped with the homologous site I in the murine silencer (Donda et al., 1996). The requirement of these sites for silencer function was examined by mutational analyses in transgenic mice. Although single deletion of any site (site I, site II, or site III) from the 434 bp mouse CD4 silencer did not affect silencer activity, combined deletions of site II with either site I or site III resulted in the loss of activity in transgenic mice (Donda et al., 1996; Duncan et al., 1996). Another study using transient transfection assays identified two functional sites (site 1 and site 2) in the 101 bp core sequence (Taniuchi et al., 2002b). Site 1 partially overlapped with site II of Siu and colleagues, but site 2 differed from the previously described sites (Fig. 2). Mutation at site 1 or site 2 in the context of the core sequence abrogated silencer function in transfection assays. Similarly, these mutations, placed in the context of the core CD4 silencer with either 50 or 30 flanking regions, resulted in complete loss of silencer activity in transgenic mice. A third site (site 3), located between sites 1 and 2, was first identified by footprinting analysis (Sawada and Littman, unpublished). Although deletion of site 3 in the context of the core silencer resulted in only partial loss of silencer activity in the transfection assay, the same deletion in the context of the silencer lacking the 50 flanking region (131–434) resulted in complete loss of silencer activity in transgenic mice (Mahanta and Littman, unpublished). Thus, the functional requirement for different sites within the silencer differed according to the assay system used and the context in which various mutations were analyzed. Resolution of this problem required development of a reliable system in which the physiological roles of various sequences within the CD4 silencer could be compared. Comparison of the functions of different motifs was accomplished by gene targeting, using homologous recombination in ES cells to introduce numerous mutations within the murine cd4 locus (Taniuchi et al., 2002b). This in vivo mapping study clearly demonstrated a physiological requirement for several sites or subregions within the CD4 silencer. Because the cd4 gene is expressed from both alleles, loss of silencer function in one allele resulted in CD4 derepression that was easily monitored by flow-cytometry, thus allowing analysis in chimeric mice generated with ES cells harboring single mutant alleles. Silencer mutations within the endogenous cd4 locus had full, partial, or no effect on CD4 silencing in DN thymocytes and CD8 lineage T cells (Fig. 2). Importantly, there were differences in the consequence of the mutations at the different stages of T cell development, and this will be discussed in greater
66
ICHIRO TANIUCHI ET AL.
Fig 2 Transcriptional cis-regulatory elements in the murine cd4 locus and functional sites within the murine CD4 silencer. The coding exons are shown as closed bars and the noncoding 50 exon is shown as an open bar. The vertical arrows indicate DNaseI hypersensitive sites. The transcriptional direction of the CD4 gene is shown by the horizontal arrow. Proximal (E4p) and distal (E4d) enhancers (located approximately 13 kb and 24 kb upstream of the transcriptional start site, respectively) and a putative intronic (E4i) enhancer (located immediately 30 to the silencer) are shown as blue square boxes. The promoter (P4) and the silencer (S4) are shown as a purple square box and orange circle, respectively. The expanded region below the map represents the 434 bp murine CD4 silencer and putative factor binding sites. The top bar shows three footprint sites (yellow circles) defined by Siu and colleagues (Duncan et al., 1996) along with putative transacting factors. The second bar shows five sites defined by transient transfection assays, transgenic reporter assays, and targeted mutagenesis at the cd4 locus (Taniuchi et al., 2002b). The core silencer (sequence 165–265) was sufficient for silencer activity in transfection assays. Site 2 and site 20 are identical to the binding motif for Runt domain transcription factor (Runx) family members. The effects of targeted mutations on CD4 gene silencing in either immature DN thymocytes or peripheral CD8þ mature T cells are shown at the bottom: ‘‘Part/uni’’ denotes partial CD4 derepression in a uniform pattern. ‘‘Part/vari’’ denotes partial CD4 de-repression in a variegated pattern. ‘‘Full’’ represents CD4 de-repression in all of the CD8þ T cells. n.t.: not tested. (See Color Insert.)
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
67
detail in a later section. Deletion of the entire silencer (1–429) or of 90 bp within the core (167–257) resulted in complete CD4 de-repression in all mature CD8-lineage cells and in DN thymocytes. This result clearly showed that the core silencer is indispensable for silencer function. Mutations of single functional sites (site 1, 2, or 3) within the core resulted in CD4 de-repression in only a proportion of mature CD8-lineage cells. However, a combination of mutations at site 1 with mutations at either site 2 or site 3 resulted in CD4 derepression in all of the mature CD8þ T cells, demonstrating a functional redundancy of these sites (Taniuchi et al., 2002b). Analysis of flanking sequences, shown to have variable requirements in transgenic reporter studies, provided additional valuable information. Deletion of site III (260–281), which includes a putative binding motif for SAF (silencer associated factor), a factor reportedly localized in nuclei of CD8þ but not CD4þ T cells, had no effect on CD4 silencing. Deletion of the 30 flanking region (279–429) affected CD4 silencing in only a minor proportion (7%) of mature CD8þ cells. In contrast, deletion of the 50 flanking region (1–130) resulted in CD4 de-repression in a large proportion (80%) of mature CD8þ cells. Deletion of sequence 1–95 resulted in CD4 de-repression in only 10% of CD8þ cells, suggesting the presence of another functional site in 95–130 (referred to as putative site 4) (Taniuchi et al., 2002b). Sequence 75–90 within the 50 flanking region, identified by footprinting analysis as site I (Duncan et al., 1996), contains a Runx binding motif (referred to as site 20 ) overlapping with an E box motif, a binding site for basic helix–loop–helix proteins. A targeted mutation in which only the Runx binding motif was mutated, leaving an intact E box motif, resulted in CD4 de-repression in a small (6%) subset of mature CD8þ T cells, similar to that observed upon deletion of sequence 1–95. However, a combination of the site 20 mutation with a mutation of the Runx binding motif in the core (site 2) resulted in complete CD4 de-repression in CD8þ T cells (Taniuchi et al., 2002a). This demonstrated a key role for the Runx binding motif in the 50 flanking region of the silencer (see following text). A physiological role for the E box sequence has not been demonstrated by this kind of analysis, although in vitro studies have suggested that it may be a binding site for HES, a target of the Notch signaling pathway (Kim and Siu, 1998). C. Trans-acting Proteins Involved in CD4 Gene Regulation 1. Proteins Regulating CD4 Expression through Enhancers Investigation of trans-acting factors involved in CD4 enhancer function has been confined to the proximal enhancer. A heterodimeric complex of two basic helix–loop–helix proteins, E2A and HEB, was shown to bind to one of the two E-box motifs in CD4-3 (Sawada and Littman, 1993). In the thymus of mice
68
ICHIRO TANIUCHI ET AL.
with a targeted disruption of a functional domain of HEB, there was the appearance of an unusual subset of CD4low/CD8þTCRint cells (Barndt et al., 2000; Zhuang et al., 1996). The kinetics of appearance of this subset in the fetal thymus suggested a delayed up-regulation of the cd4 gene during T cell ontogeny in the absence of a functional HEB protein. A similar population of cells was also observed in mice harboring heterozygous mutations for both heb and e2a (hebþ/ e2aþ/ mice). These results suggest that activation of CD4 is sensitive to the gene-dosage of HEB and E2A, and they are consistent with the involvement of the HEB/E2A heterodimeric complex in CD4 gene activation. This interpretation must be tempered, however, by the observation that compromised HEB and E2A function results in developmental arrest at the b-selection stage in thymopoiesis. The apparent defect in CD4 up-regulation thus occurs in the setting of defective developmental progression, and may not be a direct consequence of reduced HEB/E2A. Some thymocytes can migrate to the periphery in the HEB-deficient mice, and CD4 expression is maintained in splenic T cells in these animals. Therefore, the requirement for HEB in CD4 gene expression may differ between immature thymocytes and mature T cells. This could be explained by the use of different enhancers at the two stages: HEB-dependent elements in E4p may be required in immature (DN and DP) thymocytes, whereas a different enhancer may provide HEB-independent activation in mature T cells. Alternatively, E2A could efficiently compensate for HEB function in mature T cells. A third possibility is that an epigenetic mechanism is involved in keeping CD4 active. HEB might therefore be necessary only for opening the CD4 locus in the initiation phase of gene activation, but would not be required subsequently to keep the locus active, due to heritable changes in chromatin. Interestingly, a similar observation was made in mice harboring a compromised CD8 enhancer (discussed in more detail later), although, in that case, there was accumulation of CD4þCD8low/TCRint thymocytes. Thus, compromised enhancer function at the CD4 and CD8 loci may result in inefficient gene activation in a proportion of cells, and lead to subsequent variegated expression. Further analyses, such as a conditional deletion of E4p or the CD8 enhancers, may provide further insight into epigenetic aspects of activation of CD4 or CD8. 2. Trans-acting Proteins that Act on the CD4 Silencer Several transcription factor-binding sites in the CD4 silencer have been shown to be functionally important in transgenic and targeted mutagenesis studies. The basic helix–loop–helix protein HES-1, a target of the Notch signaling pathway, was shown in vitro to bind to one of these motifs, the E box sequence located in site I (Kim and Siu, 1998). In a T cell line, HES-1 repressed reporter gene expression through the E-box sequence in a
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
69
dose-dependent manner (Kim and Siu, 1998). This result was consistent with a proposed function of Notch in regulation of the CD4/CD8 lineage decision. However, inactivation of Notch1 at the DP stage had no effect on lineage choice, suggesting that Notch signaling may not be important in CD4 silencing (Wolfer et al., 2001). In RAG2-defective host mice reconstituted with HES-1-deficient progenitors, T cell development was arrested at the DN stages (Tomita et al., 1999). However, in irradiated host mice, HES-1-deficient progenitors gave rise to mature T cells, including normal mature CD4CD8þ SP cells, suggesting no role for HES-1 in the lineage choice (Kaneta et al., 2000). Further studies are required to determine if the HES-1-binding E box has a role in CD4 gene regulation. Two other factors proposed to have a function in CD4 silencing are c-Myb and SAF, shown in vitro to bind to site II and site III, respectively (Fig. 2) (Allen et al., 2001; Kim and Siu, 1999). Combined mutations of the c-Myb-bindingmotif and the SAF binding site led to the loss of silencer function in transgenic reporter mice (Duncan et al., 1996; Kim and Siu, 1999). Site II overlaps with site 1 identified by Taniuchi et al. (Fig. 2). However, the Myb-binding motif is not conserved between the mouse and human CD4 silencer, and the consensus sequence is different from the minimum functional sequence of site 1, characterized by fine mapping in transfection assays (Taniuchi et al., 2002b). It is therefore unlikely that Myb binding to this site is required for silencer function. A role for SAF is also difficult to assess at this stage. This homeobox protein was identified in a screen for factors binding to the site III sequence, and it was reported to localize to the nucleus in CD8þ, but not CD4þ, T cells (Kim and Siu, 1999). However, there has been no functional analysis of the role of SAF in silencing. CD4 silencing in mature CD8þ cells was normal in the absence of the SAF binding motif (Taniuchi et al., 2002b), although it is possible that this site provides a redundant function that can only be revealed by analysis of compound mutations. Whereas evidence for the involvement of many transcription factors in the regulation of CD4 expression remains circumstantial, recent genetic studies have identified two transcription factors that are clearly required for the negative regulation of CD4 (Taniuchi et al., 2002a). These proteins are members of the Runt domain transcription factor (Runx) family. There are three mammalian members of the Runt domain family, Runx1– 3, that encode a subunits that bind to the Runx binding motif (50 -PuACCACA-30 ) by making heterodimeric complexes with a common b subunit, Cbfb/Pebp2b (Wheeler et al., 2000). Fine mapping analysis in 1200M cell transfection assays revealed that the minimal functional sequence of site 2 (232GACCACA238) in the silencer core corresponded to a consensus Runx binding motif (Taniuchi et al., 2002a). A second Runx binding motif (site20 , 81AACCACA87) was identified in the
70
ICHIRO TANIUCHI ET AL.
50 flanking region. Both of the Runx binding motifs were required for full CD4 silencer activity. Specific mutations of either site resulted in variegated CD4 de-repression in mature CD8þ cells, while mutations of both Runx motifs resulted in full CD4 de-repression in all mature CD8-lineage T cells, indicating that Runx sites are indispensable for establishment of epigenetic CD4 silencing. However, in immature DN thymocytes, the level of CD4 expression (or de-repression) when both Runx sites were mutated was lower than that upon deletion of the entire CD4 silencer (Taniuchi et al., 2002a). Thus, the function of Runx sites is likely to be partially compensated by other functional elements in immature DN thymocytes, but not in thymocytes developing into cytotoxic lineage cells, in which epigenetic CD4 silencing is being established. This difference in mechanism of repression or silencing is discussed in greater detail in the next section. Although transcripts for all three runx genes appear to be present in all thymocyte subsets, two of the three genes were shown to be required for regulating CD4 expression at distinct developmental stages (Taniuchi et al., 2002a). Runx1 was shown to be required for CD4 repression in immature DN thymocytes, while Runx3 was shown to be required for establishment of epigenetic CD4 silencing in CD8 lineage T cells. Because null mutations of runx1 result in an early lethal phenotype, the role of this gene in thymocytes was studied by using conditional inactivation of LoxP-flanked runx1 with Cre recombinase expressed at different stages of development. When runx1 was inactivated early in DN thymocytes, using Lck–Cre transgenic mice, CD4 was de-repressed in DN cells to a level similar to that observed when both Runx binding sites were mutated (Taniuchi et al., 2002a). Mice homozygous for runx3 mutations die perinatally, but fetal thymic development can be examined. In Runx3-deficient fetal thymi, CD4 repression in immature DN thymocytes was normal. However, RAG2-null host mice reconstituted with runx3-mutant progenitors displayed either full or variegated de-repression of CD4 in mature CD8-lineage cells, which differed from what was observed with the double Runx site mutations (Taniuchi et al., 2002a). The variegation in CD4 de-repression is likely due to a partial compensatory function of Runx1. Using a different strain of Runx3-deficient mice, in which runx3 inactivation is tolerated beyond the perinatal stage, Groner and colleagues showed full derepression of CD4 in CD8 lineage T cells of mice with the compound runx1þ/ runx3/ mutant genotype (Woolf et al., 2003). The relative contribution of Runx1 to the establishment of epigenetic CD4 silencing remains unclear. There was no apparent loss of CD4 silencing in CD8 lineage cells when runx1 was inactivated at different stages of thymocyte differentiation (Taniuchi et al., 2002a). Runx1 inactivation in DN thymocytes of runx1f/f/ Lck-Cre mice severely blocked the generation of DP and also mature thymocytes and resulted in a reduced number of peripheral mature CD4þ T cells
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
71
(Taniuchi et al., 2002a). However, the efficiency of runx1 excision in mature T cells was lower than that in thymocytes, consistent with an essential role for Runx1 during selection events in the thymus. When runx1 was inactivated in DP thymocytes, in runx1f/f/CD4-Cre mice, positive selection was compromised, but there was no CD4 de-repression in those CD8þ T cells that reached the secondary lymphoid organs, despite very efficient inactivation of runx1 in these cells (Egawa, Taniuchi, and Littman, unpublished). It is possible that Runx1 and Runx3 have equivalent abilities to initiate silencing of CD4 in cells destined for the CD8/cytotoxic T cell lineage. Because Runx3 appears to be expressed primarily in CD8 SP medullary thymocytes, while Runx1 is expressed at highest levels in immature cortical thymocytes, the loss of Runx3 would therefore more readily result in CD4 de-repression. A role for a mammalian SWI/SNF chromatin remodeling complex in CD4 silencing has also been proposed. CD4 de-repression was observed in immature DN thymocytes in which the function of the BAF complex, a mammalian counterpart of the yeast SWI/SNF complex, was compromised. Haploinsufficiency of Brg1 (ATPase subunit) compounded with expression of a dominant negative form of BAF57 (a DNA binding subunit containing an HMG-box) resulted in partial CD4 de-repression in immature DN thymocytes, and in CD4 de-repression in a minor proportion of mature CD8þ T cells (Chi et al., 2002). CD4 de-repression caused by impaired BAF function was enhanced in mice harboring a mutation in site 1 of the CD4 silencer, but this was observed only in immature DN thymocytes, not in mature CD8þ cells. Association of the BAF complex with the CD4 locus was demonstrated by chromatin immunoprecipitation (ChIP) assays in a T cell line, but it remains unclear whether the BAF complex directly binds to the CD4 silencer. Interestingly, the CD8 gene was poorly up-regulated in a proportion of cells corresponding to the DP stage when BAF function was compromised. Therefore, the BAF chromatin remodeling complex appears to function reciprocally at these two loci in early thymocyte differentiation: it contributes to repressing the CD4 locus and to activating the CD8 locus. Similarly, runx1 inactivation at the immature DN stage resulted in impaired CD8 up-regulation, in addition to the partial defect in CD4 repression. Although further genetic and biochemical studies are required, these results suggest that Runx1 functions at target loci to direct either repression or activation, in part by recruiting BAF complexes. D. Distinct Mechanisms of CD4 Silencing at Two Developmental Stages A common cis-regulatory element, the CD4 silencer, is clearly required for repression of CD4 both in DN thymocytes and in CD8 SP thymocytes that give rise to mature cytotoxic CD8þ T cells. The silencing mechanisms at these
72
ICHIRO TANIUCHI ET AL.
different stages of development are likely to share some general features, but they are also thought to be fundamentally different. The early silencing must be reversible, since thymocytes turn on CD4 following b-selection. In contrast, CD4 remains stably silenced in mature cytotoxic T cells (although there may be an exception in some activated human CD8þ T cells, in which CD4 can be re-expressed (Kitchen et al., 1998) ). Stable or heritable states of gene expression are governed by alterations in the structure of chromatin. Regulation of chromatin structure is achieved largely through post-translational modification of histones, which results in recruitment of diverse protein complexes (Jenuwein and Allis, 2001). It has been proposed that CD4 silencing in DN thymocytes is the result of active repression, which is reversible and does not involve extensive remodeling of chromatin, whereas silencing in CD8 lineage thymocytes is irreversible, probably due to an imprint that alters the chromatin structure at the CD4 locus (Taniuchi et al., 2002b). The latter would result in formation of heterochromatin, which is inaccessible to the transcriptional activation machinery. Although there is as yet no direct evidence for differences in histone modification or chromatin structure at the repressed CD4 locus in thymocytes at different stages of development, there are several lines of evidence that support this model, and these are discussed here. Targeted mutations within the core sequence of the silencer resulted in compromised CD4 silencing, manifested by partial de-repression of CD4 in both immature DN thymocytes and in mature CD8-lineage T cells. However, the patterns of CD4 de-repression were different at these stages: there was uniform de-repression in immature CD4CD8 DN thymocytes, but variegated de-repression in mature CD8-lineage cells (Taniuchi et al., 2002b). Variegated gene expression, or position effect variegation (PEV), is usually observed in transgenic mice or at sites adjacent to chromosomal translocations, and it is thought to be due to modification of chromatin structure (Festenstein et al., 1999). The results suggested that, in DN thymocytes, CD4 is actively repressed by a combination of transcription factors. Loss of binding of any one of these factors would result in partial but uniform de-repression of CD4 expression (Fig. 3). In contrast, in cells committed to the CD8 lineage, loss of binding to any single site in the silencer would reduce the probability of recruiting a complex that modifies chromatin during a critical developmental window. If the complex is recruited, then silencing is established and maintained. However, if the complex is not recruited during this time frame, the locus would not be modified and CD4 would be de-repressed (Fig. 3). Further analysis showed that CD4 silencing in mature cytotoxic T cells from mice with silencer mutations displayed the characteristic stochastic property attributed to heterochromatin-mediated gene silencing. Comparison of heterozygous and homozygous mice harboring a site 1 silencer mutation showed that the ‘‘on-or-off’’ status was determined stochastically on each allele.
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
73
The variegated CD4 de-repression was already observed in mature (TCRhighHSAlow) thymocytes, indicating that the on or off status was likely to be determined in developing thymocytes after positive selection. Once cells succeeded in silencing CD4 in the absence of a binding site within the silencer, the silenced status was maintained stably through subsequent mitoses (Taniuchi et al., 2002b). This is a key feature indicating that the silencer functions epigenetically in CD8 lineage T cells. Proof that the silencer is required for initiation, but not for maintenance, of CD4 silencing in CD8þ T cells was provided by studies of mice in which the CD4 silencer could be deleted at different stages of development. Gene targeting in ES cells was used to flank a 1.6 kb segment of murine cd4 intron 1, which includes the entire silencer, with two loxP sequences (Sil flox allele) (Zou et al., 2001). Expression of Cre recombinase resulted in excision of the loxP-flanked silencer. Similarly to the germline deletion, excision of the CD4 silencer in DP thymocytes, in CD4-Cre transgenic mice, resulted in derepression of CD4 in all mature CD8þ T cells. In contrast, in vitro deletion of the CD4 silencer in purified CD4CD8þ SP cells from spleen, by using a Cre-encoding retrovirus, did not result in CD4 de-repression, even after several mitoses (Zou et al., 2001). This clearly showed that the silencer is required for establishment, but not for the maintenance, of CD4 silencing. It is likely that a chromatin-modifying complex, recruited by silencer-binding factors during a developmental window as cells differentiate along the CD8 lineage, marks the CD4 locus with an epigenetic tag that is then inherited in the absence of the CD4 silencer. Insight into the nature of the temporal window during which silencing is established comes from mice in which the silencer was excised after cells committed to the CD8 lineage. The Sil flox mice were bred to transgenic mice in which Cre was regulated by an enhancer (E81, see following text) from the murine cd8ab locus that was shown to direct expression specifically in mature (HSAlow) CD8-lineage thymocytes. Remarkably, CD4 was expressed in CD8þ T cells in which the silencer was deleted, even though CD4 expression had initially been extinguished as the cells progressed to the CD48þHSAhi stage following lineage commitment (Zou et al., 2001). This result suggested that a certain time window was necessary to complete chromatin modification for epigenetic CD4 silencing. It will be of considerable interest to determine if the reversible CD4 silencing observed at this early stage following lineage commitment is mechanistically similar to that observed in DN thymocytes. In yeast, a model of stepwise chromatin modification was proposed for heterochromatinization at the silent mating type loci. This is initiated by deacetylation of histone by a histone deacetylase (HDAC), followed by methylation of lysine 9 in histone 3 by histone methyl-transferase (HMT), and then recruitment of the yeast homologue of heterochromatin
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
75
protein-1 (HP-1), one of major heterochromatin structural components (Nakayama et al., 2001). In mice, HP-1 was shown to be involved in gene silencing at centromeric regions, because overdosage of HP-1b by use of a transgene enhanced the silencing effect in the peri-centromeric regions, and suppressed PEV (Festenstein et al., 1999). Taniuchi and colleagues showed that the HP-1b transgene suppressed CD4 de-repression in CD8þ T cells from mice harboring a mutation at site 3 in the CD4 silencer. However, the HP-1b transgene did not alter the level of uniform CD4 de-repression in immature CD4CD8 DN thymocytes (Taniuchi et al., 2002b). Therefore, overdosage of HP-1 enhanced CD4 silencing only in mature T cells, which is consistent with the involvement of this heterochromatin component in irreversible epigenetic silencing, at the late stage of thymocyte development, and not in reversible repression of CD4 in DN thymocytes. The distinct roles of Runx1 and Runx3 in silencing at different stages of thymocyte development could also be interpreted as evidence that unique mechanisms are involved at each stage. However, it is also equally likely that the requirement for Runx1 in DN thymocyte active repression and for Runx3 (with some contribution from Runx1) in CD8 SP thymocyte silencing is simply due to the expression patterns of these transcription factors. Runx proteins are known to recruit HDACs by interacting with several corepressor molecules, including Groucho/TLE, which binds to the highly conserved C-terminal sequence found in all Runt domain family members, as well as Sin3A Fig 3 A model for distinct mechanisms of silencer-mediated CD4 repression at two developmental stages. (A) In immature CD4CD8 DN thymocytes, several CD4 silencer binding factors, including the BAF chromatin remodeling complex, together recruit corepressor molecules, resulting in reversible transcriptional repression (active repression). Runx sites (site 2 and site 20 ) would be occupied by Runx1 at this stage. At the transitional stage from CD4þCD8þ DP thymocytes to CD4CD8þ SP cytotoxic-lineage T lymphocytes, lineage specific modifications of chromatin structure (small orange circle) are established through the function of distinct machinery (orange square) recruited by the CD4 silencer binding factor complex. We propose that this epigenetic modification is preceded by the recruitment of a reversible complex similar to that found in DN thymocytes. Altered chromatin structure would contain HP-1 molecules and serve as a heritable mark for epigenetic maintenance of the silenced status. Runx sites would be occupied mainly by Runx3 at this stage. (B) Compromised silencer function due to a mutation of site 1 results in partial uniform de-repression of CD4 in immature DN thymocytes (left). During the transition from the CD4þCD8þ DP stage to CD8þ SP thymocytes, at which epigenetic silencing is established, the compromised silencer function results in one of two possible outcomes at the CD4 locus. In a fraction of the CD8-lineage T cells, modification of chromatin is complete enough for epigenetic inheritance of the silenced status. However, in the rest of these cells, modification of chromatin is not complete enough to shut off the CD4 gene. Following subsequent cell divisions, the amount of CD4 transcription would be dependent on the status of chromatin modification and would thus vary. The mixture of cells harboring silenced or activated CD4 results in variegated CD4 de-repression. HP-1 contributes to the successful establishment of the epigenetic mark. (See Color Insert.)
76
ICHIRO TANIUCHI ET AL.
(Levanon et al., 1998; Lutterbach et al., 2000; Wheeler et al., 2000). It is therefore possible that the Runx proteins contribute to active repression of CD4 by recruiting HDACs in both DN and CD8 SP thymocytes. In the CD8 SP thymocytes, following transition from the HSAhi to the HSAlo stage, there is likely to be the additional recruitment of the epigenetic machinery, which is dependent on the presence of Runx factors and induces locus heterochromatinization that is stably maintained even in the absence of the CD4 silencer by epigenetic mechanisms. E. Link of CD4 Silencing to Lineage Specification A major incentive for studying signaling pathways that regulate coreceptor expression is the likelihood that these are shared with pathways involved in cell fate determination of DP thymocytes. For this reason, Runx3 was a good candidate for a factor involved not only in CD4 silencing as cells committed to the CD8 lineage, but also in specification of the cytotoxic lineage. Indeed, there was a reduction in the number of CD8þ T cells in secondary lymphoid organs of RAG2-deficient mice reconstituted with runx3/ fetal liver cells (Taniuchi et al., 2002a). Similar results were observed in viable runx3/ mice (Woolf et al., 2003). In the thymus, generation of mature (TCRhighHSAlow) CD8þ thymocytes was normal in animals reconstituted with the mutant progenitors but was reduced in the viable mutant mice, although not to the extent observed in the periphery. This phenotype was not due to a defect in lineage commitment, however. Although CD8þ T cells from secondary lymphoid organs of these mice had defective TCR-mediated proliferative responses, after activation with IL-2 they had normal cytotoxic activity and normal expression of perforin, a protein critical for CTL function (Taniuchi et al., 2002a). CD4þ cells in Runx3-deficient mice had normal proliferative responses following TCR crosslinking or alloantigen stimulation. The reduction in number of CD8þ but not CD4þ T cells in secondary lymphoid organs is most likely due to defective homeostatic signaling in the former. Continuous interaction with MHC is required for survival of naive peripheral T cells (Goldrath, 2002), and loss of signaling in the absence of Runx3 would be expected to result in selective loss of the CD8þ T cells. Studies of the half-life of CD8þ versus CD4þ T cells in mice deficient for Runx3 will be important to determine if this is indeed the mechanism accounting for the reduced cellularity. Runx3 is therefore likely to be essential for the TCR-mediated response of CD8þ T cells to antigen stimulation rather than for induction of cytotoxic functions. This may be a common feature of Runx function in T cells, since inactivation of runx1 during thymocyte differentiation resulted in both defective b-selection and positive selection, which require pre-TCR and TCRab signal transduction, respectively. It will be of interest to identify genes, other
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
77
than CD4, that are involved in TCR signaling and are regulated by Runx1 and Runx3 at these different stages of T cell development. It remains unclear how lineage specificity of CD4 silencing is regulated. Although Runx3 mRNA was detected in CD4 SP thymocytes, albeit at a lower abundance than in CD8 SP thymocytes (Taniuchi et al., 2002a), immunohistochemical analysis suggests that Runx3 protein is present only in CD8 SP and not in CD4 SP thymocytes (Woolf et al., 2003). Runx3 gene expression may therefore be sufficient to induce CD4 silencing. Activation of runx3 transcription may be one component of the CD8 lineage program, and CD4 silencing would therefore be one of the consequences of this program. At this time, it is unclear if expression of Runx3 would be sufficient to impose silencing in developing thymocytes. It is possible that other components that bind to the silencer (e.g., to sites 1, 3, and 4) are constitutively present, and that expression of Runx3 is the key factor that results in silencing. Alternatively, the other factors may likewise be regulated differentially in the CD4 versus CD8 lineage, either at the transcriptional, translational, or post-translational level, and may thus also regulate silencing in the CD8 SP thymocytes. It will be important to identify the other silencer-binding factors and also to characterize the mechanism by which Runx3 expression is regulated, as this may hold the key to the pathway that specifies the cytotoxic T cell lineage. IV. Regulation of CD8 Gene Expression
In contrast to the CD4 coreceptor molecule, which is expressed as a monomer at the cell surface, CD8 is expressed either as a CD8aa homodimer or as a heterodimer formed by the CD8a and CD8b polypeptides. DP thymocytes and conventional TCRab cytotoxic T cells express CD8ab. The CD8a and CD8b genes are closely linked, which suggests that they are coordinately regulated in these cells (Gorman et al., 1988). However, since intraepithelial lymphocytes (IEL) from the gut (Jarry et al., 1990; Lefrancois, 1991) and CD8þ dendritic cells (DC) (Vremec et al., 1992) express only CD8aa homodimers, there must exist independent cis-regulatory elements specific either for CD8a and/or CD8b. A. Cis-regulatory Elements Involved in CD8 Regulation Early studies on the CD8a and CD8b promoters and on promoter-proximal regions failed to reveal CD8-specific cis-regulatory elements (for a review on CD8 promoters, see Ellmeier et al., 1999). Subsequent DNase hypersensitivity (DH) analyses over the entire CD8ab locus (referred to hereafter as the cd8 locus in mouse) led to the identification of four clusters (I, II, III, and IV) of DH sites within an 80 kb murine genomic fragment (Hostert et al., 1997a)
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
79
and six clusters (I to VI) within a 95 kb human genomic fragment (Kieffer et al., 1997). Transgenic mice generated with these large genomic fragments displayed appropriate developmental stage- and lineage-specific expression of the transgenic CD8a and b genes, demonstrating that the major cis-regulatory elements are located within these fragments. Interestingly, mosaic expression of the transgene was observed, most likely due to position effect variegation (Festenstein et al., 1996). This suggests that a locus control region (LCR, a cis-acting element that mediates position-independent and copy numberdependent expression of a transgene; for review, see Festenstein and Kioussis, 2000) is either not required to facilitate expression of CD8a and CD8b in their endogenous context or was omitted from the transgenic constructs. Additional transgenic reporter expression assays were used to study and dissect the different DH clusters in more detail, and several genomic fragments involved in the regulation of CD8 expression were identified (Ellmeier et al., 1997, 1998; Hostert et al., 1998, 1997a,b; Kieffer et al., 1996, 1997; Zhang et al., 1998, 2001). At least four different genomic fragments isolated from the murine cd8 locus were able to direct expression in a developmental stage-, subset-, and lineage-specific mode (Fig. 4). Since the genomic fragments used in the transgenic assay contained DH sites, it is likely that the enhancer activities co-localize with the hypersensitivity sites. The first enhancer identified, designated E8I or CIII-1,2, had activity only in mature CD8 SP thymocytes and in CD8þ T cells (Ellmeier et al., 1997; Hostert
Fig 4 Summary of characterization of cis-regulatory regions in the murine cd8 locus. Upper part: Schematic map of the cd8a and cd8b loci on mouse chromosome 6. Vertical arrows indicate individual DNase I hypersensitivity (DH) sites that have been grouped to DH clusters I–IV (Hostert et al., 1997a). Horizontal arrows indicate the location and transcriptional orientation of the cd8a and cd8b genes, while the open and closed bars indicate coding and noncoding exons, respectively. All BamHI (B), but only relevant EcoRI (E), sites are shown. The black horizontal bars show the genomic fragments used to define E8I, E8II, E8III, and E8IV. It is very likely that the enhancer activities within these genomic fragments overlap with some of the DH sites that map within the fragments. Middle part: Graphic representation of the genomic fragments used in transgenic reporter expression assays. The enhancer activity of the various fragments is shown at the right. The references reporting the activities are: T1 and T2 (Hostert et al., 1997a); T3 (Ellmeier et al., 1997; Hostert et al., 1997b); T4 (Hostert et al., 1997b); T5 (Hostert et al., 1998); T6 (Hostert et al., 1998; Zhang et al., 1998); T7–T10 (Ellmeier et al., 1998). þ indicates strong enhancer activity, þ/ weak activity, and – no enhancer activity. Nd: not determined. Lower part: The bars indicate the genomic region deleted in enhancer-deficient mice. The expression of CD8 in the absence of the enhancer is shown at the right. The references reporting the enhancer deletions are: K1 (Ellmeier et al., 1998; Hostert et al., 1998); K2 and K3 (Ellmeier et al., 2002); K4 (Garefalaki et al., 2002). þ indicates normal CD8 expression, þ/ reduced CD8 expression, and – no CD8 expression. ‘‘Var’’ indicates variegated expression of CD8. Nd: not determined. (See Color Insert.)
80
ICHIRO TANIUCHI ET AL.
et al., 1997b). Its up-regulation coincided with the transition of CD8 lineage thymocytes from the TCRintHSAhi to the TCRhiHSAlo stage, which marks the transition of selected cells from the thymic cortex to the medulla. Another enhancer, E8III (CIV-3), directed expression only in immature DP thymocytes. Enhancer E8II (CIV-4,5) directed expression both in DP thymocytes and in CD8þ SP thymocytes and T cells (Ellmeier et al., 1998). Finally, the cisregulatory element E8IV (CIV-1,2) displayed low activity in CD4þ SP and mature T cells in addition to DP and CD8 lineage cells (the significance of the low-level activity in helper T cells is currently not understood) (Ellmeier et al., 1998). While all the cis-acting elements were active in thymic-derived T cells (at least at certain developmental stages), only E8I also directed expression in IEL (Ellmeier et al., 1997), which have been proposed to be of extrathymic origin, although this remains controversial (Guy-Grand et al., 2003; Leishman et al., 2002). This suggested that E8I specifically regulates expression of CD8a (see following text). Furthermore, it was also shown that combinatorial interactions between cis-elements exist (Hostert et al., 1998). The combined activity of DH site cluster II, which by itself has no enhancer activity, and cluster III directs expression of a reporter gene not only in CD8þ T cells (as one would expect since cluster III, containing CIII-1,2(E8I), directs expression in the mature CD8þ T cell lineage), but also in DP thymocytes. Taken together, these studies indicate that lineage-specific regulation of CD8a and CD8b gene expression during T cell development is achieved through a complex regulatory network that utilizes several closely linked cis-regulatory elements with distinct developmental stage-, subset-, and lineage-specific functions (Fig. 4). The results from the transgenic reporter expression assays raise the question of why so many different, and probably partially redundant, cis-acting elements are required for the regulation of CD8 expression. One could argue that, in the context of the endogenous CD8 locus, the enhancers that show activity in the same subsets, such as E8I and E8II in CD8 SP and mature CD8þ T cells and E8II and E8III in DP thymocytes, are together required for high-level expression of CD8a and CD8b. When analyzed in transgenic reporter assays isolated from their genomic context, they therefore display similar activities. Another possible reason for the requirement of multiple cis-elements is that some of the enhancers may direct specifically the expression of either CD8a or CD8b within the thymus-derived T cell lineage. Because it is difficult to experimentally test these possibilities in transgenic reporter assays, new insights have come from studies in mice with specific targeted mutations in cd8 regulatory sites. To investigate whether different elements in the cd8 locus have unique regulatory functions and to overcome the limitations of the transgenic reporter system, a systematic deletional analysis of the various enhancers and
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
81
cis-elements in the mouse germ line has been initiated. Based on the results from transgenic reporter expression assays, one would have predicted that (1) individual deletions of enhancers should (at least) lead to a reduction of CD8 expression in the subsets in which the enhancers show activity, and that (2) combined deletions of enhancers with similar T cell subset activities should lead to a more dramatic reduction of CD8 expression compared to individual deletions. Dependent on whether some of the enhancers are specific for CD8a or CD8b, one may also expect a reduction in the expression of only one of these coreceptor genes. These predictions have been recently tested for three cis-elements: the mature CD8þ T cell enhancer E8I, the DP and CD8 SP specific E8II, and DH site cluster II that contributes to DP-specific gene expression in transgenic mice. In agreement with the predictions based on the transgenic reporter studies, mice homozygous for deletion of E8I (D1/D1) had a 3- to 5-fold reduction of CD8a expression levels on IEL, particularly on the TCRgdþ cells (Ellmeier et al., 1998; Hostert et al., 1998). This indicates that E8I is the major regulatory element for CD8a expression on IEL. In contrast, even though E8I alone is sufficient to direct expression in CD8 SP thymocytes and in mature CD8þ T cells, expression of CD8ab was largely normal in these thymus-derived cells in the D1/D1 mice. There was a very slight reduction (about 1.3-fold) in the CD8ab level in mature thymocytes, but not in peripheral T cells (Ellmeier et al., 1998). This may be significant in the context of sequential functions of CD8 enhancers during thymocyte maturation, and will be discussed in greater detail. Mice with targeted deletions of E8II (D2/D2) had normal expression of CD8 in thymocytes and in both thymus-derived CD8þ T cells and IELs. Since, in transgenic mice, both E8I and E8II direct expression in mature CD8þ T cells, it was possible that these two enhancers could compensate for each other in this subset. In addition, in E8II-deficient mice, E8III or cluster II (in combination with other regulatory regions) could similarly compensate to direct CD8 expression in DP thymocytes. These possibilities were tested by analyzing mice double-deficient for E8I and E8II (D1D2/D1D2 mice). In contrast to individual deletions, deletion of E8I and E8II had a major effect on the expression of CD8 during thymocyte development, but not in mature CD8 lineage cells (Ellmeier et al., 2002). A population of ‘‘CD8-negative’’ DP thymocytes appeared that was indistinguishable from DP thymocytes by expression of other surface markers and by functional phenotype. Remarkably, a very similar phenotype with an even higher proportion of CD8-negative DP thymocytes was observed in mice with a deletion of DH cluster II (Garefalaki et al., 2002). The concurrent appearance of CD8-negative DP thymocytes and DP cells is consistent with variegation of expression of CD8 in the absence of either E8I/E8II or cluster II, which suggests that precursor cells in the mutant mice undergo
82
ICHIRO TANIUCHI ET AL.
stochastic establishment or loss of CD8 gene expression. As a consequence, fewer DP thymocytes were present and fewer mature CD8þT cells developed. These results revealed a novel function of the cis-regulatory elements and enhancers that cannot be predicted by transgenic reporter analyses. They additionally suggested that there is partial redundancy of enhancers involved in initiation of CD8 gene expression in ISP or DP thymocytes. Even in the absence of either both E8I and E8II or cluster II, a majority of thymocytes expressed CD8 in the DP compartment, suggesting that after initiation of expression, an epigenetic mechanism keeps the CD8 locus in an ‘‘on’’ configuration. Surprisingly, expression of CD8 on those cells in which it was up-regulated (i.e., DP thymocytes and peripheral CD8þT cells) was only slightly reduced in the mutant mice. It will be necessary to perform additional targeted mutational analyses in mice to determine if enhancers other than E8I, E8II, and cluster II are required to initiate and sustain expression of CD8 in these cells, or, indeed, whether there is an epigenetic mechanism that renders mature cells independent of further function of these cis-regulatory elements. As has been mentioned, E8I directs reporter gene expression in CD8aaþ IEL in transgenic mice (Ellmeier et al., 1997) and its targeted deletion confirmed that it is the major enhancer that directs expression of CD8a in this lineage (Ellmeier et al., 1998; Hostert et al., 1998). However, a subset of CD8aa-expressing TCRgdþ IEL in E8I-deficient mice continued to express surface CD8aa homodimers, albeit at lower levels (Ellmeier et al., 1998; Hostert et al., 1998). Because none of the other identified enhancers directed transgene expression in IEL, a possible explanation remained that unknown enhancer elements could compensate for loss of E8I in this particular CD8aalowTCRgdþ IEL subset. Surprisingly, E8II, which did not show any activity in CD8aaþ IEL in transgenic mice (Ellmeier et al., 1998), was found to compensate, at least partially, for the loss of E8I. In D1D2/D1D2 mice, there was almost complete absence of CD8a expression in TCRgdþ IEL and a further reduction of CD8a expression in CD8aaþTCRabþ IEL compared to D1/D1 animals (Ellmeier et al., 2002). E8I and E8II are therefore the cisregulatory elements that direct expression of CD8a in CD8aa homodimerexpressing IEL of the TCRgd lineage. In CD8aaþ IEL of the TCRab lineage, additional elements must be able to direct low-level expression of CD8a. As has been mentioned, CD8aa homodimers are also expressed on splenic DC. However, neither E8I nor E8II was able to direct the expression of a reporter gene in DC (Jung, Ellmeier, and Littman, unpublished). In addition, CD8a expression on DC was unaltered in E8I and E8II single knockout mice or in E8I/E8II double-deficient mice (Ellmeier and Littman, unpublished). Thus, the regulatory elements required for CD8a expression in DC remain to be identified.
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
83
B. Trans-acting Factors and Chromatin Remodeling in CD8 Gene Regulation The results from the CD8 enhancer- and cluster II-deficient mice suggested that the regulation of chromatin is an important step in the activation of CD8a and CD8b during T cell development (Kioussis and Ellmeier, 2002). More direct evidence that chromatin remodeling is indeed required in the regulation of CD8 expression comes from recent studies of the mammalian SWI/SNFlike BAF complex. In addition to its role in CD4 silencing (as has been described), the BAF complex also regulates the activation of CD8 and both BAF57 (an HMG box-containing factor) and Brg1 (an ATPase required for chromatin remodeling) have been implicated in this process (Chi et al., 2002). The first indication came from the analysis of CD8a expression levels in BAF57DN transgenic animals. Mice heterozygous for the BAF57DN transgene expressed lower levels of CD8a on DP thymocytes compared to nontransgenic littermates, and this phenotype was even more pronounced in mice homozygous for the transgene. Furthermore, haplo-insufficiency of Brg1 (achieved by generating brg1þ/ mice) led to the appearance of a population of CD4þCD8CD3 thymocytes (which was not caused by de-repression of CD4 in DN cells). Although it was not formally demonstrated whether these thymocytes are phenotypically (except with respect to CD8 expression) and physiologically similar to DP cells, this population was reminiscent of the CD8-negative DP cells that develop in mice with either cluster II or combined E8I and E8II deletions. These results suggest a link between some of the cis-regulatory elements and the BAF complex. Another factor that has been implicated in the activation of the CD8a and CD8b loci is Ikaros, a transcription factor with multiple functions in hematopoiesis (Georgopoulos, 2002). A study in which antibodies specific for Ikaros were used to perform ChIP analysis revealed an association of Ikaros with sequences within the CD8 locus (Harker et al., 2002). Interestingly, the Ikaros-binding regions overlap with DH sites within DH clusters II and III. Furthermore, it was shown that haploinsufficiency of Ikaros causes an increase in the variegation of transgenic reporter genes that were driven by genomic fragments containing cluster II and/or cluster III. This effect seemed to be specific for CD8 regulatory elements, since the degree of variegation caused by control hCD2 regulatory elements was unaffected by Ikaros haploinsufficiency (Harker et al., 2002). In addition, the effect of Ikaros (and related family members such as Aiolos) was also seen at the endogenous cd8a and b loci. Compound mutations of the genes encoding Ikaros and Aiolos (Ikarosþ/ Aiolos/) led to the appearance of immature CD4þCD8 cells (Harker et al., 2002), reminiscent of the CD8-negative DP cells observed in enhancer-deficient mice and in mice carrying mutations
84
ICHIRO TANIUCHI ET AL.
in members of the BAF complex. A similar population of cells has also been observed in mice in which runx1 was inactivated with the Lck-Cre transgene (Taniuchi et al., 2002a). Together, these findings suggest that Ikaros and Runx1 may bind to various enhancers in the CD8 locus, and that they recruit the BAF chromatin remodeling complex, making the locus accessible to the transcriptional machinery. Alternatively, BAFbinding may precede the recruitment of Ikaros, Runx1, and other factors, and may thus remodel chromatin to permit sequence-specific binding of these factors. Elucidation of the relationship between the transcription factors and the BAF chromatin remodeling complex awaits ChIP analysis at different stages of thymocyte differentiation with strains of mice bearing mutations within the cd8 locus or in genes encoding the various trans-acting factors. C. E8i in Memory Cell Differentiation: Is E8I a Target of TCR Signaling? A surprising new twist to the CD8 regulation story comes from the recent observation by Cheroutre and colleagues that a selected subset of conventional CD8abþ T cells transiently expresses CD8aa homodimers not only upon in vitro TCR stimulation but, more importantly, also upon in vivo activation with antigen (Madakamutil et al., 2004). This induction was revealed by staining with tetramers of the class Ib molecule TL1, which binds selectively to CD8aa homodimers and not CD8ab heterodimers. The excess synthesis of CD8a after induction presumably results in preferential formation of cell surface CD8aa homodimers due to the limiting concentration of CD8b, which is only found in heterodimers. Remarkably, the induction of CD8a was found to be required for survival of the activated effector cells that subsequently differentiate into memory CD8þ T cells. The induction of CD8aa homodimers upon activation of CD8abþ T cells was abrogated in E8I-deficient mice both in vivo and in vitro, indicating that E8I is not only the major enhancer regulating expression of CD8aa on IEL, but is also required for up-regulation of CD8aa on cells destined to become memory T cells (Madakamutil et al., 2004). Although E8I-deficient mice were able to mount a normal primary immune response against LCMV, they failed to develop a significant population of LCMV-specific memory T cells. Thus, activation of E8I by TCR signaling in CD8þ CTL results in up-regulation of CD8aa, which is required for subsequent generation or survival of memory CTL. The upregulation of CD8aa is consistent with the observation of reduced CD8b expression on human memory CTL (Konno et al., 2002) and presumably occurs transiently in only a small subset of effector CD8þ T cells that are destined to differentiate into memory T cells.
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
85
This surprising result calls for a reevaluation of the function of E8I, at least beyond the DP stage in the thymus. Expression of CD8aa homodimers in IEL is clearly dependent on E8I, and, as in memory CTL, this may require TCR-mediated signaling. In the thymus, E8I appears to contribute to induction of CD8 expression in DP thymocytes, and it also appears to function late after positive selection to ensure that the level of CD8 is optimal on SP cells. It is possible that at this stage, when cells transit from the TCRintHSAhi to the TCRhiHSAlo phenotype, and presumably migrate from the cortex to the medulla, E8I also functions in response to TCR-mediated signaling. In the context of the ‘‘CD8 reversal model’’ for lineage specification (Brugnera et al., 2000), it is expected that CD8 is regulated at different stages of development. Following positive selection signaling, DP expression is extinguished, presumably due to cessation of E8III activity (and of other enhancers that cooperate with E8III). Cells selected by interaction with MHC class I would then undergo CD4 silencing, concomitant with activation of another set of CD8 enhancers, which has yet to be identified but which could include E8II and E8IV, both of which direct expression in DP and CD8 SP thymocytes. This would restore high levels of CD8ab heterodimer, and the potential for the TCR–coreceptor complex to resume signaling by interacting with self-MHC. We propose that this would result in a TCR-mediated signal that activates E8I (and, possibly, expression of genes required for migration of the cells from the cortex to the medulla). Finally, future studies will have to focus on the analysis of the developmental stage-specific regulation of enhancer and DH cluster activities and on their interplay to ensure proper expression of CD8. One could imagine that the accessibility of the enhancers for trans-factors is developmentally regulated and therefore determines whether an enhancer is active or not in a particular subset. Thus, the enhancer would contain information for the recruitment of chromatin remodeling activities at the proper developmental stage. Alternatively, a different set of trans-acting factors that are either repressed or induced at the onset of positive selection would regulate CD8 expression in immature versus mature thymocytes, respectively. Whether an enhancer is functional or not would be determined by the presence of the trans-acting factor. The identification of the enhancer binding factors will certainly help to reveal which of the models (which are, of course, not mutually exclusive) is correct. D. Enhancer Specificity for CD8a versus CD8b A question that has not been directly addressed in the studies already described is how specificity of CD8a and b gene expression is achieved in different T cell lineages. Since the clusters of DH sites that contain at least five
86
ICHIRO TANIUCHI ET AL.
different cis-regulatory elements are in close proximity to each other and since CD8a and CD8b display T cell lineage-dependent differences in their expression pattern, a tight regulatory interaction between the CD8a and CD8b genes and the enhancers must exist. One could speculate that E8I, which is necessary and sufficient to direct expression in CD8aaþ IEL (Ellmeier et al., 1997, 1998; Hostert et al., 1998), is likely to function only in conjunction with the CD8a promoter and may therefore be specific for regulating CD8a expression. However, additional transgenic expression assays indicate that E8I together with the CD8b promoter is able to direct expression of a reporter gene in IEL (Ellmeier and Littman, unpublished). Thus, incompatibility between E8I and the CD8b promoter does not seem to explain why E8I, which is active in IEL, fails to direct CD8b gene expression in this T cell lineage. It is more likely that an insulator element (Bell et al., 2001) may be localized between E8I and the CD8b promoter, thus preventing enhancer and promoter interactions. V. Conclusion
Close examination of how the CD4 and CD8 genes are regulated during T lymphocyte development, not only in the thymus but also in secondary lymphoid organs, has provided us with valuable insight into mechanisms of lineage specification. Further studies in this area promise to uncover how helper versus cytotoxic T cells differentiate, and, possibly, even how effector T cells give rise to subsets of long-lived memory T cells with specialized activation properties. In a more general sense, examination of these loci has provided a unique opportunity to study epigenetic regulation in vertebrate development. The CD4 locus remains the only vertebrate gene currently shown to undergo developmentally regulated epigenetic silencing, and as such, it presents an ideal system for analyzing how heterochromatin is established during developmental processes in higher eukaryotes. Acknowledgments W. Ellmeier is supported by the Austrian Research Fund (FWF) and the START program of the Austrian Ministry of Education, Science, and Culture, and D. R. Littman is an Investigator of the Howard Hughes Medical Institute.
References Adlam, M., and Siu, G. (2003). Immunity 18, 173. Allen, R. D., 3rd, Kim, H. K., Sarafova, S. D., and Siu, G. (2001). Mol. Cell. Biol. 21, 3071. Baixeras, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., and Piatier-Tonneau, D. (1992). J. Exp. Med. 176, 327. Barndt, R. J., Dai, M., and Zhuang, Y. (2000). Mol. Cell. Biol. 20, 6677. Bell, A. C., West, A. G., and Felsenfeld, G. (2001). Science 291, 447.
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
87
Brugnera, E., Bhandoola, A., Cibotti, R., Yu, Q., Guinter, T. I., Yamashita, Y., Sharrow, S. O., and Singer, A. (2000). Immunity 13, 59. Cantor, A. B., and Orkin, S. H. (2001). Curr. Opin. Genet. Dev. 11, 513. Chi, T. H., Wan, M., Zhao, K., Taniuchi, I., Chen, L., Littman, D. R., and Crabtree, G. R. (2002). Nature 418, 195. Chong, M. M., Cornish, A. L., Darwiche, R., Stanley, E. G., Purton, J. F., Godfrey, D. I., Hilton, D. J., Starr, R., Alexander, W. S., and Kay, T. W. (2003). Immunity 18, 475. Davis, C. B., and Littman, D. R. (1994). Curr. Opin. Immunol. 6, 266. Donda, A., Schulz, M., Burki, K., De Libero, G., and Uematsu, Y. (1996). Eur. J. Immunol. 26, 493. Duncan, D. D., Adlam, M., and Siu, G. (1996). Immunity 4, 301. Ellmeier, W., Sawada, S., and Littman, D. R. (1999). Annu. Rev. Immunol. 17, 523. Ellmeier, W., Sunshine, M. J., Losos, K., Hatam, F., and Littman, D. R. (1997). Immunity 7, 537. Ellmeier, W., Sunshine, M. J., Losos, K., and Littman, D. R. (1998). Immunity 9, 485. Ellmeier, W., Sunshine, M. J., Maschek, R., and Littman, D. R. (2002). Immunity 16, 623. Festenstein, R., and Kioussis, D. (2000). Curr. Opin. Genet. Dev. 10, 199. Festenstein, R., Sharghi-Namini, S., Fox, M., Roderick, K., Tolaini, M., Norton, T., Saveliev, A., Kioussis, D., and Singh, P. (1999). Nat. Genet. 23, 457. Festenstein, R., Tolaini, M., Corbella, P., Mamalaki, C., Parrington, J., Fox, M., Miliou, A., Jones, M., and Kioussis, D. (1996). Science 271, 1123. Garefalaki, A., Coles, M., Hirschberg, S., Mavria, G., Norton, T., Hostert, A., and Kioussis, D. (2002). Immunity 16, 635. Georgopoulos, K. (2002). Nat. Rev. Immunol. 2, 162. Gillespie, F. P., Doros, L., Vitale, J., Blackwell, C., Gosselin, J., Snyder, B. W., and Wadsworth, S. C. (1993). Mol. Cell. Biol. 13, 2952. Goldrath, A. W. (2002). Microbes Infect. 4, 539. Goldrath, A. W., and Bevan, M. J. (1999). Nature 402, 255. Gorman, S. D., Sun, Y. H., Zamoyska, R., and Parnes, J. R. (1988). J. Immunol. 140, 3646. Gorman, S. D., Tourvieille, B., and Parnes, J. R. (1987). Proc. Natl. Acad. Sci. USA 84, 7644. Guy-Grand, D., Azogui, O., Celli, S., Darche, S., Nussenzweig, M. C., Kourilsky, P., and Vassalli, P. (2003). J. Exp. Med. 197, 333. Hanna, Z., Simard, C., Laperriere, A., and Jolicoeur, P. (1994). Mol. Cell. Biol. 14, 1084. Harker, N., Naito, T., Cortes, M., Hostert, A., Hirschberg, S., Tolaini, M., Roderick, K., Georgopoulos, K., and Kioussis, D. (2002). Mol. Cell 10, 1403. Hayday, A., Theodoridis, E., Ramsburg, E., and Shires, J. (2001). Nat. Immunol. 2, 997. Hernandez-Hoyos, G., Sohn, S. J., Rothenberg, E. V., and Alberola-Ila, J. (2000). Immunity 12, 313. Hori, S., Nomura, T., and Sakaguchi, S. (2003). Science 299, 1057. Hostert, A., Garefalaki, A., Mavria, G., Tolaini, M., Roderick, K., Norton, T., Mee, P. J., Tybulewicz, V. L. J., Coles, M., and Kioussis, D. (1998). Immunity 9, 497. Hostert, A., Tolaini, M., Festenstein, R., McNeill, L., Malissen, B., Williams, O., Zamoyska, R., and Kioussis, D. (1997a). J. Immunol. 158, 4270. Hostert, A., Tolaini, M., Roderick, K., Harker, N., Norton, T., and Kioussis, D. (1997b). Immunity 7, 525. Izon, D. J., Punt, J. A., and Pear, W. S. (2002). Curr. Opin. Immunol. 14, 192. Jaenisch, R., and Bird, A. (2003). Nat. Genet. 33 (Suppl.), 245. Jarry, A., Cerf-Bensussan, N., Brousse, N., Selz, F., and Guy-Grand, D. (1990). Eur. J. Immunol. 20, 1097. Jenuwein, T., and Allis, C. D. (2001). Science 293, 1074. Kaneta, M., Osawa, M., Sudo, K., Nakauchi, H., Farr, A. G., and Takahama, Y. (2000). J. Immunol. 164, 256.
88
ICHIRO TANIUCHI ET AL.
Keefe, R., Dave, V., Allman, D., Wiest, D., and Kappes, D. J. (1999). Science 286, 1149. Keppler, O. T., Welte, F. J., Ngo, T. A., Chin, P. S., Patton, K. S., Tsou, C. L., Abbey, N. W., Sharkey, M. E., Grant, R. M., You, Y., Scarborough, J. D., Ellmeier, W., Littman, D. R., Stevenson, M., Charo, I. F., Herndier, B. G., Speck, R. F., and Goldsmith, M. A. (2002). J. Exp. Med. 195, 719. Kieffer, L. J., Bennett, J. A., Cunningham, A. C., Gladue, R. P., McNeish, J., Kavathas, P. B., and Hanke, J. H. (1996). Int. Immunol. 8, 1617. Kieffer, L. J., Yan, L., Hanke, J. H., and Kavathas, P. B. (1997). J. Immunol. 159, 4907. Killeen, N., and Littman, D. R. (1996). Curr. Top. Microbiol. Immunol. 205, 89. Killeen, N., Sawada, S., and Littman, D. R. (1993). EMBO J. 12, 1547. Kim, H. K., and Siu, G. (1998). Mol. Cell. Biol. 18, 7166. Kim, W. W., and Siu, G. (1999). J. Exp. Med. 190, 281. Kioussis, D., and Ellmeier, W. (2002). Nat. Rev. Immunol. 2, 909. Kitchen, S. G., Korin, Y. D., Roth, M. D., Landay, A., and Zack, J. A. (1998). J. Virol. 72, 9054. Konno, A., Okada, K., Mizuno, K., Nishida, M., Nagaoki, S., Toma, T., Uehara, T., Ohta, K., Kasahara, Y., Seki, H., Yachie, A., and Koizumi, S. (2002). Blood 100, 4090. Kronenberg, M., and Gapin, L. (2002). Nat. Rev. Immunol. 2, 557. Lefrancois, L. (1991). Semin. Immunol. 3, 99. Lefrancois, L., and Olson, S. (1994). J. Immunol. 153, 987. Leishman, A. J., Gapin, L., Capone, M., Palmer, E., MacDonald, H. R., Kronenberg, M., and Cheroutre, H. (2002). Immunity 16, 355. Leung, R. K., Thomson, K., Gallimore, A., Jones, E., Van den Broek, M., Sierro, S., Alsheikhly, A. R., McMichael, A., and Rahemtulla, A. (2001). Nat. Immunol. 2, 1167. Levanon, D., Goldstein, R. E., Bernstein, Y., Tang, H., Goldenberg, D., Stifani, S., Paroush, Z., and Groner, Y. (1998). Proc. Natl. Acad. Sci. USA 95, 11590. Li, E. (2002). Nat. Rev. Genet. 3, 662. Lutterbach, B., Westendorf, J. J., Linggi, B., Isaac, S., Seto, E., and Hiebert, S. W. (2000). J. Biol. Chem. 275, 651. Madakamutil, L. T., Christen, U., Lena, C. J., Wang-Zhu, Y., Attinger, A., Sundarrajan, M., Ellmeier, W., von Herrath, M. G., Jensen, P., Littman, D. R., and Cheroutre, H. (2004). Science, in press. Manjunath, N., Shankar, P., Stockton, B., Dubey, P. D., Lieberman, J., and von Andrian, U. H. (1999). Proc. Natl. Acad. Sci. USA 96, 13932. Miyazaki, T., Dierich, A., Benoist, C., and Mathis, D. (1996). Science 272, 405. Nakayama, J., Rice, J. C., Strahl, B. D., Allis, C. D., and Grewal, S. I. (2001). Science 292, 110. Nakayama, K., Yamamoto, R., Ishii, S., and Nakauchi, H. (1993). Int. Immunol. 5, 817. Salmon, P., Giovane, A., Wasylyk, B., and Klatzmann, D. (1993). Proc. Natl. Acad. Sci. USA 90, 7739. Sands, J. F., and Nikolic-Zugic, J. (1992). Int. Immunol. 4, 1183. Sawada, S., and Littman, D. R. (1991). Mol. Cell. Biol. 11, 5506. Sawada, S., and Littman, D. R. (1993). Mol. Cell. Biol. 13, 5620. Sawada, S., Scarborough, J. D., Killeen, N., and Littman, D. R. (1994). Cell 77, 917. Sebzda, E., Mariathasan, S., Ohteki, T., Jones, R., Bachmann, M. F., and Ohashi, P. S. (1999). Annu. Rev. Immunol. 17, 829. Singer, A. (2002). Curr. Opin. Immunol. 14, 207. Singh, H., DeKoter, R. P., and Walsh, J. C. (1999). Cold Spring Harb. Symp. Quant. Biol. 64, 13. Siu, G., Wurster, A. L., Duncan, D. D., Soliman, T. M., and Hedrick, S. M. (1994). EMBO J. 13, 3570. Siu, G., Wurster, A. L., Lipsick, J. S., and Hedrick, S. M. (1992). Mol. Cell. Biol. 12, 1592. Taniuchi, I., Osato, M., Egawa, T., Sunshine, M. J., Bae, S. C., Komori, T., Ito, Y., and Littman, D. R. (2002a). Cell 111, 621.
CD4/CD8 LINEAGE CHOICE: NEW INSIGHTS
89
Taniuchi, I., Sunshine, M. J., Festenstein, R., and Littman, D. R. (2002b). Mol. Cell 10, 1083. Tomita, K., Hattori, M., Nakamura, E., Nakanishi, S., Minato, N., and Kageyama, R. (1999). Genes Dev. 13, 1203. Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., and Hercend, T. (1990). J. Exp. Med. 171, 1393. von Boehmer, H., and Fehling, H. J. (1997). Annu. Rev. Immunol. 15, 433. von Boehmer, H., Teh, H. S., and Kisielow, P. (1989). Immunol. Today 10, 57. Vremec, D., Zorbas, M., Scollay, R., Saunders, D. J., Ardavin, C. F., Wu, L., and Shortman, K. (1992). J. Exp. Med. 176, 47. Weiss, A., and Littman, D. R. (1994). Cell 76, 263. Wheeler, J. C., Shigesada, K., Gergen, J. P., and Ito, Y. (2000). Semin, Cell Dev. Biol. 11, 369. Wolfer, A., Bakker, T., Wilson, A., Nicolas, M., Ioannidis, V., Littman, D. R., Lee, P. P., Wilson, C. B., Held, W., MacDonald, H. R., and Radtke, F. (2001). Nat. Immunol. 2, 235. Woolf, E., Xiao, C., Fainaru, O., Lotem, J., Rosen, D., Negreanu, V., Bernstein, Y., Goldenberg, D., Brenner, O., Berke, G., Levanon, D., and Groner, Y. (2003). Proc. Natl. Acad. Sci. USA 100, 7731. Workman, C. J., and Vignali, D. A. (2003). Eur. J. Immunol. 33, 970. Wurster, A. L., Siu, G., Leiden, J. M., and Hedrick, S. M. (1994). Mol. Cell. Biol. 14, 6452. Zhang, X. L., Seong, R., Piracha, R., Larijani, M., Heeney, M., Parnes, J. R., and Chamberlain, J. W. (1998). J. Immunol. 161, 2254. Zhang, X. L., Zhao, S., Borenstein, S. H., Liu, Y., Jayabalasingham, B., and Chamberlain, J. W. (2001). J. Exp. Med. 194, 685. Zhuang, Y., Cheng, P., and Weintraub, H. (1996). Mol. Cell. Biol. 16, 2898. Zou, Y. R., Sunshine, M. J., Taniuchi, I., Hatam, F., Killeen, N., and Littman, D. R. (2001). Nat. Genet. 29, 332.
This Page Intentionally Left Blank
advances in immunology, vol. 83
CD4/CD8 Coreceptors in Thymocyte Development, Selection, and Lineage Commitment: Analysis of the CD4/CD8 Lineage Decision ALFRED SINGER* AND REMY BOSSELUT{ {
*Experimental Immunology Branch Laboratory of Immune Cell Biology National Cancer Institute Bethesda, Maryland 20892
I. Introduction
The T cell arm of the adaptive immune system is composed mainly of T lymphocytes expressing ab T cell receptors (TCR) that recognize antigenic peptides presented by Major Histocompatibility Complex (MHC) encoded molecules. ab T cells can be divided into two major subpopulations based on whether their TCR recognize antigenic peptides presented by MHC class I (MHC-I) or MHC class II (MHC-II) molecules. Notably, ab T cells which recognize peptide/MHC-I complexes express CD8 coreceptor molecules and function mainly as cytolytic effector cells, while ab T cells which recognize peptide/MHC-II complexes express CD4 coreceptor molecules and function mainly as helper cells. The concordance among TCR MHC specificity, coreceptor expression, and function displayed by ab T cells is critical for competent functioning of the adaptive immune system and is established during differentiation in the thymus (Cosgrove et al., 1991; Grusby et al., 1991; Kaye et al., 1989; Koller et al., 1990; Kruisbeek et al., 1983, 1985; Marusic-Galesic et al., 1988; Sha et al., 1988; Teh et al., 1988; Zijlstra et al., 1990). This chapter will focus on the role of CD4/CD8 coreceptor molecules in thymocyte development and on potential mechanisms of the CD4/CD8 lineage decision. II. Early Thymocyte Development
A. T/B Lineage Decision Mature ab T cells are generated from a relatively small number of lymphocyte precursors that initially migrate into the thymus. Even though they have migrated into the thymus, these early lymphocyte precursors still have the potential to differentiate into either T or B cells (Izon et al., 2001, 2002b; Koch et al., 2001; Wilson et al., 2001). Which cell type they actually differentiate into is influenced by the cell fate determining molecule Notch (Izon et al., 2002a; Koch et al., 2001; Pui et al., 1999; Radtke et al., 1999; Schmitt and Zuniga-Pflucker, 2002). Notch is an unusual transmembrane 91 Copyright 2004, Elsevier Inc. All rights reserved. 0065-2776/04 $35.00
92
ALFRED SINGER AND REMY BOSSELUT
protein that is cleaved during biosynthesis so that it consists of two noncovalently associated protein fragments: an extracellular fragment containing the Notch extracellular domain and a membrane-bound fragment containing the Notch transmembrane/intracellular domains (Lai, 2002). Interaction of the Notch extracellular domain with its extracellular ligands triggers further enzymatic cleavage of the Notch intracellular fragment near the inner leaf of the plasma membrane, freeing the intracellular domain from the plasma membrane. The released Notch intracellular domain (Notch-IC) translocates to the nucleus where it activates gene transcription. Activation of Notch-1 in the thymus by interaction with its extracellular ligands Jagged and Delta-like induces lymphocyte precursors to differentiate into T cells (Schmitt and Zuniga-Pflucker, 2002); without Notch activation, lymphocyte precursors in the thymus differentiate into B cells (Izon et al., 2002a,b; Koch et al., 2001; Radtke et al., 1999). In fact, Notch-1 can promote differentiation of lymphocyte precursors into T-lineage cells even outside the thymus, in such nontraditional T cell sites as bone marrow and in vitro cultures (Allman et al., 2001; Pui et al., 1999; Schmitt and Zuniga-Pflucker, 2002). Reciprocally, interference with Notch activation in the thymus by ectopic expression of Notch ligand modifiers, such as Lunatic fringe, interferes with T-lineage commitment and results in the intrathymic accumulation of B cells (Koch et al., 2001). Thus, lymphocyte precursors adopt the B-lineage unless they are directed by activated Notch to differentiate into T cells. B. DN Thymocytes T cell differentiation in the thymus has been subdivided into discrete stages of development based on thymocyte expression of the coreceptor molecules CD4 and CD8 (Fig. 1). The earliest thymocytes are CD48 (DN, double negative), which then differentiate into CD4þ8þ (DP, double positive) cells, which, in turn, finally differentiate into mature CD4þ8 or CD48þ (SP, single positive) cells. During the DN stage of differentiation, early T lineage cells proliferate, express the Recombination Activating Genes (RAG-1 and RAG-2), initiate TCR gene rearrangements, and undergo selection to identify cells that have generated productive TCRb gene rearrangements. These events occur sequentially in developing DN thymocytes, permitting DN thymocytes to be further subdivided into developmental subsets based on surface expression of CD44 and CD25 (Godfrey and Zlotnik, 1993; Godfrey et al., 1993; Pearse et al., 1989). DN thymocyte subsets are named DN1 through DN4, in order of their appearance during development. The earliest T-committed cells in the thymus are DN1 and are identified as CD44þ25; DN2 thymocytes are CD44þ25þ; DN3 thymocytes are CD4425þ; and DN4 thymocytes are CD4425 and will differentiate into DP thymocytes (Fig. 1).
ANALYSIS OF THE CD4/CD8 LINEAGE DECISION
93
Fig 1 Simplified scheme of thymocyte development based on surface expression of CD4 and CD8 coreceptors. DN thymocytes can themselves be subdivided into subpopulations based on surface expression of CD44 and CD25.
The first of two thymocyte proliferative phases occurs in DN1 and DN2 thymocytes prior to RAG expression and prior to TCR gene rearrangements (Kawamoto et al., 2003). This early proliferative phase is required to expand the number of precursor cells in which TCRb gene rearrangements occur so that as many different productive TCRb gene rearrangements as possible will be expressed in the developing thymocyte pool. Expression of RAG proteins occurs at the DN2 and DN3 stages of differentiation, during which three of the four TCR gene loci (b, g, d) undergo rearrangements. Cells successfully rearranging both TCRg and TCRd gene loci are diverted from the ab lineage to differentiate into gd T cells (Bonneville et al., 1989). Cells successfully rearranging the TCRb gene locus and expressing TCRb protein are identified at the DN3 stage by a selection event known as ‘‘b-selection’’ that signals continued differentiation. DN3 cells express the invariant signaling components of the TCR complex CD3g, d, e, and zeta which, in mature T cells, require association with both TCRa and TCRb chains to be assembled into a functional signaling complex (Frank et al., 1990). However, in place of TCRa chains, which are generally not expressed in DN thymocytes, DN3 cells express an invariant chain, pre-Ta, (Fehling et al., 1995; Saint-Ruf et al., 1994) that functions as a surrogate for TCRa and can assemble with TCRb to form the ‘‘pre-TCR’’ signaling complex that is transported to the cell surface where it transduces survival signals by, in part, activating NFkb (Aifantis et al., 2001, 2002; Voll et al., 2000). Signaling by pre-TCR complexes appears to require only export from the ER to the cell surface and is thought to occur without ligand engagement (Haks et al., 2003; Irving et al., 1998; O’Shea et al.,
94
ALFRED SINGER AND REMY BOSSELUT
1997). The signals generated by pre-TCR complexes induce differentiation into DN4 stage cells which then undergo a second proliferative burst prior to expression of CD4/CD8 coreceptor proteins and differentiation into DP thymocytes. This second round of thymocyte proliferation assures that each productive TCRb gene rearrangement is replicated in multiple daughter cells prior to initiation of TCRa gene rearrangement in late DN4 and early DP thymocytes. As a result, each TCRb protein has a variety of potential partner TCRa proteins. Thus, the first proliferative expansion at the DN1 and DN2 stages increases the diversity of TCRb proteins represented in the repertoire, and the second proliferative expansion at the DN4 stage increases the diversity of potential TCRa proteins that can partner with each TCRb protein. The result is a clonally diverse population of immature DP thymocytes that expresses a hugely diverse ab TCR repertoire. C. DP Thymocytes As a consequence of b-selection, DP thymocytes undergoing TCRa gene rearrangements already contain TCRb proteins. For TCRa, proximal gene rearrangements can be followed by distal gene rearrangements with the result that DP thymocytes have the potential to sequentially rearrange the same TCRa gene locus several times (Guo et al., 2002; Petrie et al., 1993). Productive gene rearrangements result in TCRa proteins that assemble with preexisting TCRb proteins to form functional ab TCR signaling complexes on the surface of DP thymocytes (Kearse et al., 1995). These ab TCR complexes are screened for their ability to engage self peptide/MHC complexes expressed on thymic stromal elements by whether they subsequently transduce a ligandstimulated intracellular signal. Since RAG expression is not terminated in DP thymocytes until TCR signals are transduced (Brandle et al., 1992; Takahama and Singer, 1992; Turka et al., 1991), TCRa gene rearrangements can continue until a TCRa protein is produced that forms an ab TCR complex which can engage intrathymic peptide/MHC complexes with sufficient affinity to stimulate a TCR signal (Buch et al., 2002; Wang et al., 1998). Interestingly, TCR gene rearrangements appear to generate ab TCR that may exhibit an intrinsic bias toward MHC recognition (Zerrahn et al., 1997), which may provide part of the explanation for why MHC complexes are virtually unique among membrane proteins in their ability to stimulate TCR signals in developing DP thymocytes. Initial ab TCR signals in DP thymocytes upregulate CD5 and CD69 surface expression and terminate RAG expression, which precludes further TCRa gene rearrangements and fixes ab TCR specificity (Bhandoola et al., 1999; Dutz et al., 1995; Swat et al., 1993; Takahama and Singer, 1992; Turka et al., 1991). Unless rescued by ab TCR signals, DP thymocytes undergo apoptosis within 1 to 3 days by a process referred to as ‘‘death by
ANALYSIS OF THE CD4/CD8 LINEAGE DECISION
95
neglect’’ (Egerton et al., 1990; Huesmann et al., 1991). So DP thymocytes that either fail to express any ab TCR complexes or express ab TCR with too low affinity for intrathymic peptide/MHC ligands to stimulate TCR signals undergo death by neglect (Kisielow et al., 1988; Mombaerts et al., 1992; Philpott et al., 1992). In contrast, DP thymocytes whose ab TCR have too high affinity for intrathymic peptide/MHC ligands are signaled to undergo apoptosis by ‘‘negative selection’’ (Kappler et al., 1987; Sha et al., 1988; Takahama et al., 1992; Teh et al., 1989). It is only those few DP thymocytes whose ab TCR have intermediate affinity for intrathymic peptide/MHC ligands that are signaled to survive and to further differentiate into SP thymocytes, by a process referred to as ‘‘positive selection’’ (Ashton-Rickardt et al., 1994; Hogquist et al., 1994; Kisielow et al., 1988; Singer et al., 1986, 1987; Teh et al., 1988). Notably, since positive selection of DP thymocytes involves differentiation into either CD4 or CD8 SP T cells, the CD4/CD8 lineage decision is an intrinsic feature of the positive selection process (Janeway, 1988; Kaye et al., 1989; Sha et al., 1988; Teh et al., 1988). III. CD4 and CD8 Coreceptor Molecules on DP Thymocytes
The CD4 and CD8 coreceptor molecules are non-rearranging transmembrane proteins whose extracellular domains bind MHC and whose intracellular domains associate with either the nonreceptor protein tyrosine kinase Lck (Glaichenhaus et al., 1991; Marth et al., 1985, 1989; Shaw et al., 1989, 1990; Turner et al., 1990; Veillette et al., 1988, 1989) or the adapter molecule LAT (Bosselut et al., 1999; Zhang et al., 1998). CD4 and CD8 coreceptor binding to MHC is not peptide specific, and is distinguished by the fact that CD4 has low affinity for MHC class II complexes while CD8 has low affinity for MHC class I complexes (Doyle and Strominger, 1987; Norment et al., 1988; Wyer et al., 1999). The CD4 and CD8 molecules are considered TCR coreceptors for several reasons (Dembic et al., 1987; Gabert et al., 1987; Janeway, 1988): (1) by virtue of their MHC binding affinity, CD4 and CD8 coreceptors can augment TCR binding to peptide/MHC complexes; (2) because of their intracellular association with Lck, CD4 and CD8 coreceptors can augment the initiation of TCR signal transduction stimulated by peptide/MHC complexes; and (3) as a result of their intracellular association with LAT, CD4 and CD8 coreceptors can augment the propagation of downstream TCR signaling events. Despite their shared ability to function as TCR coreceptors, CD4 and CD8 are structurally distinct molecules. CD4 is a monomer while CD8 is a disulfide-linked dimer composed either of two different chains (CD8a and CD8b) which form CD8ab heterodimers or two similar chains which form CD8aa homodimers (Ledbetter and Seaman, 1982; Ledbetter et al., 1981);
96
ALFRED SINGER AND REMY BOSSELUT
CD8bb homodimers are never expressed on the murine cell surface as they are retained within the endoplasmic reticulum (Blanc et al., 1988; Devine et al., 2000; Gorman et al., 1988; Norment and Littman, 1988). The majority of CD8 surface complexes on DP thymocytes consist of CD8ab heterodimers, although CD8aa homodimers are also present on the cell surface (Norment and Littman, 1988). In mouse thymocytes, CD8 heterogeneity is further increased by expression of both full-length and alternatively spliced CD8a RNAs, which encode full-length CD8a and truncated CD8a0 proteins lacking a cytosolic tail (Zamoyska et al., 1985). So CD8 surface complexes on murine DP thymocytes potentially consist of 5 different protein complexes composed of disulfide-linked CD8ab, CD8a0 b, CD8aa, CD8a0 a, and CD8a0 a0 chains. Intracellular Lck binding to CD4 and CD8 coreceptor molecules is mediated by a dicysteine motif that is present in the cytosolic tails of both CD4 and CD8a, but absent from CD8b and CD8a0 (Glaichenhaus et al., 1991; Shaw et al., 1989, 1990; Turner et al., 1990; Veillette et al., 1988, 1989). LAT binds to the same or overlapping intracellular sites as Lck on CD4 and CD8a, with the result that Lck and LAT compete with each other for coreceptor binding (Bosselut et al., 1999; Wiest et al., 1996) with Lck binding predominating over that of LAT. Interestingly, more Lck and LAT are bound to CD8ab than to CD8aa surface complexes despite the latter complexes having twice as many potential binding sites (Bosselut et al., 1999; Irie et al., 1995, 1998). Either the CD8b cytosolic tail somehow improves binding of Lck and LAT to the CD8a tail, or two CD8aa chains structurally interfere with one another and diminish Lck’s ability to bind to either chain. In any event, only three of the five different CD8 complexes expressed on murine DP thymocytes (CD8ab, CD8aa, CD8a0 a) have any ability to bind intracellular Lck, and none of them binds Lck as well as CD4 does. Despite large intracellular pools of Lck in DP thymocytes, the pool of Lck that is available to surface CD4 and CD8 is limiting (Wiest et al., 1993, 1996). It has been estimated that there are four times as many CD8 complexes as CD4 molecules on the surface of DP thymocytes, yet CD4 surface molecules bind quantitatively more Lck than do CD8 surface complexes because Lck occupancy of surface CD4 molecules is 10-fold greater than Lck occupancy of surface CD8 complexes (Wiest et al., 1993). Fully 25 to 50% of surface CD4 molecules on DP thymocytes are associated with intracellular Lck, while only 2.5% of surface CD8 complexes on the same DP thymocytes are associated with intracellular Lck (Wiest et al., 1993). There are several explanations for the significantly higher Lck occupancy of surface CD4 than surface CD8 molecules, including: (1) greater affinity of Lck for the tail of CD4 versus CD8a; (2) heterogeneity of surface CD8 complexes, some of which include tailless CD8a0 molecules which cannot bind any Lck at all; and (3) the fact that CD8 surface molecules without associated intracellular Lck can remain on the
ANALYSIS OF THE CD4/CD8 LINEAGE DECISION
97
cell surface while CD4 surface molecules without associated intracellular Lck tend to be internalized and removed from the cell surface (Pelchen-Matthews et al., 1991, 1992). The consequence of higher Lck occupancy of CD4 than CD8 coreceptors is that extracellular CD4 engagements induce Lck aggregation and Lck kinase activation far more efficiently than do extracellular CD8 engagements (Wiest et al., 1993, 1996). Because experiments examining CD4/CD8 lineage fate may manipulate the amount of CD4 and CD8 on the cell surface, it is important to consider the effects that quantitative changes in coreceptor expression might have on coreceptor function in DP thymocytes. Since the amount of Lck available to surface coreceptors is limiting, surface CD4 and CD8 compete with one another for intracellular Lck binding. As a result, increases or decreases in surface expression of either CD4 or CD8 can alter the Lck signaling competence of either or both coreceptor molecules. Because Lck binds most efficiently to CD4, changes in CD4 surface expression have the most pronounced impact on Lck signaling in DP thymocytes. Quantitative decreases in CD4 surface expression increase coreceptor signaling by CD8, as revealed by the observation that absent CD4 expression in CD48 mice results in significantly increased Lck association with surface CD8 complexes and significantly increased CD8 signaling ability (Wiest et al., 1996). Paradoxically, while quantitative increases in CD4 surface expression decrease CD8 coreceptor signaling (Teh et al., 1991; van Oers et al., 1992; Wiest et al., 1996), marked transgenic CD4 overexpression increases the number of surface CD4 molecules that lack associated intracellular Lck and therefore decreases CD4 coreceptor signaling competence, as extracellular CD4 engagements are now less efficient at aggregating and activating intracellular Lck (Nakayama et al., 1993). While quantitative changes in CD4 expression have the greatest impact on coreceptor signaling function, transgenic overexpression of CD8ab heterodimers increases the relative distribution of available Lck toward CD8, improving CD8 signaling ability (Bosselut et al., 2000, 2001; Chan et al., 1994; Robey et al., 1992). Thus, experimental manipulations that alter the number of either CD4 or CD8 coreceptor molecules on the cell surface can affect the signaling function of both coreceptor molecules. DP thymocytes in the thymus are in close physical contact with cortical thymic epithelial cells that express exceptionally high levels of MHC-II (Jenkinson et al., 1981; Van Ewijk et al., 1980). The high levels of MHC-II engage surface CD4 molecules on DP thymocytes even without concurrent TCR engagement, resulting in ‘‘constitutive’’ low level Lck activation (Nakayama et al., 1989, 1990; van Oers et al., 1994; Wiest et al., 1993). One consequence of such Lck kinase activation by intrathymic CD4/MHC-II interactions is Lck depletion, resulting in decreased amounts of Lck available to surface coreceptors and decreased amounts of Lck available for subsequent
98
ALFRED SINGER AND REMY BOSSELUT
TCR signaling (Wiest et al., 1996). CD4-induced Lck kinase activation also directly affects the structure of surface TCR complexes on DP thymocytes by inducing the phosphorylation of some TCR ITAMs, which result in the p21 form of phospho-zeta rather than the p23 form of phospho-zeta that has been associated with full TCR activation (Madrenas et al., 1995; Nakayama et al., 1989; van Oers et al., 1994). The phosphorylated TCR ITAMs on DP thymocytes recruit ZAP-70 molecules which are not themselves phosphorylated and so remain enzymatically inactive. It has been estimated that over one-third of surface TCR complexes on DP thymocytes contain phosphorylated ITAMs that have been bound by inactive ZAP-70 molecules (Wiest et al., 1996). Such surface TCR complexes on DP thymocytes resemble nonfunctional TCR complexes on mature T cells after engagement of antagonist ligands (Madrenas et al., 1995; Sloan-Lancaster et al., 1994). Indeed, structural changes in surface TCR induced by intrathymic CD4/MHC-II diminish TCR signaling competence in DP thymocytes, at least in response to strong ligands. It has been suggested that these same structural changes may actually increase TCR responsiveness to weak TCR ligands and so may promote positive selection of DP thymocytes in response to intrathymic self-peptide/ MHC complexes (Davey et al., 1998; Lucas et al., 1999; Stefanova et al., 2003). In addition to affecting TCR structure, intrathymic CD4/MHC-II interactions downregulate the number of TCR complexes present on the surface of DP thymocytes (Bonifacino et al., 1990; Cosgrove et al., 1991; Grusby et al., McCarthy et al., 1988; Nakayama et al., 199